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Abstract 
 
Advances in endoscopic practice are challenging traditional views on how neoplasia 
should be managed in the gastrointestinal system. Identifying pre-malignant changes 
in the gut is central to successful early management of most cancers.  There has 
been rapid growth in the equipment and technology available for evaluating 
potentially neoplastic lesions in the gastrointestinal tract. However, the evidence 
base for how they should be used is limited. This thesis investigates the use of 
chromoendoscopy and ‘virtual computed chromoendoscopy’ in the gastrointestinal 
tract for the identification, assessment and management of early gastrointestinal 
neoplasia.  
 
The first part of the thesis reviews data on the health burden of gastrointestinal 
neoplasia. It reviews the background research into advanced endoscopic techniques 
in the colon and oesophagus and outlines the deficiencies in the published literature.  
 
Chapters 7-9 describe the development and validation of a new tool (N.A.C.) for in-
vivo histology prediction of colonic polyps <10mm in size using Flexible Spectral 
Imaging Colour Enhancement (FICE) and indigo carmine (IC) chromoendoscopy 
without optical magnification. Chapter 7 describes a study to determine the optimum 
FICE setting for assessment of polyps. Setting 4 came out as the best setting for this 
purpose. Chapters 8 and 9 describe two studies to define the key surface features 
associated with neoplastic and non-neoplastic polyps using first a picture based 
study and then in an in-vivo study. N.A.C. was then used in a prospective cohort 
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study of polyp assessment in a Bowel cancer Screening Population, described in 
Chapter 10. A prospective study of 232 polyps <10mm in size was performed. FICE 
and IC significantly improved the accuracy of the in-vivo diagnosis of polyps as 
compared to WLI endoscopy. In-vivo prediction of polyp histology allowed the 
endoscopist to set the correct surveillance interval in 83% of cases using WLI alone 
and in 97% of cases using either FICE or IC based on BSG guidelines. Chapter 11 
describes a study which attempts to identify the role of high resolution (HD) 
endoscopes in lesion characterization. HD endoscopes significantly improved the 
ability of the endoscopist to make an in vivo diagnosis using FICE compared to 
standard resolution endoscopes with FICE but had no effect on the WLI or IC 
predicted diagnosis. 
 
Chapter 12 describes the use of acetic acid in a cohort study for the identification of 
neoplasia within Barrett’s oesophagus to establish the sensitivity and specificity of 
the technique. Acetic acid chromoendoscopy had a sensitivity of 95.5% and 
specificity of 80% for the detection of neoplasia. There was a correlation between 
lesions predicted to be neoplasic by acetic acid and those predicted by histological 
analysis (r=0.98). There was a significant improvement in the detection of neoplasia 
using acetic acid compared with white light endoscopy (P=0.001). This method is 
then refined in a second study by attempting to exploit the aceto-whitening reaction. 
This is described in Chapter 13. Data from 146 areas of Barrett’s was collected from 
121 patients. 84% were male. Mean age 69. In total 72/86 metaplasia, 6/14 LGD, 
26/27 HGD, 15/15 IMC and 12/12 areas of invasive cancer were recognised 
correctly by the endoscopist. A ROC curve was produced for the identification of high 
risk neoplasia (HGD, IMC and invasive cancer) using the aceto-whitening timings. 
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The area under the curve was 0.93 (95% C.I.0.89-0.97), demonstrating a low 
probability that a randomly chosen positive case will exceed the value for a randomly 
chosen negative case. Using a cut off threshold of 142 seconds a sensitivity for 
neoplasia of 98% (95% C.I. 89-100) and specificity of 84% (95% C.I. 74-91) was 
achieved. 
 
The final chapter of the thesis discusses the clinical impact of the research and how 
it could be introduced to clinical practice. It reflects on where deficiencies in the 
published literature still exist where the future research needs are.   
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Introduction 
Gastrointestinal malignancies represent a significant health burden, with colonic, 
oesophageal and gastric cancer being the 3rd, 9th and 10th most common 
malignancies respectively in the UK (1). With the exception of pancreatic cancer, 
survival has improved significantly over the last 3 decades, with survival rates 
doubling for oesophageal and colonic malignancies. Unfortunately despite these 
advances there is significant world wide variation in both the prevalence and survival 
from these conditions.  
 
Oesophageal cancer is the 9th most common cancer in the UK, with 7800 people 
diagnosed every year, accounting for 5% of all cancer deaths in the UK. Rates have 
increased by 50% over the last 30 years (2). It is more common in men than women, 
with an incidence of 8.8-14.1 per 100,000 in men, and 4.8-5.7 per 100,000 in 
women. (3). The 5 year survival remains low at 9% (4), which is primarily due to 
cancer being diagnosed at a late stage. There is therefore a need for early diagnosis 
so that the disease can be managed at an early and treatable stage. 
 
A significant risk factor for adenocarcinoma of the oesophagus is Barrett’s 
epithelium, an acquired pre-malignant condition, caused by reflux of gastric contents 
into the oesophagus. The gastric acid damages the normal squamous epithelium, 
becoming replaced by a columnar epithelium. The newly updated definition by the 
British society of Gastroenterology defines Barrett’s as ‘an endoscopically apparent 
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area above the oesophagogastric junction that is suggestive of Barrett's which is 
supported by the finding of columnar lined oesophagus on histology’ (5) (6).   
 
Barrett’s oesophagus affects up to 1.6% of the general population (7). It is found in 
15-20% of gastrointestinal endoscopies performed for symptoms of reflux and the 
incidence is increasing in the West (2) (8). It has the potential to progress into 
adenocarcinoma. Risk factors for this include male gender, age >45, long segment 
(>8cm) disease, a history of longstanding reflux, early age of onset of gastro-
oesophageal reflux disease (GORD), duodeno-gastrooesophageal reflux, mucosal 
damage and family history (6).  
 
Colorectal cancer represents a major health burden in the West, accounting for 
550,000 deaths per year worldwide (1). Whilst the adenoma to carcinoma pathway is 
not fully understood, the vast majority of cases arise on a background of 
adenomatous colonic polyps. This is important as removal of these lesions provides 
a potential method of cancer prevention which has led to the development of 
colonoscopy based screening programmes to detect these pre-malignant changes. 
Early evidence has suggested that this is an effective method of reducing cancer 
incidence (9).  
 
Advances in endoscopic practice are challenging traditional views on how we should 
be managing cancer in the gastrointestinal system.  Over the last 10 years there has 
been a period of rapid growth in the equipment and technology available for 
evaluating potentially malignant lesions in the gastrointestinal tract. These include 
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advanced endoscopes with high definition screens, image processors and 
magnification facilities, endomicroscopes and dye sprays for enhancing mucosal 
patterns. Many of these are being used in daily practice. However, the evidence 
base for how they should be used, and their effectiveness in predicting histology and 
changing patient management is limited. It is widely accepted that correctly 
identifying high risk pre-malignant changes in the gut is central to successful early 
management of most cancers. This includes both the detection of dysplastic areas 
within Barrett’s oesophagus and the correct classification of polyps as either 
hyperplastic, adenomas or polyp cancers. The development of these new 
technologies;  chromoendoscopy, ‘virtual chromoendoscopy’ using digital image 
enhancement techniques built into the endoscopes (Flexible Spectral Imaging Colour 
Enhancement (FICE), Narrow Band Imaging and i-scan) and high resolution 
endoscopes have  opened up a wealth of new possibilities which have yet to be fully 
explored.  
 
At the same time as new technologies have been emerging the development of the 
Bowel Cancer Screening Programme (BCSP) within the UK has increased the 
number of colonoscopies being performed in the age group 59-70 yrs. It is known 
that patients in this age group have a very high incidence of polyps. Targets in 
colonoscopy have driven up standards in lesion detection, with compulsory reporting 
of adenoma detection rates in the U.K. However, not all polyps are adenomas as 
50% of small lesions (<10mm in size) are hyperplastic, which have negligible 
malignant potential. Due to a lack of in-vivo diagnostic techniques it is current policy 
that all polyps are removed and sent for histological examination, exposing patients 
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to the risks of polypectomy, including bleeding and colonic perforation, whilst 
providing already stretched health service providers with a significant expense in 
terms of histological assessment of these polyps. In the oesophagus it is current 
policy to offer regular surveillance gastroscopy to patients with Barrett’s in an attempt 
to identify the development of dysplasia. However, this is still being done with 
protocol driven, non targeted biopsies which is time consuming, expensive and still 
misses dysplastic lesions. If we are to be able to offer appropriate targeted 
endoscopic treatments in both of these areas it is important that the lesions can be 
assessed accurately. 
In recent years there has been considerable development in techniques for 
examining both the upper and lower gastrointestinal tract. This has included the 
introduction of numerous dye sprays, including acetic acid in the oesophagus and 
indigocarmine in the colon, and the development of electronic imaging techniques, 
including Narrow Band Imaging and FICE. However, the evidence base is 
incomplete. Much of the published data comes from the Far East in different patient 
populations to those seen by the Western endoscopist. Disease incidence and 
prevalence for most gastrointestinal malignancies show considerable worldwide 
variation. In particular there is very little Barrett’s in Japan and most of Asia, resulting 
in a paucity of publications into this condition. The problem facing the Western 
endoscopist is therefore a lack of understanding of how these emerging techniques 
fit together and how to apply advanced endoscopic imaging techniques to the 
management of Western patients. 
The American Society of Gastrointestinal Endoscopy (ASGE) has recently launched 
a new initiative to identify important clinical questions related to endoscopy and to 
establish the diagnostic and therapeutic threshold for the endoscopic techniques to 
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resolve these clinical questions (10). This is known as PIVI (preservation and 
incorporation of valuable endoscopic innovations) and has been developed to direct 
endoscopic technology development towards resolving these important clinical 
issues in endoscopy. A concern has been that measures need to be taken to avoid 
the widespread use of an endoscopic technology before clinical studies 
demonstrating effectiveness have been performed. Likewise, potentially valuable 
innovations are being prematurely abandoned due to a lack of utilization. The first 
remit of the PIVI has been to investigate real time endoscopic assessment of the 
histology of diminutive colonic polyps. The ASGE has issued the following 
statements: 
1) In order for colorectal polyps<5mm in size to be resected and discarded 
without pathologic assessment, endoscopic technology (when used with high 
confidence) used to determine histology of polyps <5mm in size, when 
combined with the histopathologic assessment of polyps >5mm in size, should 
provide a 90% agreement in assignment of post-polypectomy surveillance 
intervals when compared to decisions based on pathology assessment of all 
identified polyps 
2) In order for a technology to be used to guide the decision to leave suspected 
rectosigmoid hyperplastic polyps <5mm in size in place (without resection), 
the technology should provide greater than 90% negative predictive value 
(when used with high confidence) for adenomatous histology. 
  
These are fundamental questions which need to be answered in regards to the 
evaluation of colonic neoplasia. It also needs to be shown whether this can be 
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applied to colonic polyps in a Western screening population. The optimal method for 
examination of these polyps needs to be established. This includes the type of 
endoscope which should be used (standard definition versus high definition) and 
whether a diagnosis can be made without optical magnification. The features of the 
polyps which can be exploited to make an accurate diagnosis needs further study. 
This essentially centres around the lesion classification system that should be used 
and whether the complex systems pioneered in Japan are the only way to establish 
an in-vivo diagnosis. The specific roles for chromoendoscopy and electronic imaging 
in the characterization of colonic neoplasia needs to be identified. In particular when 
to choose a certain technique needs to be investigated as does the benefit of using 
dye spray in addition to electronic imaging. Furthermore, how in-vivo diagnosis fits 
into an assessment protocol needs to be established. In particular whether there is a 
benefit in terms of cost saving, should be examined. Finally the adverse effects 
arising from an incorrect in-vivo diagnosis should be studied. 
 
The ASGE has not yet released a PIVI for the assessment of Barrett’s. However, a 
group of 60 clinicians and scientists from 14 different countries working in 10 
separate disciplines have developed the Barrett’s Dysplasia and Cancer Taskforce 
Consensus Group (BADCAT). The aims of this group is to produce evidence based 
guidelines for best clinical and cost effective management of high grade dysplasia 
and early mucosal cancer in Barrett’s oesophagus, which are likely to form the basis 
of all future national guidelines around the world. One of the areas covered by this 
review is advanced endoscopic imaging and some of the studies from this thesis 
have contributed towards this document, and will be discussed later in Chapter 12. 
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The most important question that needs to be answered in Barrett’s oesophagus is 
whether neoplasia can be routinely observed during endoscopy. If so, how frequently 
this is possible with white light needs to be established, before the benefits of any 
enhancement technique can be demonstrated. The role of acetic acid 
chromoendoscopy in improving the visualization of neoplasia within Barrett’s needs 
to be addressed, and in particular how the acetic acid technique should be used and 
the results interpreted. 
 
The purpose of the studies described in this thesis is to answer most of the 
questions raised above. Specifically, the studies aim to evaluate the concept of in-
vivo diagnosis and the role of advanced endoscopic techniques in facilitating an 
accurate in-vivo diagnosis. The work will focus on detecting early neoplasia in both 
Barrett’s and colonic polyps. These are common problems facing the Western 
endoscopist and are increasing in prevalence (3) (1). 
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Hypothesis 
 
Modern endoscopic techniques of chromoendoscopy and vascular enhancement can 
be used to localise and characterize neoplasia within the gastrointestinal tract 
 
Aims of this thesis 
 
1) To establish whether the vascular enhancement technique FICE and indigo 
carmine chromoendoscopy can be used to characterize polyps in the colon 
without optical magnification 
2) To establish whether acetic acid chromoendoscopy can be used to localise 
and characterise neoplasia within Barrett’s oesophagus 
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Objectives of the thesis 
 
3) To establish the optimum FICE setting for the assessment of the surface and 
vascular patterns and structures of colonic neoplasia. 
4) To develop and validate a lesion assessment tool for use with the FICE 
electronic imaging system. 
5) To apply these tools to a Western bowel cancer screening population and 
establish whether in-vivo diagnosis is possible in this patient group. 
6) To establish whether there is additional benefit from using indigocarmine after 
assessment with the electronic imaging modality FICE. 
7) To establish whether neoplasia within Barrett’s oesophagus is visible 
endoscopically using white light gastroscopy. 
8) To assess the accuracy of acetic acid dye spray in the detection of Barrett’s 
neoplasia during gastroscopy.  
9) To explore and analyse the aceto-whitening reaction seen after acetic acid 
dye spray, and to develop this as an objective assessment tool for the 
differentiation of different stages of neoplasia. 
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Chapters 2 and 3 consider the current evidence base for the emerging imaging 
technologies in both the lower and upper gastrointestinal tract respectively. This 
includes an extensive review of the literature describing the use of indigocarmine, 
methylene blue and acetic acid chromoendoscopy, the role of vascular enhancement 
techniques, including narrow band imaging (NBI), Flexible Spectral Imaging Colour 
Enhancement (FICE), i- scan, and confocal endomicroscopy. They discuss the 
limitations of the current published literature and investigate the current research 
needs in detail. Chapter 4 is a technical overview of how FICE works to enhance the 
vasculature of the gastrointestinal system.   
 
Chapters 5-11 describe the experimental work conducted into the characterization of 
colonic neoplasia. This begins with the development and validation of a novel 
classification system for colonic polyps using FICE with standard endoscopes 
followed by an in-vivo study using this tool on polyps <10mm in a bowel cancer 
screening population. The specific role for the technique will be examined, and 
whether there is additional gain from dye spray with indigo carmine after a diagnosis 
with FICE has been made is also evaluated. The effect on clinical outcome from an 
incorrect diagnosis is examined and a cost evaluation for replacing traditional 
histological examination with an in-vivo diagnosis within the Bowel Cancer Screening 
Programme is reviewed. The data is then subdivided into procedures performed with 
standard definition and high definition endoscopes and the effects of this on 
diagnostic accuracy calculated.  
 
38 
 
Chapter 12 describes the experimental work conducted into the evaluation of 
Barrett’s neoplasia using acetic acid chromoendoscopy. It begins with the 
development of an assessment protocol which is then used in both a screening and 
high risk population to detect neoplasia within Barrett’s. The accuracy for white light 
examination is established and the additional gain from acetic acid calculated. The 
technique is then refined in Chapter 13 by a further study exploring whether the 
differential loss of acetowhitening between Barrett’s metaplasia and dysplasia can be 
exploited to further improve the accuracy of neoplasia detection.  
 
Finally the results from all of the experimental work are drawn together in Chapter 
14. In particular the clinical implications of the findings are discussed, and how they 
can be applied to U.K. endoscopic practice. Areas where uncertainty still remains are 
identified along with the need for future research. 
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Chapter 2 
 
Colonic neoplasia 
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Colonic neoplasia 
Colorectal cancer is a significant health concern. There are 1.4 million new cases 
each year, accounting for an estimated 550,000 deaths worldwide (1).  Although 
much has been learnt about the molecular events leading to colorectal cancer, there 
is still no cure for advanced disease. There is therefore an urgent need to develop 
better disease prevention strategies. Colorectal cancer develops in a series of well-
defined steps; from normal mucosa to adenomatous polyp through varying degrees 
of dysplasia and finally adenocarcinoma (1). Because of this adenoma-carcinoma 
sequence of events there has been a drive in recent years in most Western countries 
to develop bowel cancer screening programmes. The concept is to find adenomas 
before they turn into cancers and remove them, or to find early cancers which can be 
surgically treated with good results.  
 
Numerous approaches have been taken to bowel cancer screening. One approach is 
to offer everyone over a cut off age (usually between 55-60) a colonoscopy. This is 
the method used in the United States. In the United Kingdom a faecal occult blood 
test has been used. This is a non invasive test which involves the patient returning 3 
stool samples to be examined for the presence of occult blood (FOB). It is about 
60% sensitive, meaning that approximately 6 out of 10 patients who undergo 
colonoscopy with positive FOBs have some form of pathology, not necessarily 
cancer). The positive predictive value of faecal occult bloods for cancer is around 
11% and between 18-35% for adenomas. (11) (12). Colonoscopy findings are 
normal in around 50% of patients with positive FOBs.  
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Whilst polyps are a common finding during colonoscopy, not all polyps are the same. 
Hyperplastic polyps have negligible potential to turn into cancer, especially when 
small (<10mm) and located in the left colon (a common site). These account for one 
third of all small polyps (13). In contrast adenomas can turn into cancer (14). Finally 
polyps can already be cancers. 
  
The management of polyps >10mm is simple as they are either adenomas which 
need removal or cancers which require surgical resection. There is a possibility of 
big polyps being hyperplastic serrated adenomas. Given the risk of malignant 
transformation, they need removal as well. It has been traditionally felt that 
hyperplastic polyps cannot be separated clinically from adenomas or polyp cancers. 
For this reason all polyps are removed. However, polypectomy is associated with 
significant risks (15) and results in an immediate cost in processing the samples, 
equipment and most importantly, increases the procedure time. 
 
Because of the difference in risk between hyperplastic and adenomatous polyps, 
there is a need for in-vivo diagnostic techniques. If the endoscopist could make a 
confident in-vivo diagnosis then hyperplastic polyps <10mm could be left in-situ or 
removed but not retrieved thus reducing pathology costs. This has been recognised 
as important by the ASGE, who have released guidelines defining the standards 
which have to be met for any technology used for in-vivo diagnosis that is intended 
to replace conventional histological examination (10). These guidelines have stated 
that for a resect and discard policy to be adopted for polyps <5mm in size, when 
endoscopic technology is combined with the histopathologic assessment of polyps 
>5mm in size, this should provide a 90% agreement in assignment of post-
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polypectomy surveillance intervals, when compared to decisions based on pathology 
assessment of all identified polyps. In order to be able to leave small (<5mm) left 
sided hyperplastic polyps in place the requirements are more stringent, and the 
technology should provide greater than 90% negative predictive value for 
adenomatous histology, if used for this purpose. 
  
There is also a need for diagnostic skills to differentiate adenomas from cancers. 
Whilst polyp cancers <10mm are rare, endoscopists are increasingly attempting to 
remove large flat polyps, rather than referring them for traditional surgical resection 
with the increased risks of associated morbidity and mortality. It is dangerous to 
attempt endoscopic resection of polyp cancers, with an increased risk of perforation 
and a high probability of lymph node metastasis. As the risk of cancer increases with 
the size of polyp, endoscopists who resect large polyps need to have very good skills 
in in-vivo diagnosis so as to avoid resecting polyps containing cancer. 
 
Unfortunately white light examination is not adequate to make an effective in-vivo 
diagnosis, with a diagnostic accuracy of around 70%. This has led to research into 
methods for enhancing the lesion surface or vascular pattern to enable a more 
detailed and discriminatory examination to be performed. There have been several 
methods that have been proposed to achieve this: 
 
1) Chromoendoscopy 
2) Electronic imaging techniques  
3) Confocal endomicroscopy 
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Unfortunately the evidence base for all of these techniques is incomplete. As a result 
it is still the accepted standard of care to resect and send all polyps regardless of 
size for histological assessment. 
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2.1: Chromoendoscopy 
Chromoendoscopy involves the application of a dye to the gastrointestinal tract. The 
intention is to both identify and characterize lesions. The techniques were pioneered 
in Japan where initial experience was in the use of the vital stain crystal violet to 
characterise colonic neoplasia. 
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2.2: Crystal violet chromoendoscopy 
Crystal violet is a vital stain that irreversibly binds to cellular structures, highlighting 
surface patterns in great detail. It was with this dye that the first attempts were made 
at in-vivo histology prediction for colonic polyps. The early work was conducted by 
Professor Kudo in Japan, where the surface patterns of 14,023 colonic lesions was 
correlated to pathology (16). An association was found between individual surface 
pits and crypts when pit patterns were examined in-vivo with magnifying 
colonoscopy(x60). The lesions were then resected, stained with haematoxylin and 
examined using stereo microscopy (x60). The following observations were made on 
the properties of the surface pits seen with magnifying colonoscopy (x 60): 
 
1) Normal round pit: The crypts were all straight and non-branching. The cells 
looked histopathologically normal. These were diagnosed as normal (100%). 
2) Small asteroid pits: The crypts were all straight and non-branching. 
Histopathologically, the cells showed slight swelling but no atypia. These 
glands were diagnosed as hyperplastic (100%).  
3) Large asteroid pits: Branching crypts. This occurred repeatedly, becoming 
smaller each time. Histopathologically, the cells were slightly swollen and 
mildly atypical. These crypts were diagnosed as hyperplastic or as serrated 
adenoma.  
4) Small round pits: The crypts were all straight and nonbranching. 
Histopathologically the cells showed borderline malignant or carcinomatous 
change. These crypts were diagnosed as borderline malignant (72%) or 
adenocarcinoma (28%). It was noted that macroscopically this pattern was 
seen most often in depressed lesions.  
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5) Oval pit: These crypts were all branching repeatedly with several round 
crypts. Histopathologically, the cells looked moderately atypical, and these 
glands were diagnosed as adenoma (100%).  
6) Gyrus-like pit: The giant crypts were all branching repeatedly with several 
round or oval shaped crypts. Histopathologically, the cells were moderately 
atypical, and again these crypts were diagnosed as adenoma. (100%), and 
were found in almost all the tubulovillous adenomas.  
7) Non-pit: Non-structural glands. Histopathology these glands were diagnosed 
as adenocarcinoma (100%) which had invaded the submucosal or deeper 
layers.  
 
The patterns were classified into categories: 
Type I: normal round pit  
Type II: small and large asteroid pits 
Type IIIs: small round pit 
Type IIIL: oval pit 
Type IV: gyrus-like pit 
Type V: non-pit pattern  
 
This became known as Kudo's classification and macroscopically they were seen on 
both protruding and depressed lesions. The findings were highly significant (16) and 
this has formed the basis for all future work into in-vivo diagnostic techniques. See 
Figure 1. 
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Figure 1: Diagrammatic representation of Kudo pit patterns (Reproduced from Kudo et al 1994 (16)) 
 
 
Professor Kudo continued the work by using magnifying endoscopes and crystal 
violet to observe and predict the histology of colonic lesions in vivo (17). The 
pathway he used for examination is shown in figure 2. 
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Figure 2: Flow chart for examination of polyps with cresyl violet (Reproduced from Kudo et al 1996 (17)) 
 
In total 2050 lesions were examined and the correlation of pit pattern to pathology is 
shown below. The authors concluded that there was an association between pit 
pattern and underlying histology, and that an in-vivo diagnosis could be made. Cresyl 
violet (0.2%) staining was used because it actually stains the margins of the pits, 
providing a clear definition of the pattern, which unlike indigo carmine is merely 
retained in the pit orifices. See table 1. 
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Pit pattern with magnifying electric videoscope  
 —————————————————————————————————— Total 
 1, 2 3S 3L 4 5  
Histopathologic 
diagnosis 
      
Adenoma 46 29 1145 150 11 1381 
Villous 
adenoma 
0 0 17 47 0 64 
Cancer 0 3 71 72 22 168 
Total 46 32 1233 269 33 1613 
Table 1: Breakdown of pit pattern by true histology (Reproduced from Kudo et al 1996 (17)) 
 
Overall it was felt that neoplastic lesions could be differentiated from non-neoplastic 
lesions with an accuracy of 81.5%. Subsequent studies showed this to be an 
underestimate of the accuracy which could in practice be obtained, and sensitivities 
of up to 98% have since been reported, which will be discussed later. It should be 
noted that a IIIs pattern was shown to represent adenoma in the majority of cases 
rather than cancer. This has been repeatedly shown in all of the subsequent studies.  
 
Kudo pit pattern analysis has been accepted as the gold standard method for the 
examination of colonic neoplasia. However, it poses a number of problems. Vital 
stains such as crystal violet are inconvenient to use. They have to be dripped onto 
the surface of the lesion and allowed to fix for several minutes, followed by adequate 
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washing prior to evaluation. This can be very time consuming. Furthermore, there 
are concerns surrounding DNA toxicity (18). For this reason it is generally accepted 
that vital stains are not practical for daily use outside of Japan or a research setting. 
This led to a search for alternative dyes.  
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2.3: Indigo carmine 
Whilst crystal violet is a vital stain, indigo carmine is a blue dye which does not bond 
to or react with human tissue in any way. It simply sits on the surface of tissues, 
highlighting surface patterns. For this reason it is a very safe dye. Furthermore, it is 
easier to use than crystal violet as the results are instant. As it does not bind to 
tissues, excess dye can be sucked away if necessary. 
Chromoendoscopy can be used for two purposes; to find polyps or to characterise 
neoplasia A Cochrane meta-analysis of clinical trials has concluded that 
chromoendoscopy with indigocarmine enhances the detection of neoplastic polyps 
(19).  
The initial work with indigo carmine for in-vivo diagnosis was conducted in Japan by 
Kato et al. who retrospectively analysed 4445 lesions using magnifying endoscopy 
with indigo carmine dye spray. All of the lesions were less than 5mm in size. Lesions 
were assessed in vivo and correlated with histopathological analysis using a similar 
methodology to that employed by Kudo et al in the previously described study. The 
findings suggested that the diagnostic accuracy for hyperplastic polyps with a type I 
or II pattern was 75%, adenomas with a type III or IV pattern 94% and invasive 
cancer with a type V pattern in 85% of cases (20). The sensitivities and specificities 
are shown in table 2.  
 
 Hyperplastic Adenoma Cancer 
Sensitivity 42% 98% 82% 
Specificity 99% 52% 99% 
Table 2: Accuracy of indigo carmine by lesion type 
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The results here show marked difference between the sensitivity and specificity. This 
data suggests that high sensitivity was achieved by compromising the specificity 
resulting in a large proportion of hyperplastic polyps being overcalled as adenomas. 
Furthermore, the data was dependent on 100x magnification with a zoom 
endoscope. 
Further work was conducted in Japan into indigo carmine (21) which investigated the 
differences between chromoendoscopy with and without magnification in the 
examination of small (<10mm) polyps. The results were encouraging, with a 
sensitivity for neoplasia of 93.1% and specificity of 76.1% being achieved. However, 
there was an improvement with magnification. This suggested that in appropriately 
skilled hands, in-vivo diagnosis was possible without the need for magnification 
endoscopy or vital stains See table 3. 
 
Table 3 Accuracy Sensitivity Specificity 
Conventional endoscopy 84% 88.8% 67.4% 
Chromoendoscopy without 
magnification 
89.3% 93.1% 76.1% 
Chromoendoscopy with 
magnification 
95.6% 96.3% 93.5% 
Table 3: comparison of accuracy of in-vivo diagnosis with white light and indigo carmine with and without optical 
magnification 
There were further studies looking at magnification endoscopy with indigo carmine 
for in-vivo histology prediction which showed similar results. (22) (23) (24) 
There has been some work done outside of Japan using magnifying 
chromoendoscopy with indigo carmine. Tischendorf et al in Germany conducted a 
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prospective cohort study of neoplastic vs non neoplastic polyps using both narrow 
band imaging and indigo carmine with zoom endoscopy. A sensitivity of 91.7% and 
specificity of 90% was achieved for indigo carmine using Kudo pit pattern analysis 
(25). A large study from the Weisbaden group in Germany compared indigocarmine 
and the electronic imaging modality FICE in the assessment of polyps <10mm. The 
primary aims of this study were lesion detection, with the intention of evaluating FICE 
for this purpose. However a sub-group of 280 lesions were assessed using 
indigocarmine for histology prediction. A sensitivity for neoplasia of 87.6% and 
specificity of 62.0% was achieved (26). High definition endoscopes were used 
without optical magnification. There was a further German study by a different group 
examining indigocarmine chromoendoscopy using high resolution endoscopes. This 
study investigated 273 lesions <5mm, with a sensitivity of 94%, specificity of 64% 
and accuracy of 83% (27). This study differed from the other studies described in 
that it only examined rectosigmoid polyps. Therefore the results could not be applied 
to right sided lesions. An American study showed similar results using standard 
resolution (410,000 pixel) endoscopy with indigo carmine, where 500 polyps <10mm 
in size found anywhere in the colon were evaluated, achieving a sensitivity of 82% 
and specificity of 82% (28). A limitation of this study was that it was a multi-centre 
multi-endoscopist study where most of the investigators were not equally 
experienced in in-vivo diagnosis. Training was via a videotape of 30 test cases with a 
separate answer sheet for the endoscopist to review prior to starting the study. This 
was not a validated training regimen and therefore this study may be 
underestimating the potential for indigocarmine as a diagnostic tool.  
There was a prospective Italian cohort study examining 240 polyps <5mm 
withmagnifying chromoendoscopy. This study reported an accuracy of 95.4%, a 
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sensitivity of 97.5% and specificity of 94.3%.These results were better than those 
seen in most of the other series (29). 
There was a United Kingdom cohort study where 1008 flat lesions of any size were 
examined using zoom endoscopy and indigocarmine. A sensitivity for neoplasia of 
98% and specificity of 92% was achieved. However, it should be noted that the 
endoscopist was permitted to use crystal violet when the pit patterns could not be 
adequately visualised with indigo carmine. Therefore this should be regarded as an 
in-vivo diagnosis study rather than a specific evaluation of indigo-carmine (30). 
Furthermore, the authors found it difficult to differentiate non invasive from invasive 
lesions, with a sensitivity of 50% and specificity of 98%. 
The strength of all of these studies is that all of the assessments were made by 
Western endoscopists, suggesting that the findings seen in the Japanese papers 
could be translated to Western practice. All but one of the studies were single centre, 
single endoscopist experiences. 
A notable point that can be observed in most of the described studies is that there is 
a trade off between adenoma sensitivity and specificity. Many of the studies with the 
highest sensitivity have a low specificity, typically between 60-70%. Whilst this is 
probably the safest approach to in-vivo diagnosis, it is not ideal. The ultimate goal for 
diminuitive polyps would be to have the ability to confidently leave small hyperplastic 
polyps, reducing the risks posed by polypectomy. To achieve this, the sensitivity and 
specificity both need to be very high. 
All of the studies described so far have required magnifying zoom endoscopes. 
These are summarised in table 4. A problem with this strategy is that this is not 
standard practice in the west. Magnifying endoscopes are larger and more difficult to 
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manoeuvre. They also have a narrower field of view. Furthermore, magnified 
assessment of lesions is time consuming. In the west, endoscopy lists are 
traditionally busy, making time constraints an unavoidable issue. This has 
discouraged many people from seriously considering in-vivo histology prediction as a 
realistic option. 
Author Country Journal Year Size Dye No polyps Sensitivity Specificity Accuracy 
Axelrad  USA Endoscopy 
 
1996 <10mm Indigo 
carmine 
410,000 CCD 
24 93% 95% NR 
Togashi Japan Dis Colon Rectum 1999 All size Ingigo 
carmine 
923 92% 73.3% 88.4% 
Kato Japan Endoscopy 2001 <5mm 
excluded 
No max 
size 
Indigo 
carmine 
4445 94% 75% NR 
Tung Taiwan Am J Gastro 2002 <10mm Indigo 
carmine 
175 93.8.% 64.6% 80.1% 
Fu Japan Endoscopy 2003 <10mm Indigo 
carmine 
206 96.3% 93.5% 95.6% 
Konishi Japan Gastrointestinal 
endoscopy 
2003 <10mm Indigo 
carmine 
405 97% 100% 93% 
 
Su Taiwan Dig Dis Sci 2004 <10mm Indigo 
carmine 
270 95.1% 86.8% 91.9% 
Hurlstone UK Gut 2004 Any size Indigo 
carmine and 
crystal violet 
1008 98% 92% NR 
Palma Italy World J 
Gastroenterology 
 
2006 <5mm Indigo 
carmine 
240 97.5% 94.3% 95.4% 
Sonwalker UK with 
Japan 
Endoscopy 
 
2007 Any size Indigo 
carmine 
709 
(513<10mm) 
91% 87% 90% 
Tiscendorf Germany Endoscopy 2007 Any size Indigo 
carmine 
200 (100 
with IC) 
91.7% 90% NR 
Ince Turkey Hepatogastroenterology 2007 Any size Indigo 
carmine 
 80% 89% 87% 
Pohl Germany American Journal of 
Gastroenterolog 
2008 <20mm Indigo 
carmine 
(picture) 
150 95.5% 73.8% 87.7% 
Togashi Japan Gastrointestinal 
endoscopy 
2009 <5mm Indigo 
carmine 
107 90% 74% 86% 
Table 4: Summary of publications stating accuracy, sensitivity and specificity of chromoendoscopy with optical 
magnification (NR=not reported). 
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Indigo carmine without optical magnification 
There has been a lack of studies published into the use of non magnifying 
endoscopes for in vivo histology prediction using indigo carmine. Whilst this may 
sound like a small difference in practice it is critical. Examining polyps with a 
magnifying endoscope allows up to 120x optical magnification. This enables tiny 
details on the surface of lesions to be seen in great detail. In the west, there has 
been so little experience with endoscopes offering optical magnification that in-vivo 
diagnosis has been dismissed by many as either impossible, or a Japanese fairy tale 
that cannot be used in the West. 
 
The first study comparing optical magnification versus standard non magnification for 
making an in-vivo diagnosis was from Japan. (31). It looked at 660 patients, who 
were allocated into two groups of 330 patients each. Polyps <10mm were included, 
with 812 lesions in total. The results were disappointing for the non-magnifying limb, 
with an accuracy of 68% for non zoom assessment compared to 92% using zoom 
endoscopes. However there was a subsequent UK study looking at indigo carmine 
with non magnifying endoscopes (32). This prospective study looked at 709 colonic 
polyps of any size. A sensitivity of 91% and a specificity of 82% was achieved. A sub 
group analysis of lesions <10mm was performed which found that size made very 
little difference to the diagnostic accuracy, with a sensitivity for neoplasia of 91% and 
specificity of 87% when examining small polyps. However, there are a number of 
important issues surrounding this study. Although it was conducted in the United 
Kingdom and the procedures were performed by a UK trained endoscopist, the 
lesion assessments were all carried out by a visiting Japanese expert. Therefore, 
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although it was of value to demonstrate that such assessments could be performed 
in a western setting, and that an in-vivo assessment may be possible without 
magnifying zoom endoscopy, it should be recognised that the assessments were not 
by western trained clinicians. As such it should be seen as a Western Japanese 
collaboration, and therefore it is difficult to be confident that the results could be 
directly applied to Western practice. A summary of the studies conducted on small 
polyps<10mm where magnification has not been used are shown in table 5. 
Currently only six studies have been published investigating this question, with 
variable results. It is therefore an area where further research is needed. A potential 
problem is that all of the studies have attempted to assess the polyps using Kudo pit 
patterns. It is important to understand that this system was designed for use with 
optical magnification. As described previously, this allows very subtle changes to be 
visualised. Whilst there certainly are elements of the Kudo patterns which can be 
seen without magnification, it is poorly understood what the subtle differences are. 
Therefore misclassification is inevitable in some cases.  
 
If a technique is to be applied in a wider sense it is critical that the assessment tool is 
robust and that it can be universally applied without need for modification by the 
individual using it. 
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Author Country Journal Year Size Dye No 
polyps 
Sensitivity Specificity Accuracy 
Axelrad 
0AM 
USA Endoscopy 1996 <10mm Indigo 
carmine 
410,000 
CCD 
24 93% 95% NR 
Eisem USA Gastrointestinal 
Endoscopy 
2002 <10mm Indigo 
carmine 
520 82% 82% 82% 
Fu Japan Endoscopy 2003 <10mm Indigo 
carmine 
206 96.3% 93.5% 95.6% 
Konishi Japan Gastrointestinal 
endoscopy 
2003 <10mm Indigo 
carmine 
405 97% 
86% 
100% 
61% 
68% 
93% 
Apel Germany Gastrointestinal 
endoscopy 
2006 <5mm Indigo 
carmine 
273 94% 64% 83% 
Pohl Germany Gut 2009 <10mm Indigo 
carmine 
280 87.6% 62.0% NR 
Table 5: Summary of publications stating accuracy, sensitivity and specificity of chromoendoscopy with indigo carmine 
on polyps<10mm without optical magnification (NR=not reported) 
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2.4: Methylene blue 
To date there has been very little published on methylene blue in the evaluation of 
polyps in the colon for in-vivo diagnosis. Unlike indigo carmine, methylene blue is a 
vital stain which is taken up into cells. Dysplastic epithelium takes up this dye less 
readily than normal gastrointestinal epithelium. There is a theoretical risk of DNA 
toxicity (33). As such there has only been one study published investigating its use in 
both lesion detection and in-vivo diagnosis in the last 30cm of the colon. The results 
were very good, claiming 100% accuracy (34). However, this study was 
predominately interested in evaluating i-scan, and more studies are needed to 
confirm whether these results can be repeated in a different setting. 
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2.5: Acetic acid 
Acetic acid is a vital stain which leads to reversible acetylation of nuclear proteins. 
This leads to vascular congestion which improves the visualisation of surface 
patterns and the vasculature. It also acts as a very effective mucolytic. Despite this 
there have been very few publications on its use in the evaluation of colonic polyps. 
A small Australian study, in collaboration with a Japanese expert, prospectively 
evaluated 73 polyps <10mm with both acetic acid and acetic acid followed by indigo 
carmine (35). Magnifying zoom endoscopes were used. The results were 
encouraging, with an accuracy of 96%, sensitivity of 95% and specificity of 95% with 
acetic acid alone. When indigo carmine was subsequently added the accuracy rose 
to 98%, with a sensitivity of 100% and specificity of 97%. The authors postulated that 
this was because of both the mucolytic effect and the aceto-whitening reaction 
accentuating the pit pattern. It is important to note that the study was very small. 
There has been a further study conducted (36). However, it was even smaller, with 
just 54 polyps examined. It was based on pictures shown to 16 different assessors (6 
gastroenterologists, 5 residents and 5 medical students) none of whom had prior 
experience in pit pattern interpretation. Perhaps, rather unsurprisingly, the results 
were poor, with a reported accuracy of 62.4%, sensitivity of 81.8% and specificity of 
41.2%.See table 6. 
Author Country Journal Date Dye Zoom No 
polyps 
Sensitivity Specificity Accuracy 
Togashi Australia Endoscopy 2005 Acetic 
acid  
Zoom 73 95% 95% 96% 
Hwan 
Kim 
Korea World Journal 
Gastroenterology 
2008 Acetic 
acid 
Zoom 54 81.8% 41.2% 62.4% 
Table 6: Comparison of studies using acetic acid chromoendoscopy 
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2.6: Vascular enhancement techniques and electronic imaging 
 
As chromoendoscopy became established as a standard of care, endoscope 
manufacturers started looking into ways of improving the endoscopes to simulate 
such techniques without the need for dyes. A criticism of chromoendoscopy by some 
endoscopists has been that it is messy and time consuming. Furthermore, it 
physically colours the mucosa, requiring extensive washing if the endoscopist 
decides that he or she wants an unstained view. There was therefore a desire for a 
push button technology to create a ‘virtual chromoendoscopy’. 
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2.7 :Narrow band imaging 
The first commercially available system came from Olympus, known as narrow band 
imaging (NBI). The concept of NBI was designed to improve the visualisation of 
mucosal surface patterns. It is bound on the principle of variable penetration of light 
depending on its wavelength. Red light penetrates deep into the submucosa but 
doesn’t help with surface pattern assessment. When blue and green light is at a 
wavelength range of 415-540nm it does not penetrate deep but enhances mucosal 
surface patterns. Blue light displays superficial capillary networks whilst green light 
highlights subepithelial vessels. The result is a high contrast image which makes the 
interpretation of surface vascular patterns possible. NBI uses a physical filter to block 
red light and to narrow the bandwidth of the blue and green light, hence improving 
visualisation of surface patterns. 
 
A lot of the early studies into narrow band imaging centred around lesion detection. 
Early studies suggested that there was some improvement (37) (38). This was not 
however repeated in later investigations (39) (40) (41) (38). The overall conclusions 
were that the gains seen in the preliminary studies were largely due to inexperienced 
endoscopists, still on a steep section of the polyp detection learning curve improving 
their polyp detection skills by using the technique, whereas when used by experts, 
who already had high adenoma detection rates, there was no gain (40).  
 
There have been numerous publications investigating the potential for In vivo 
histology prediction using narrow band imaging (42) (43) (44) (45) (46) (47) (38) (48) 
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(49). Similar results have been achieved to those seen with indigocarmine. There 
have been several publications which have concentrated on non-magnifying 
endoscopes, the most notable being the DISCARD study from St. Marks hospital. It 
should be noted however that this was predominately a study of in-vivo diagnosis, 
and the use of indigocarmine was allowed. Whilst the authors argued that this was 
only needed in a minority of cases, it is difficult from the study to ascertain the 
efficacy of NBI on its own. Another study compared the accuracy of NBI with and 
without magnification (50). This showed no statistically significant difference with or 
without magnification. However, the polyps were not assessed in-vivo. Pictures were 
taken and then reviewed after the procedure by two endoscopists. Therefore the 
results have to be interpreted with caution. 
The surface patterns seen with NBI are similar but not identical to Kudo’s pit patterns 
(as previously described). NBI enhances vessels around the pits, whereas Kudo’s 
patterns are the actual pattern of distribution of pits on the surface of the polyp. It has 
been commented that in practice these are very similar to pit patterns. However, it 
has led to the development of new classification systems specifically for NBI, based 
around meshed capillary vessels (51) (52) and vascular pattern intensity, which have 
been validated against Kudo pit pattern analysis (53). To visualise capillary patterns 
it is necessary to have optical magnification and both of these classification systems 
were validated using HD magnifying endoscopes. In practice however, these 
classification systems have been applied both with and without optical magnification.  
See Figures 3 and 4. 
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Figure 3: Sessile 3mm tubular adenoma showing the Kudo type III pit pattern and strong vascular pattern intensity 
 
 
                                     
Figure 4: 3mm hyperplastic polyp showing the kudo type II pit pattern and weak vascular pattern intensity 
 
Unlike the studies into indigocarmine dye spray, where Japanese research 
predominates, the work into NBI have come from a larger range of countries.This 
perhaps reflects the reluctance of western endoscopists to embrace dye spray. It 
should be noted however that the largest NBI study (1473 polyps) comes from Japan 
(48). See table 7. 
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Of all of the vascular enhancement techniques the biggest evidence base exists for 
NBI. Furthermore it is a tool where classification systems and assessment 
techniques have been developed specifically for use with it. Unlike all of the other 
vascular enhancement techniques data has been produced from more than one 
centre, suggesting that the techniques are reproducible in expert hands. 
Unfortunately all of the data has been produced using high definition equipment and 
it is necessary to assume, at present, that this is a prerequisite for in-vivo diagnosis. 
This may however not actually be the case and a study is justified to review the 
requirement for high definition equipment. As most studies have come from expert 
tertiary referral centres, it is important to explore how applicable these findings are to 
a wider group of endoscopists by performing multicentre studies.  
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Author Country Journal Year Modality Endoscope No Sensitivity Specificity Accuracy 
Machida Japan Endosc 2004 NBI Zoom 43 100% 75% NR 
Chiu Taiwan Gut 2007 NBI 
(pictures) 
Zoom 
non zoom 
180 82-86% 
87-95% 
59-83% 
71-88% 
81-82% 
87-90% 
Rastogi USA GIE 2008 NBI HD (38) 123 86-92% 86-92% NR 
Sikka USA Endosc 2008 NBI HD without 
magnificatio
n 
80 95% 90% NR 
Rogart USA GIE 2008 NBI Zoom 265 80% 81% 80% 
East UK Endosc 2008 NBI HD+zoom 116 88% 91% 89.6% 
Ragstog
i 
USA Am J 
Gastro 
2009 NBI  HD without 
magnificatio
n 
236 
all 
size 
96% NR 93% 
Ignjatovi
c 
UK Lancet 
Onc 
2009 NBI with 
IC 
HD 278 94% 89% 93% 
Sano Japan GIE 2009 NBI HD+zoom 150 96.4% 92.3% 95.3% 
Wada Japan GIE 2009 NBI 
(pictures) 
HD+zoom 617 90.9% 97.1% NR 
Henry USA GIE 2010 NBI 
(retrospect
ive 
pictures) 
Uncertain 126 93% 88% 91% 
Wada Japan Dig 
Endosc 
2010 NBI Uncertain 147
3 
88.9% 98.9% 98.2% 
Wang USA GIE 1999 AFI Prototype 
system 
18 83% 100% NR 
Tischen
dorf 
German
y 
Endosc 2010 NBI 
(pictures) 
HD with and 
without 
zoom 
200 87.9% 
92.1% 
90.5% 
89.2% 
NR 
Buchner USA GIE 2010 NBI HD non 
zoom 
41 84% 75% 80.5% 
Eker Sweden Gut 1999 AFI Prototype  46 100% 96% NR 
Mccallu
m 
UK GIE 2008 AFI Prototype 
system 
75 85% 81% NR 
Van 
Den 
Broek 
The 
Netherla
nds 
Clinical 
Gastro 
and 
Hepat 
2009 Trimodal 
imaging 
HD + zoom 208 99% 35% 63% 
Table 7: Accuracy, sensitivity and specificity for narrow band imaging (NBI), auto fluorescence imaging (AFI) and trimodal 
imaging. IC= indigo carmine, HD= high definition NR= not reported 
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2.8: Flexible spectral imaging colour enhancement (FICE) 
After the introduction of narrow band imaging by Olympus other endoscope 
manufactures followed suit with their own systems for vascular enhancement. Unlike 
NBI, which utilises a physical filter, FICE is a post processor technology which 
captures spectral reflectance by a colour CCD video endoscope. This is sent to a 
spectral estimation matrix processing circuit contained in the video processor. The 
reflectance spectra of corresponding pixels that make up the conventional image are 
mathematically estimated. From these spectra, it is feasible to reconstruct a virtual 
image of a single wavelength. Three such single-wavelength images can be selected 
and assigned to the red, green, and blue monitor inputs, respectively, to display a 
composite colour-enhanced multi band image in real time. In practice this can be 
used like narrow band imaging to remove data from the red part of the waveband 
and narrow the green and blue spectra. However, the system is flexible. It has 10 pre 
set digital filter settings with the ability to program more. See table 8.  
FICE: pre set bandwidths (nm) 
Preset 0 1 2 3 4 5 6 7 8 9 
R 500 500 550 540 520 500 580 520 540 550 
G 445 470 500 490 500 480 520 450 415 500 
B 415 420 470 420 405 420 460 400 415 400 
Table 8: FICE pre set bandwidths (nm) 
Whilst FICE is a technically more complex technology than NBI, and therefore 
potentially more flexible, this can prove offputting to clinicians who can find the 
multitude of different settings confusing. This has not been helped by the relatively 
small amount of research conducted into the system. 
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The largest study into the in-vivo histology prediction of colonic polyps comes from 
the Weisbaden Group in Germany. They conducted a prospective study of 150 
polyps <2cm and compared to indigocarmine dye spray with low (50x) and high 
(100x) magnification using high resolution endoscopes (650,000 pixel CCD). The 
study was performed by taking static pictures of each polyp and reviewing them by 3 
different readers after the procedure (54).  They found that an accuracy of 83% and 
90%, sensitivity of 89.9% and 96.6% and specificity of 73.8% and 80.3% could be 
achieved with low and high magnification, respectively. The results were essentially 
the same with Indigo carmine with no statistically significant difference observed 
between the two modalities. There are some important criticisms to note about this 
study. As it is based on static images it is unclear whether the results are directly 
transferrable to in-vivo diagnosis on a busy list. Furthermore, as lesions over 1cm 
were allowed, it is unclear whether these results could be achieved with smaller 
diminuitive polyps which are arguably harder to assess. Furthermore, no attempt 
was made to assess lesions without any magnification and only high definition 
(650,000 pixel CCD) endoscopes were used. Given that in most of the units around 
the world which use Fujnon equipment, 410,000 pixel standard definition scopes are 
the norm and this is an important consideration. Many people who have used FICE 
comment that the image quality is very poor and that is mostly due to the limitations 
of the SD endoscope and not due to FICE. 
The same team went on to conduct a further prospective randomised study with the 
primary aim to investigate the impact of FICE on adenoma detection rates (ADR) 
(26). Again high definition endoscopes were used but the optical magnification 
function was not utilised. It showed that FICE did not improve ADR. FICE and indigo 
carmine were both able to differentiate adenomas from hyperplastic polyps<10mm in 
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size. There was a sensitivity of 93% and specificity of 61.2% in differentiating 
adenomas from hyperplastic polyps with FICE, comparable but not superior to that of 
indigocarmine (90.4%), with no statistically significant difference between the two 
techniques observed (p=0.44).  Again it can be seen that specificity has been 
sacrificed to achieve an adequate sensitivity. Whilst safe, this approach does limit 
the cost benefit position of in-vivo diagnosis, with an overall accuracy of 84.7%. 
There are further problems with the methodology of this study. The authors did not 
develop a specific tool for assessing polyps with FICE, instead relied on Kudo’s pit 
patterns which are not validated for FICE. It is generally accepted that pit patterns 
are not well visualised with any form of optical enhancement. Therefore although the 
results of the study are encouraging they may not represent what can truly be 
achieved with the technology. Furthermore, it is important to recognise that the 
primary end point of the study was not lesion differentiation, but lesion detection. 
Therefore whilst this study is a step towards understanding FICE, it should be seen 
more as a proof of concept than a final definitive answer. 
There has been a Japanese study looking at histology prediction using FICE. This 
study was quite small, looking at 107 polyps <5mm in size and utilised optical 
magnification with high definition scopes. With high magnification (100x) a sensitivity 
of 93% specificity of 70% and accuracy of 87% was achieved. There was a small 
drop in accuracy with low (50x) magnification (87%) (23).  This was an in-vivo study 
and is essentially supportive of the results from the Weisbaden group. Again it does 
not answer the question of whether similar results are achievable with standard 
definition or non-magnifying endoscopes. Again Kudo’s patterns were used for the 
assessments and the study was also quite small and performed by Japanese 
experts.  
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Not all studies support these findings. There was a recent study in which five 
endoscopists assessed 144 pictures of 19 polyps to establish the diagnostic 
accuracy of WLI, FICE and indigo carmine in making a histology prediction for 
diminuitive polyps <10mm in size. The results were disappointing, with a mean 
diagnostic accuracy for WLI of 57%, FICE without zoom of 58.9% and IC without 
zoom of 70.5% (55). It should be noted that the methodology of this study could be 
criticised in many ways. The number of lesions was extremely small and it was 
picture based. Furthermore, It is unclear how experienced the endoscopists were in 
making an in-vivo diagnosis. They achieved similar (poor) results with indigocarmine 
which is out of keeping with previous studies. Furthermore, the Sano classification 
was used to assess the lesions with FICE. This is a system designed for Narrow 
band imaging (51). Practically, the appearances are different with FICE to NBI, and 
the Sano classification has never been validated for use with FICE. It is therefore 
hard to say that this study is a true reflection of what can actually be achieved with 
FICE. 
 
Similar to narrow band imaging, FICE enhances vascular patterns. As a result it is 
not possible to directly describe Kudo’s pit patterns. Unfortunately there is no widely 
adopted classification system which can be used with FICE. A study from Brazil has 
described a surface pattern system which is not dissimilar to Kudo pit pattern 
classification but describing vascular patterns seen with FICE (56). The study 
enrolled 309 lesions ranging in size from 1-50mm, with 242 lesions <5mm in size. 
Again only high definition endoscopes were used and no attempt to examine without 
magnification was made. The authors commented that they felt optical magnification 
was essential for analysis of vascular patterns. An accuracy of 98.3% sensitivity of 
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99.2% and specificity of 94.9% was achieved. The advantage of including larger 
lesions was that 22 cases of colorectal cancer could be examined, enabling a 
classification system to be validated. However, it does mean that the very high 
sensitivity and specificity cannot be directly compared to the other studies looking at 
much smaller lesions. The authors did not attempt to analyse accuracy on the basis 
of lesion size. 
There has been a study which has compared confocal endomicroscopy, narrow 
band imaging and FICE against each other. (57) This reported a sensitivity of 73% 
and specificity of 68% for FICE, sensitivity of 84% and specificity of 75% for NBI and 
a sensitivity of 91% and specificity of 76% for probe based confocal 
endomicroscopy. Optical high definition scopes were used but optical zoom was not. 
Because the number of polyps in either the NBI (41) or FICE (78) assessments was 
small the confidence intervals were very wide. The results for NBI were worse than 
other studies have reported. The FICE results were also much lower than expected 
but confocal was surprisingly much better than anticipated. 
FICE has been examined for the detection of colorectal neoplasia. As with narrow 
band imaging, results have been disappointing, with several randomised controlled 
trials showing no improvement in lesion detection (58) (59) (26).  
Subjectively many endoscopists are confused with FICE. Literature is sparse, with 
most of the studies being either small, picture based assessments, or assessing 
large lesions (which are arguably easy to call). Due to the complexity of the system 
many have been left confused regarding the application and practical usefulness of 
the various FICE settings.  
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FICE is a technology which shows promise in in-vivo histology prediction. Whilst 
early results are encouraging published literature remains sparse and has come from 
only three groups using high definition magnifying endoscopes, so its widespread 
use and application remains questionable. There is also a lack of validated tools for 
use with FICE and it is unclear which setting is optimal for the examination of colonic 
lesions.  Further work is required to determine whether the experiences of the 
Weisbaden Group can be repeated in other centres, whether the technique is viable 
using standard definition scopes and whether optical magnification is required. 
Although the negative studies are either picture based or are a sub-group analysis of 
a study into another technology, they should not be dismissed. It could not at present 
be recommended as a replacement to histological analysis and the evidence base is 
not strong enough to call for a multi-centre study of reproducibility until it is 
established whether in-vivo diagnosis is possible at all using this system.  See table 
9 for a summary of the studies.  
Author Country Journal Year Modality Endoscope No Sensitivity Specificity Accuracy 
Pohl German Am J 
Gastro 
2008 FICE 
(picture) 
HD low and 
high 
magnificatio
n<20mm 
150 89.9% 
 
96.6% 
73.8% 
 
80.3% 
83% 
 
90% 
Pohl German Gut 2009 FICE 
(subgroup 
analysis) 
HD non 
zoom<10m
m 
321 
<10
mm 
93% 61.2% 84.7% 
Togashi Japan GIE 2009 FICE HD low 
(50x) and 
high  (100x) 
magnificatio
n<5mm  
107 93% 70% 87% 
Teixiera Brazil GIE 2009 FICE HD with 
zoom polyps 
up to 50mm 
309  99.2% 94.9% 98.3% 
Parra-
Blanco 
Spain World 
Journal  
Gastro 
2009 FICE 
(picture) 
HD with and 
without 
zoom<5mm 
(picture) 
19  NR NR 58.9% 
 
70.5% 
Buchner USA Gastro-
enterolo
gy 
2010 FICE 
(sub-group 
analysis) 
HD non 
zoom any 
size 
78 73% 68% 72% 
Table 9: Summary of papers published using FICE for in-vivo diagnosis. NR=not reported 
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2.9: i-scan 
The most recent introduction to vascular enhancement has come from Pentax. In 
many ways i-scan is a similar technology to FICE. It is a post processor 
reconstruction from spectral reflectance data. At present high definition 1.3 million 
pixel CCD endoscopes are available which have been marketed for use with this 
system. However, these are not equipped with optical magnification.   
 
Early studies using i-scan have suggested that increased lesion detection can be 
achieved using the surface pattern enhancement setting (60). This study is 
surprising given the opposite findings with NBI and FICE. These results could be 
explained by the endoscopist improving during the course of the study and it is 
unclear whether these same benefits would be seen by a larger cohort of 
experienced endoscopists. The study also made an in-vivo histology prediction on 
145 polyps <10mm with a sensitivity of 98%, specificity of 100% and accuracy of 
98.6%, using Kudo pit patterns. There has been a further study by the same group 
which claims that i-scan can identify more small lesions than white light. Again this 
study also looked at in-vivo diagnosis, claiming 100% accuracy for both 
chromoendoscopy and methylene blue in the examination of the last 30cm of the 
colon (34). However, there is a lack of research into this technique. Again, although 
the technique enhances vascular structures, the image is very different to that 
achieved with NBI or FICE. Therefore it would be incorrect to assume that the results 
seen with these techniques are transferrable. Further research is needed urgently 
with this technology. 
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2.10: Confocal endomicroscopy 
All of the techniques so far described have revolved around enhancement of either 
surface patterns or surface details. Confocal microscopy attempts to go a stage 
further and provide the endoscopist with a dynamic microscopic image during 
endoscopy. A low powered laser is focused onto the tissues and the lens used to 
focus the beam is both the condenser and objective folding optical path. As a result, 
the illuminated point coincides with the point of deflection within the specimen. Light 
emanating from this point is focused onto a detector, with light from outside of the 
illuminated point rejected. The term ‘confocal’ is derived from the illumination and 
detection systems existing in the same focal plane. The image is created by 
measuring light from successive points by scanning in a raster pattern. The result is 
a greyscale cross section of the specimen. Planes at multiple depths can be 
obtained, up to a maximum depth of 250 µm (61). 
 There are currently two manufacturers of CE marked confocal microscopes for use 
in the gastrointestinal tract. Pentax have a dedicated endoscope with a confocal 
microscope built into the tip (EC3870CIKF). This utilises an argon laser delivering an 
excitation wavelength of 488nm at a power output of <1 mW. It can capture at up to 
1.6 frames/second at 1024x1024 pixels. Slice thickness is 0.7µm with a 475x475µm 
field of view. The endoscope also provides a conventional view, enabling standard 
white light endoscopy to be performed until a lesion requiring examination is found. 
Focal distance can be adjusted in real time from the controls of the endoscope. 
Cellvizio have created a probe based system. This system consists of a small 2.5mm 
probe which is passed down the biopsy channel in a standard endoscope. This has a 
field of view of 600x500 µm at 12 frames per second. Both of the systems require 
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intravenous administration of  an enhancement marker, fluorescein dextran (10% 
w/v) to enhance the image.  
A study of 115 polyps using the Pentax endomicroscope reported a sensitivity 
90.3%, specificity 95.7% and accuracy 93.9% for polyps <10mm in size. For polyps 
>10mm a sensitivity of 97.3%, specificity of 100% and accuracy 97.3% was reported 
(62). A study performed in the United Kingdom on 162 lesions showed similar 
results, with a sensitivity of 97.4%, specificity of 99.3% and overall accuracy of 
99.1% (63). A very small study using the Cellvizio miniprobe looked at 36 colorectal 
lesions and reported an accuracy of 91.7%, sensitivity of 92.3% and specificity of 
91.3% (64). A further small study of 32 lesions using the miniprobe reported a 
sensitivity of 100%, specificity of 84.6% and accuracy of 92.3%. A much larger study 
compared miniprobe confocal endomicroscopy against NBI and FICE, reporting a 
sensitivity of 91% (57) and specificity of 76%. It claimed that the results 
demonstrated a statistically significant benefit from the probe based confocal 
endomicroscope over NBI or FICE. However, the results seen with vascular 
enhancement were unimpressive and out of keeping with previous NBI studies. 
Furthermore, although the results with vascular enhancement were analysed 
separately for NBI and FICE, it is quite difficult to comment whether the differences 
between these two different vascular techniques are significant, as the numbers in 
each group were very small and the confidence intervals wide. If the results with the 
confocal probe are compared to the other studies conducted with NBI they are not 
particularly impressive. It should be noted that probe based endomicroscopy is 
marketed on a per-use per patient basis. Each probe can only be activated a set 
number of times, so whilst it can be used for any number of polyps in a single patient 
it has a cost for every patient it is used in. This is around £250 per use. This is 
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difficult to justify when such good results have been reported with magnifying 
endoscopes and chromoendoscopy with indigocarmine. This is not an issue for the 
Pentax endomicroscope. However, the scopes and equipment are expensive. To run 
an average list requires at least 3 colonoscopes. Therefore there would be a 
significant initial financial outlay with this setup. Another problem with confocal 
endomicroscopy is that it requires the endoscopist to learn how to interpret what are 
essentially histopathological sections. It is currently unclear what the learning curve 
is for this. Given the reluctance amongst Western endoscopists to adopt optically 
magnifying endoscopes into routine practice, it is reasonable to question whether 
there would be issues regarding uptake of confocal endomicroscopy into daily use. It 
is likely that if such techniques become established, it is more likely to be in the 
assessment of challenging high risk lesions where the questions are is a lesion 
cancer or an adenoma with atypical pit pattern / appearance, and whether it is 
suitable for endoscopic resection or not. Unfortunately the technical limitations of 
confocal endoscopy limit the depth of assessment to 250µm. This means that it 
cannot be used to establish whether a lesion penetrates beyond SM-1 invasion, 
which is of prognostic significance. See table 10.    
 
Author Country Journal Year Modality Endo-
scope 
No Sensitivity Specificity Accuracy 
Hurlstone UK Br J 
Surg 
2008 Confocal Pentax 162 97.4% 99.3% 99.1% 
Meining Germany Clinical 
gastro 
and 
hepatol 
2007 Confocal Cellvizio 36 92.3% 91.3 91.7% 
Xie China Endo-
scopy 
2010 Confocal Pentax 115 90.3% 95.7% 93.9% 
Depalma Italy Dig Liver 
Dis 
2010 Confocal Cellvizio 32 100% 84.6% 92.3% 
Buchner USA Gastro-
enterolo
gy 
2010 Confocal Cellvizio 119 91% 76% 87% 
Table 10: Summary of papers published using confocal endomicrooscopy for in-vivo diagnosis 
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2.12 High definition endoscopy 
Recent years have seen a dramatic change in the resolution of endoscopy 
equipment. In a similar manner to the introduction of high definition television and 
computer equipment into the home, all of the main endoscopy equipment being 
actively marketed is making claims to be ‘high definition’. It is important to appreciate 
that when describing the resolution of a setup, there are three independent aspects 
of importance; the capture resolution of the charge coupled device (CCD) in the 
endoscope itself, the output resolution of the endoscopy stack and the display 
resolution of the visual display unit. In addition to absolute resolution of the screen, 
the refresh rate and temporal resolution (progressive scan or interlaced picture) can 
also affect image quality, particularly if the picture is rapidly changing. It is important 
how these are connected together, as a significant degradation in picture quality can 
occur if a digital signal has to be converted into an analogue one for transfer from 
stack to screen.  
Studies into high definition endoscopy have proved problematic for a number of 
reasons. Endoscope manufacturers are defensive regarding the resolution of 
components of their equipment, and often use confusing terminology for marketing. 
Olympus have declined to reveal what the resolution of their ‘high definition’ and 
‘high resolution’ endoscopes actually is. Therefore it is very difficult to define what 
these terms, other than a marketing phrase, mean for their equipment. Fujinon have 
officially provided this study with the absolute resolution of their standard definition 
and high definition (Super) CCD chips as 410,000 and 650,000 pixels respectively, 
although this information has not been available in the public literature until now. 
Pentax on the other hand have publically declared the resolution of their CCD as 1.3 
million pixels.  All of the stacks output 1.3 million pixels via digital outputs to the 
78 
 
visual display unit. Fujinon HD endoscopes therefore utilize a 2:1 interpolation factor. 
In contrast no interpolation occurs for Pentax endoscopes. It is unknown what this 
factor is for Olympus systems. 
 
It should be noted that in all of the studies performed examining the role of electronic 
imaging in making an in-vivo diagnosis high definition endoscopes have been used. 
A similar picture is seen for conventional chromoendoscopy. It is therefore difficult to 
ascertain whether this is a pre-requisite for the use of these techniques. However, at 
present most of the endoscopes in use across the Western world are standard 
definition. Therefore if in-vivo diagnosis is to be widely adopted, endoscopists need 
to feel confident that the published evidence is applicable to their equipment. 
Furthermore, if endoscopy units are to make effective business cases for upgrading 
their equipment to perform in-vivo diagnosis, robust evidence needs to be produced 
to support that it is actually superior to existing equipment. 
There has been very little published directly comparing standard definition to high 
definition endoscopy. A retrospective study performed by the Mayo Clinic in the 
United States of America compared adenoma detection rates between standard and 
high definition Olympus endoscopes (65). It found that HD endoscopy resulted in a 
significantly higher detection rate (28.8% vs 24.3%). A study looking at the Pentax 
system compared HD endoscopy with i-scan to standard definition endoscopy 
without i-scan (60). It looked at 220 patients and found a significant benefit in 
adenoma detection (38% vs 13%) using high definition endoscopes. It should be 
noted that this is not a pure study of high definition endoscopy but also utilized the 
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surface enhancement capabilities of i-scan, and it did not attempt to define what 
contribution i-scan made to the improved detection rate.  
Not all of the published literature supports a benefit from high definition endoscopes 
in lesion detection. A study of 130 patients randomized to standard or high definition 
endoscopy reported that there was no significant gain from HD colonoscopies (66). A 
meta-analysis of the published literature concluded that there were only marginal 
differences between standard and high definition colonoscopy in lesion detection and 
that there was no benefit in the identification of high risk adenomas (67). 
To date there has been no published literature comparing high definition to standard 
definition endoscopy in lesion characterization.  
In summary the role of high definition endoscopy in clinical practice has not yet been 
adequately defined. It could be argued that eventually all endoscopes will be high 
definition as departments slowly replace older equipment. However, this is likely to 
take time and there is currently a lack of clarity as to whether the results published 
using high definition equipment can be applied using older standard definition 
endoscopes. In the current era of austerity, it is difficult to justify the economic outlay 
for replacing functional older equipment without clear evidence of benefit. 
It is again important to be cautious before extrapolating the findings from one 
manufacturer to the others. To define benefit, studies will need to be conducted 
separately for each technology as the potential gains may be greater for some 
systems than others. It is important not to confuse screen resolution with the 
resolution of the CCD within the endoscope itself. 
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2.12: Summary 
There have been some studies which have shown that in-vivo diagnosis is possible. 
The best evidence is for indigocarmine using high definition endoscopes with optical 
magnification. Of the vascular enhancement techniques narrow band imaging is the 
best described and it is probably possible to achieve similar results to those seen 
with indigocarmine, again using high definition magnifying endoscopes. Other novel 
technologies such as confocal endomicroscopy have shown promise but are 
hampered by an unknown learning curve and significant capital outlay. It is unclear 
how all of these technologies fit together in routine clinical practice 
 
There are key deficiencies in the current knowledge base. Most of the large studies 
have been conducted in Japan, with a significantly different patient population and 
disease incidence. The training and job pattern of Japanese endoscopists is different 
to that practiced in the West (dedicated colonoscopists in Japan versus general 
gastroenterologists in Northern America and Europe), which makes it easier for 
Japanese doctors to attain and maintain skills in magnifying endoscopy and in-vivo 
diagnosis. Furthermore, the research has not been uniform across the different 
techniques available. Much of the available literature has established what can be 
achieved in a tertiary referral centre environment with magnifying endoscopes and 
dyes, which do not reflect standard practice in a Western setting. Even the studies 
into vascular enhancement have all been largely conducted on Narrow Band 
Imaging, with limited applicability to the other electronic imaging systems.  
As a result, there is still significant scepticism in the West as to whether in-vivo 
diagnosis of colonic polyps is possible in Western hands on routine lists. As a result, 
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standard practice is still to remove all polyps. If a clear evidence base is not 
established in tightly defined clinically relevant patient groups with appropriately 
validated tools for assessment, this position will not change. 
 
The biggest potential area for in-vivo diagnosis in a Western setting is on Bowel 
Cancer Screening lists. It has been recognised that polyp detection in this group is 
very high, so the cost savings of in-vivo diagnosis will be equally high (68). However, 
very few studies have been conducted on this cohort of patients. 
 
In order to achieve these goals it will be necessary for robust tools to be developed 
for in-vivo diagnosis. Whilst the Pit Pattern Assessments pioneered by Professor 
Kudo have formed a solid base for further work, they ideally require magnifying 
endoscopes to work at their best.They were essentially developed for differentiating 
adenoma from cancer for endoscopic mucosal resection work and are impractical to 
apply on a high volume list. Furthermore, it is generally accepted that they are sub-
optimal for the assessment of the vascular patterns seen with the commonly 
available electronic imaging techniques (NBI, FICE and i-scan). Whilst criteria have 
been developed for Narrow Band Imaging, there are very few tools available for 
FICE or i-scan. Of note, whilst NBI is a single setting technology, FICE and i-scan 
can be used with a wide range of different settings and there has been very little 
work conducted with these technologies to demonstrate which setting should be 
used for any given task. 
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It is important that in the development of these tools, attention is paid to Western 
endoscopic practice. Assessments have to be both accurate and straight forward to 
perform. Any assessment criteria which relies on subtle differences in complex 
patterns using optical magnification, are likely to be of use in a research setting and 
in highly specialised, low volume centres only . There needs to be different tools for 
a high volume screening population looking at low risk lesions, to those used for 
tertiary centre assessment of high risk large lesions. This is a point which has been 
consistently overlooked.  
It is critical that the tool being used to assess the polyps is carefully defined. In many 
ways the growth of new technologies has outstripped the rate of research backing up 
or disproving their usefulness. It is often tempting to try and extrapolate findings from 
one, conceptually similar device, to another. If misdiagnosis is to be prevented, then 
this approach must be avoided. In particular, terminology must be defined so that 
endoscopists understand the strengths and limitations of a particular setup. It is also 
important to understand the implications of standard definition and high definition 
endoscopes in in-vivo diagnosis, especially in conjunction with electronic 
enhancement techniques like FICE. It is necessary to be precise regarding whether 
results are being achieved using standard definition or high definition setups, and 
what is actually meant by high definition such as the CCD resolution, screen 
resolution and connections between stack and screen.   
New technologies will not be adopted if practising clinicians cannot find a robust 
evidence base for their use. In particular in-vivo diagnosis will never be considered a 
safe alternative to conventional histological analysis (the current standard of care) if 
the case for it is hazy, inprecise or based on slim poorly researched evidence. 
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In summary If in-vivo diagnosis is to become a reality, there are a number of 
deficiencies in current knowledge which need to be addressed: 
1) Validated lesion assessment tools need to be developed to facilitate in-vivo 
diagnosis using the various different imaging modalities 
2) Whether in-vivo diagnosis of colonic polyps can be performed by Western 
endoscopists on Western patients  
3) Whether the experiences of a few, well trained endoscopists, can be 
expanded to a larger population model 
4) What populations are most suitable for in-vivo diagnosis? 
5) Whether acceptable results can be achieved with indigocarmine without 
magnifying endoscopes 
6) Whether FICE and i-scan can achieve similar results to those seen with 
Narrow Band Imaging and what settings should be used to achieve this 
7) Whether acceptable results can be achieved using Narrow Band Imaging, 
FICE or i-scan without magnifying endoscopes 
8) What effect high definition endoscopes have on the above imaging modalities 
(needs repeating on all systems with and without magnification) 
9) The cost impact of in-vivo diagnosis    
10) The effect of a missed diagnosis 
11) Potential roles for technology such as confocal endomicroscopy 
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Chapter 3 
Barrett’s Oesophagus 
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Barrett’s oesophagus 
 
Oesophageal cancer is the 9th most common cancer in the UK, accounting for 5% of 
all cancer deaths in the UK. Unfortunately, rates have continued to rise over the last 
30 years. For reasons which are unclear, it is more common in men than women, 
with an incidence of 8.8-14.1 per 100,000 in men, compared to 4.8-5.7 per 100,000 
in women. (3). Patients typically present with vague early symptoms. This makes 
early diagnosis very difficult, with most cancers identified at a late stage where the 
only treatment options are palliative. This is reflected with a 5 year survival of 9% (4).  
There are known risk factors for oesophageal cancer. Sadly these include many 
factors which cannot be changed, such as male gender, age >45, early age of onset 
of GORD, duodeno-gastrooesophageal reflux, mucosal damage and family history 
(6).  
 
It is known that one of the most significant risk factors for adenocarcinoma of the 
oesophagus is Barrett’s epithelium. This is an acquired pre-malignant condition 
which effects up to 1.6% of the general population (7). The incidence is increasing in 
the West, mirroring that of oesophageal cancer (2) (8). It is caused by the reflux of 
gastric contents into the oesophagus, and is found in 15-20% of gastrointestinal 
endoscopies performed for symptoms of reflux. The gastric acid damages the normal 
squamous epithelium, which becomes replaced by a columnar epithelium as a 
protective measure. The newly updated definition by the British Society of 
Gastroenterology defines Barrett’s as ‘an endoscopically apparent area above the 
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oesophagogastric junction that is suggestive of Barrett's which is supported by the 
finding of columnar lined oesophagus on histology’ (5) (6).   
 
There is not a national screening policy for the detection of upper gastrointestinal 
malignancy or for Barrett’s. However, once Barrett’s is detected patients are entered 
into a surveillance programme. The benefits of this are controversial, as the absolute 
risk of malignant transformation is low, 0.8-1.5% per annum. Some studies have 
concluded that because of this there is no benefit to surveillance (6). Computer 
modelling has been used to predict an effective balance point for surveillance 
intervals, and a widely used interval for surveillance endoscopy is 2 years (69). The 
two yearly gastroscopy involves quadrantic random biopsies every 2cm as a part of 
the standard protocol. The cost per life year saved is around £19,000.  
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3.1: Chromoendoscopy in Barrett’s oesophagus 
Dysplasia in Barrett’s is very subtle and difficult to see. As a result of this, 
conventional protocols are based on multiple biopsies in an attempt to capture this 
dysplasia, based on the conventional wisdom that suggests that the more biopsies 
we take, the higher the chance of diagnosing neoplasia. However, random biopsies 
are not ideal for identifying neoplasia within Barrett’s. There are a range of 
techniques available for examining the oesophagus in detail, and can help improve 
the neoplasia pick up rate. Chromoendoscopy can be used to identify areas of 
Barrett’s metaplasia and dysplasia. Several dyes have been used, with most of the 
research examining methylene blue (MB), indigo carmine (IC) and acetic acid (AA). 
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3.2: Methylene blue 
Methylene blue 0.5% (MB) is an absorptive stain which highlights areas of 
specialised columnar epithelium. It stains both the nucleus and cytoplasm of cells, 
with the nucleus typically staining a deeper colour. It has predominately been used 
for identifying specialized columnar epithelium (70) (71) (72) (73). In some small 
studies it has been suggested that dysplasia and cancer are detected more 
frequently than with random 4 quadrant biopsies (74). Unfortunately MB is 
inconvenient to use. It must be left in contact with the mucosa for 3 minutes followed 
by vigorous washing to clear away excess dye. As a result the endoscopic 
appearances are unpredictable, subjective and not reproducible (75). There have 
also been concerns raised about DNA toxicity with MB so it is falling out of favour. A 
meta-analysis of studies found no benefit in either the detection of intestinal 
metaplasia or neoplasia (76) and therefore its use cannot be recommended at 
present. 
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3.3: Indigo carmine 
Whilst Indigo carmine has been used in many studies looking at colonic neoplasia, it 
has not been studied to such a degree in the oesophagus. As in the colon, it is not 
absorbed by the oesophageal and Barrett’s mucosa, but accumulates in the pits and 
valleys between cells, highlighting the architecture (77). It is a contrast agent which 
can highlight mucosal irregularities and has been very helpful in the colon. However, 
results have been less encouraging in the oesophagus. There have been two studies 
which have suggested that it may help in the detection of Barrett’s dysplasia (78) 
(79). However, these trials have been hampered by small numbers of patients with 
dysplasia or cancer. Therefore results should be interpreted with caution. The 
mechanism of action and poor evidence base makes this an unlikely dye to be of use 
in the diagnosis of dysplasia. 
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3.4: Acetic acid 
 
Acetic acid 2.5% (AA) when sprayed onto Barrett’s mucosa causes a reversible 
acetylation of nuclear proteins to occur. This leads to an acetowhitening reaction, 
with increased opacity of the mucosal surface (80). It also causes vascular 
congestion and improves surface pattern evaluation (80). This potentially enables 
the early recognition of neoplasia. See figure 5. It has been used successfully in the 
oesophagus for the identification of Barrett’s metaplasia.  
 
 
Figure 5: Oesophagus: A: routine endoscopic appearances. B: post acetic acid chromoendoscopy 
(Obtained using an Olympus standard definition gastroscope) 
 
One of the earliest studies used acetic acid to identify small islands of residual 
Barrett’s metaplasia after endoscopic treatment of Barrett’s (81). It examined a small 
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population of 21 patients, reporting positive results. The same team went on to 
conduct a study of 49 patients with Barrett’s metaplasia and defined the mucosal 
surface patterns associated with specialised intestinal metaplasia (82). Using 
magnifying endoscopes, 129 areas were examined and four different mucosal 
patterns defined; round pits (I),reticular (II), villous (III) and ridged (IV). It concluded 
that the yield for intestinal metaplasia was 0% for pattern I, 11% for pattern II, 87% 
for pattern III and 100% for pattern IV. Overall, a sensitivity for intestinal metaplasia 
of 96.5% a specificity of 88.2% and accuracy of 92.2% was achieved. This study did 
not have any dysplasia cases in it. A further small study examined 28 patients where 
72 biopsies of Barrett’s metaplasia were taken. A sensitivity for metaplasia of 95.5% 
and specificity of 24.9% was achieved (83). Whilst this was a very small study six 
biopsies did show high grade dysplasia. Three of these had been suspected at the 
time of the endoscopy due to two particular mucosal patterns, a local loss of the 
normal ridged cribriform pattern and hypervascularisation of the mucosa. 
A further randomised crossover study was undertaken using acetic acid for the 
detection of Barrett’s metaplasia (84). This was again very small, consisting of just 
32 patients. Patients were randomized to either standard video endoscopy with 
quadrantic biopsies or to magnifying endoscopy with acetic acid. All patients were re-
examined after 14 days post initial endoscopy with the corresponding procedure. It 
found that magnifying endoscopy enabled the prediction of Barrett’s epithelium with 
a sensitivity of 100% and specificity of 66% and accuracy of 83.8%. The biopsies 
obtained following exposure to acetic acid yielded a significantly higher percentage 
of tissues containing Barrett’s metaplasia (78%) compared to random biopsies 
(57%). Again this study had no dysplasia cases and the authors recognised this as a 
limitation of the study. A further small study of 20 patients again demonstrated the 
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effectiveness of acetic acid in the identification of Barrett’s metaplasia, with a 
sensitivity of 100%, specificity of 82% and accuracy of 90% (85). 
Not all of the studies published using acetic acid for the identification of intestinal 
metaplasia gave positive results. A prospective randomized study of 137 patients 
concluded that random biopsies of endoscopically apparent Barrett’s oesophagus 
yielded specialized intestinal metaplasia at the same rate with random biopsies as 
with acetic acid targeted biopsies (86).  
An important question is whether acetic acid could be used to detect and localise 
neoplasia. It has been successfully used in the detection of squamous neoplasia of 
the cervix during colposcopy (87). Whilst no randomised controlled trials for its use 
for this purpose in the oesophagus exist, early cohort studies have demonstrated 
effectiveness in the identification of dysplasia. The sensitivity for the identification of 
neoplasia has been suggested to be 71-100%, with a specificity between 80-99%. 
An early cohort study of 100 patients attempted to investigate whether neoplasia 
could be localised using acetic acid (88). It classified the mucosal patterns as either 
normal (uniform reticulum along the entire columnar lined oesophagus) or abnormal 
(reticulum presenting areas of rough or irregular appearance). Dysplasia was found 
in 86.7% of rough or irregular areas compared to 0% in areas with a normal pattern. 
This corresponded to a sensitivity for neoplasia of 100% and a specificity of 97.7%. 
The study was limited by the low number of dysplasia / cancer cases in the series of 
just 15 patients. A further study examined 394 pictures taken from 96 patients with 
Barrett’s epithelium after dye spray with 1.5% acetic acid. It characterized the 
mucosa into three pit patterns, I-dotted round pits, II-villous and ridged, III-irregular 
and distorted, with the latter representing neoplasia. The images were shown to 6 
blinded assessors. High grade intraepithelial neoplasia or cancer was correctly 
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identified in 89% cases, with intestinal metaplasia correctly called in 92% cases (89). 
The study showed very little intraobserver variability, with a kappa score of 0.959. It 
was however only a study of static images and therefore how applicable it is to live 
endoscopy is unclear. A further prospective cohort study supported these findings, 
again using mucosal pit patterns to predict histology (90). The primary end point was 
detection of intestinal metaplasia, dysplasia and cancer. All of the procedures were 
recorded and viewed by three endoscopists. Still images were taken from the videos 
and shown to six different endoscopists. The authors found that there was a high 
yield of metaplasia and dysplasia in the biopsies taken, with columnar lined 
epithelium in 6 patients, specialized intestinal metaplasia in 49 patients, low grade 
dysplasia in 5 patients, high grade dysplasia in one patient and adenocarcinoma in 
three patients. 24% of patients had a histological upgrade when compared to their 
previous surveillance endoscopy. There was good inter and intra-observer 
agreement in assessing pit-patterns with Kappa values of 0.571 and 0.709 
respectively. The study was limited by the very small volume of dysplasia in the 
study. Furthermore, it was not an in-vivo localization study and as such the results 
have to be interpreted with caution.  A study of 57 patients looked at a high risk 
population with both acetic acid and FICE. There were 30 patients with high grade 
dysplasia or early cancer in the cohort. On a per lesion analysis it found a sensitivity 
of 87% for dysplasia. This did not change significantly when an analysis was 
performed on a per patient basis, with a sensitivity of 83%. Similar results were 
obtained using FICE (91). 
Review of the literature suggests that to date there has been no single, well powered 
study to conclusively support the role of acetic acid in the diagnosis of neoplasia in 
Barrett’s. Most of the studies have been trying to identify Barrett’s epithelium or 
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intestinal metaplasia with the help of acetic acid. However, some of the small series 
have shown a potential for acetic acid to be used as a tool for the diagnosis of 
neoplasia in Barrett’s. There are still no objective criteria related to acetic acid 
assisted diagnosis of neoplasia in Barrett’s. 
This thesis will aim to evaluate the role of acetic acid in the diagnosis of Barrett’s 
neoplasia and will also aim to establish some objective criterion for acetic acid 
assisted diagnosis of Barrett’s neoplasia. 
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3.5: Electronic imaging in Barrett’s oesophagus 
Electronic imaging techniques are widely available and have been used in the 
evaluation of Barrett’s oesophagus. Narrow band imaging has been used more 
commonly than the other two techniques, FICE and i-scan.  
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3.6: Narrow Band imaging 
Narrow band imaging (NBI) has been used in the examination of Barrett’s 
oesophagus, utilising the principles described in the last chapter. It carries the 
potential advantage over chromoendoscopy techniques that it can be activated at the 
push of a button on the endoscope. It highlights mucosal vascular patterns to 
enhance abnormal neoplastic areas. The earliest study was conducted in Japan and 
was published in 2004 (92). It looked at images from 11 patients viewed with both 
conventional white light and NBI and compared the quality of the images for 
visualization of the oesophagogastric junction, capillary vessels and columnar lined 
oesophagus, on a four point scale. The authors found that in all cases, visualization 
was superior with NBI and that endoscopic and histological diagnoses correlated 
more closely with NBI than with white light. This led to teams across the world 
conducting studies aimed at defining the endoscopic features of Barrett’s metaplasia 
and neoplasia when viewed with the system.  
An open label study from North America used images of Barrett’s metaplasia viewed 
with Narrow Band Imaging to define the patterns in Barrett’s mucosa (93). Of the 51 
patients examined, 28 had intestinal metaplasia, 8 had low grade dysplasia, 7 had 
high grade dysplasia and 8 had cardia-type mucosa. A ridge or villous pattern was 
predictive of intestinal metaplasia with a sensitivity of 93.5% and specificity of 86.7%. 
High grade dysplasia was associated with an irregular distorted pattern with a 
sensitivity of 100% and specificity of 98.7%. The authors commented that NBI was 
unable to distinguish intestinal metaplasia from low grade dysplasia. It should be 
recognised that with just 7 high grade dysplasia cases seen in this series, the 
predictive value for neoplasia should be interpreted with caution. A similar picture 
study from the Netherlands (94) reported similar results in 63 patients with 198 
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areas. Intestinal metaplasia was characterized by villous/gyrus-forming vessels 
(80%) which had regular vascular patterns, or a flat mucosa with regular normal 
appearing long branching vessels (20%). In contrast high grade dysplasia was 
characterized by three abnormalities; an irregular or disrupted mucosal pattern, 
irregular vascular pattern or abnormal blood vessels. They found that all areas of 
neoplasia had at least one of these findings, with 85% having 2 or more. The study 
reported a sensitivity of 94% and specificity of 76% for neoplasia. However, the small 
size of the study (48 areas of high risk neoplasia) makes interpretation of these 
results difficult. A Japanese group also published a study in 2007 looking at 217 sites 
from 58 patients with Barrett’s oesophagus (95). Of these cases, 6 had superficial 
adenocarcinoma. This study concentrated on examining the role of fine mucosal 
patterns and the additional gain from the examination of capillary patterns. In this 
study the results were not quite so impressive. Intestinal metaplasia could be 
identified by the presence of a cerebriform mucosal pattern with a sensitivity of 56%, 
specificity of 79%, or by a deoxyribonucleic acid (DNA) pattern (sensitivity 77%, 
specificity 94%). All 6 cancers were correctly identified. The additional examination 
of capillary patterns improved this further. The authors concluded that this was 
important for detecting metaplasia and neoplasia in Barrett’s.  
 
 A study from Nottingham in the United Kingdom attempted to define Barrett’s 
oesophagus in terms of microstructural and microvascular patterns (96). A total of 
344 areas from 50 patients with Barrett’s oesophagus were examined. It was found 
that a regular microstructural pattern with tubular/linear or villous patterns was 
associated with intestinal metaplasia in 90.6% of lesions. An absent microvascular 
pattern was associated with metaplasia in 98.5% of cases. The combination of a 
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regular microstructural pattern (tubular / villous or linear) with an absent 
microvascular pattern could detect intestinal metaplasia with 100% sensitivity and 
78.8% specificity. It was also noted that the presence of an irregular microvascular / 
microstructural pattern could help predict the presence of high grade dysplasia with a 
sensitivity of 90% and specificity of 100%. Unfortunately there were only 10 cases of 
dysplasia in the study, four of which were low grade, making it difficult to draw any 
firm conclusions. Furthermore, the system was complex. In a larger prospective 
cohort study from the same group, 109 patients were examined in an attempt to 
develop and validate a simple classification system based on the same concepts 
(97). In total 1021 distinct areas were examined. Four patterns were identified: 
Round pits with regular microvasculature (A), villous/ridge pits with regular 
microvasculature (B), absent pits with regular microvasculature (C) and distorted pits 
with irregular microvasculature (D). Columnar mucosa without intestinal metaplasia 
was associated with the type A pattern. The positive predictive value (PPV) and 
negative predictive value (NPV) for this was 100% and 97%. Types B and C were 
associated with intestinal metaplasia, with a PPV of 88% and NPV of 91%. Type D 
was associated with high grade dysplasia with a PPV of 81% and NPV of 99%. On 
the basis of the positive results obtained in this study, the same authors attempted to 
use this classification system to predict histology from pictures taken from 75 areas 
in 21 patients using both NBI and white light (98). Five expert endoscopists reviewed 
the images. A sensitivity of 88.9% was achieved with NBI compared to 71.9% with 
white light. NBI was significantly superior to white light for the prediction of dysplasia. 
 
Based on the positive findings from these validation exercises, work began on 
evaluating whether NBI could be used prospectively to detect advanced dysplasia 
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more efficiently than with mapping biopsies. A tandem endoscopy study involving 65 
patients compared standard resolution endoscopy to NBI. It found that NBI directed 
biopsies detected dysplasia in more patients (57%) compared to biopsies taken 
using standard resolution endoscopy (43%) (99).  
 
A potential drawback with narrow band imaging has been the lack of intraobserver 
agreement between endoscopists when using the classification systems described 
above. A recent study compared the three most commonly used classification 
systems by showing 84 high quality videos from 32 patients to nine independent 
endoscopists, who had not been involved in the development of the classification 
systems (100). The global accuracy was 46% and 47% using the systems described 
by the British and American studies, and 51% with the classification system 
described by the Amsterdam group. Accuracy for dysplasia was 75% using all three 
systems, with an accuracy for intestinal metaplasia ranging from 57%-63%. The 
intraobserver agreement was fair to moderate, with a kappa of 0.34 for the 
Nottingham system, 0.47 for the Amsterdam system and 0.44 for the North American 
classification system. The authors concluded that all three systems revealed 
substantial limitations when assessed externally and that as a result, NBI could not 
replace random biopsies for histopathological analysis.  
A systemic review of the evidence for Narrow Band Imaging has concluded that 
whilst the body of literature for this technique is growing it is still unclear whether it is 
adequate for the detection of Barrett’s (101). 
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3.7: Auto-fluorescence 
At around the same time as the introduction of Narrow Band Imaging another 
technology was under development known as Auto-fluorescence imaging (AFI). This 
is a novel technique which is based on the principle of variable fluorescence 
between tissues. Normal mucosa, when exposed to light, emits a green fluorescence 
as compared to magneta / pink fluorescence in neoplastic areas within the mucosa. 
This principle is exploited by the technique of AFI to detect early neoplasia. Initial 
studies used this technique on its own as a single imaging modality. They suggested 
that whilst neoplasia detection rates were very good (91%), with a 2.8 fold increase 
in dysplasia detection (102), a 51% false positive rate limited its use. (103).  
 
3.8: Tri-modal imaging 
It was becoming clear that there were inherent problems associated with the 
subjective classification systems developed for use with NBI. The poor intraobserver 
agreement seen when these tools were used by clinicians independent from the 
research teams who had developed them, suggested that on its own, NBI had an 
inadequate and variable sensitivity for the identification of neoplasia within Barrett’s 
that was very operator dependent. This led to the concept of tri-modal imaging being 
developed. Whilst the false negative rate of autoflourescence would prevent it from 
being used as a solo imaging modality, it could be used to identify abnormal areas. 
These could then be examined in detail with high resolution white light (HRE) and 
narrow band imaging. The concept is that HRE and AFI act as a red flag, highlighting 
potential abnormal areas which may have been overlooked during NBI assessment 
and improving the sensitivity over that of NBI alone. The focused assessment of 
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these higher risk areas flagged up by AFI using Narrow Band Imaging could then 
identify those which are actually normal, improving the specificity of the test above 
that normally achieved with AFI. Therefore the best features of both AFI and NBI 
would be exploited in the form of an integrated test. The initial work into this concept 
was led from the Academic Medical Centre in Amsterdam, where a multi-centre 
prospective cohort study of high risk patients was conducted (104). Five centres 
were involved and a total of 84 patients were examined. The initial results were 
excellent. AFI identified all 16 patients with neoplasia previously seen with high 
resolution white light but also identified an additional 11 patients with early neoplasia 
that had not been previously seen. Whilst the false positive rate for AFI was high at 
81%, NBI reduced this to 26%. This led the same team to investigate tri-modal 
imaging further with a tandem endoscopy study. This produced interesting results. It 
examined 87 high risk patients with suspected neoplasia who underwent tri-modal 
imaging guided assessment (with targeted and random biopsies), followed by white 
light assessment (targeted and random biopsies) 8-12 weeks later (105). It found 
that whilst tri-modal imaging improved the targeted detection of neoplasia, there was 
no significant difference in the overall yield of neoplasia for tri-modal imaging, 
compared to standard video endoscopy and mapping biopsies. It was essentially a 
negative study with the authors concluding that at present, this imaging modality 
cannot be seen as a replacement for mapping biopsies, even in a high risk 
population. See table 12. 
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3.9: FICE 
Fujinon has developed a technology for vascular enhancement, known as FICE. As 
described in the previous chapter rather than using filters it utilises a post processor 
technology to digitally reconstruct spectral data to enhance particular wavelengths.  
A prospective cohort study of 72 patients demonstrated that the identification of 
Pallisade vessels using FICE, provided clear demarcation between Barrett’s mucosa 
and the gastric mucosa which was superior to standard white light endoscopy (106). 
This study did not attempt to diagnose dysplasia and used transnasal Fujinon 
endoscopes. These are very small with a more limited field of view and no optical 
magnification. As such they may not be the optimum way of using FICE. A further 
prospective cohort study of 57 patients compared FICE with random biopsy in 
patients with suspected high grade intraepithelial neoplasia or early cancer. A 
sensitivity of 92% and specificity of 97% for FICE was achieved (91). There was high 
grade dysplasia or early cancer in 24/57 patients. Therefore, whilst small, this study 
is encouraging. Due to its nature as a post processor technology, FICE can utilise a 
wide range of different frequencies for lesion enhancement.  
All of the ‘virtual chromoendoscopy’ techniques (NBI, FICE and i-scan) produce 
different appearances. Although some of the skills are transferrable, additional 
training is normally required to transfer between systems. 
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3.10: i-scan 
 
i-scan is the most recent form of electronic imaging introduced on the Pentax 
endoscopes. From a technical standpoint it is similar to FICE in that it is a post-
processor technology that takes spectral reflectance data to reconstruct an image of 
specific frequencies. Unfortunately, there have been no papers published at all using 
i-scan for the detection of neoplasia within Barrett’s. As such, one can only speculate 
at present as to whether it will prove useful for this application.  
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3.11: Confocal endomicroscopy 
Confocal endomicroscopy is a new technology for obtaining true in vivo histology. 
Studies in Barrett’s surveillance have suggested that associated neoplasia could be 
predicted with a sensitivity of 96.4% (107). It has been shown that confocal 
endomicroscopy improves the yield of neoplasia in apparent Barrett’s oesophagus, 
compared to a 4 quadrant random biopsy protocol (108). There is limited evidence 
that it is also effective in the identification of gastric cancers (109). This technique 
only works once neoplasia has been identified by the endoscopist using other 
endoscopic techniques, so it does not help improve detection but can improve the 
confidence for diagnosis. This is an excellent experimental technique which has yet 
to find a major clinical role. See figure 6. 
                
Figure 6: Barrett's high grade dysplasia visualized with the Cellvizio miniprobe 
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1
st
 Author Journal Year  Design No patients Modality Results 
Sharma Gut 
 
2003 Prospectiv
e cohort 
80 
24 dysplasia 
6 HGD 
 
Indigo 
carmine 
Surface patterns in Barrett’s 
97% IM ridged / villous 
17% circular 
LGD all ridged / villous 
HGD all irregular / distorted 
Canto GIE 2000 Cohort 
study 
43 patients Methylene 
blue 
metaplasia  
Some 
dysplasia  
Neoplasia was diagnosed in 
significantly more MB targeted 
specimens (12% vs. 6%) and in 
significantly more patients (44% vs. 
28%) than by random biopsy 
technique.  
Canto Endo-
scopy 
2001 Ex and en 
vivo cohort 
study 
methylene 
blue 
47 patients 
and 48 
oesophagect
omy 
specimens 
methylene 
blue  
dysplastic 
tissue 
Ex vivo accuracy for IM=87% in vivo 
accuracy for IM=90% 
Light to absent staining  and moderate 
to marked heterogeneity  were 
significantly associated with high grade 
dysplasia or cancer  
Kouklakis  Endo-
scopy 
2003 Cohort 
study 
975 patients 
3900 biopsy 
specimens 
Methylene 
blue 
metaplasia 
Methylene blue improved the sampling 
of IM compared to random biopsy (88% 
vs 1.4%) 
Ngamrueng
phon 
GIE 2009 meta-
analysis 
450 patients  
9 studies 
Methylene 
blue 
There was no significant  improvement 
in detection of IM  or neoplaisa 
 
Guelrud  GIE 1996 Cohort 21 patients 
post endo 
therapy 
Acetic acid 
metaplasia 
Acetic acid enhanced the ability to 
identify remnant islands of Barrett’s 
metaplasia 
Guelrud  GIE  2001 Cohort 
study 
49 patients acetic acid 
with HRE 
Standard endoscopy identified an 
endoscopic pattern in 1.5% of the 
areas, 
standard endoscopy and acetic acid in 
8.5%, magnification endoscopy alone 
in 38%,  
enhanced magnification endoscopy in 
all 129 endoscopic areas. 
Enhanced magnification endoscopy 
was effective in identifying IM in BE.  
Meining  Endo-
scopy 
2004 Cohort 
study 
video 
sequences 
51 patients acetic acid 
and 
methylene  
blue 
No differences observed before and 
after instillation of acetic acid or 
methylene blue staining for the 
detection of IM 
Reaud  Gastroent
erol Clin 
Biol  
2006 Cohort 
study  
28 patients 
 
Acetic acid 
IM  zoom 
endoscopy  
sensitivity and specificity for metaplasia 
of  95.5% and 42.9% 
  
Hoffman  GIE  2006 RCT  with 
crossover  
31 patients Acetic acid 
metaplasia
No 
dysplasia 
sensitivity 100%  
specificity  66% 
accuracy 83.8% 
 Fortun  
 
Alimen 
Pharmaco
& 
Therapeut 
2006 Cohort 
study with 
historical 
controls 
64 patients 
compared to 
62 historical 
controls 
9 neoplasia 
Acetic acid 
+ zoom 
24% had a histological upgrade with 
AA enhanced magnification endoscopy. 
Detection of IM of 74% and  there were 
two additional cancers found 
Ferguson  Am J 
Gastroent
erol 
 RCT 137 patients Acetic acid 
intestinal 
metaplasia 
No difference between AA targeted and 
random biopsies in yield of IM. 
Pech  Acta 
Gastroent
erol Belg. 
2008 Cohort 
study 
20 patients Acetic acid 
metaplasia 
Accuracy 90% 
Sensitivity 100% 
Specificity 82% 
Longcroft-
Wheaton  
Clin 
Gastroent
erol 
Hepatol 
2010 Cohort 
study 
190 
procedures 
Acetic acid 
non zoom 
Sensitivity 95.5% 
Specificity 80% 
Pohl  Am J 
gastroente
rology  
2010 Cohort 
study 
701 patients Acetic acid Sensitivity 96.7% 
Specificity  66.5% 
Table 11: Chromoendoscopy studies in Barrett's oesophagus. AA= acetic acid, MB= methylene blue,BE= Barrett’s 
oesophagus,  IM=intestinal metaplasia, LGD=low grade dysplasia, HGD= High grade dysplasia, HRE= high resolution 
endoscopy 
 
106 
 
 
Author  Journal Year Design No patients Modality Results 
Pohl  Endo-
scopy  
2007 RCT cross 
over 
57 patients 
24 HGIN early 
cancer 
FICE and 
acetic acid 
sensitivity  83% AA 
Sensitivity 92% FICE  
Specificity 97% AA and FICE 
Osawa  J Gastro 2009 Prospective 
cohort 
72 patients FICE Identification palisade vessels 
Hamamoto  J gastro  Picture 
study 
11 patients NBI Surface characteristics seen with 
NBI and WLI. 
Sharma  GIE   2006 prospective 
cohort study. 
51 patients 
15 dysplasia 
NBI IM: Sensitivity 93.5%, specificity 
86.7%.  
HGD The sensitivity 100%, 
specificity 98.7%, 
Anagnostopoulos  Alimenta
ry 
pharmac
ol ther  
2006 Cohort study 50 patients 
344 areas 
10 patients  
dysplasia 
NBI Identification patterns 
IM Sensitivity 100%, Specificity 
78.8% 
Kara  GIE  2006 Picture 
study 
63 patients 
198 areas 
NBI Identification patterns. SIM 
Villous/gyrus 80% 
Flat long branching vessels 20% 
HGIN Irregular mucosal vascular 
patterns 
Sensitivity neoplasia 94% 
Specificity 76% 
Goda  GIE  2007 Picture 
study 
217 areas 
from 58 
patients 
NBI Identification of surface patterns.All 
intramucosl cancer correctly 
identified 
Curvers 
 
GIE  2009 Systemic 
review 
40 
publications 
NBI Whether NBI improves the 
detection 
of early neoplastic lesions in BE is, 
unclear. 
Wolfsen  Gastro-
enterol 
 
2008 Tandem 
endoscopy 
study 
65 patients, all 
with previously 
detected 
dysplasia 
NBI More dysplasia and higher grades 
of dysplasia were found by NBI 
than with  standard resolution white 
light endoscopy  
Singh Scand J 
Gastro 
2009 Prospective 
series  
21 patients NBI Accuracy 88.9%, superior to WLI 
for detection of dysplasia 
Singh   Endo-
scopy 
2008 Prospective 
cohort study 
109 patients NBI NBI-Z grading corresponded to the 
histological diagnosis. The PPV 
and NPV for type A pattern 
(columnar mucosa without 
intestinal metaplasia) were 100% 
and 97% respectively; for types B 
and C (intestinal metaplasia) they 
were 88% and 91%, and for type D 
(high-grade dysplasia) 81% and 
99%  
Ortner  
 
Gut  2003 Prospective 
cohort study 
53 patients AFI Dysplasia was detected at a rate 
2.8-fold higher with AFI Compared 
to random biopsy 
Curvers  
 
Gut 2008 Prospective 
multi-centre 
study. 
84 patients. 
30 HGIN / EC 
 
AFI + NBI AFI detected an additional 11 
patients with early neoplasia that 
were not identified with HRE. In 
three patients no abnormalities 
were seen but random biopsies 
revealed HGIN.  
AFI detected an additional 102 
lesions; 19 contained HGIN/EC. 
False positive rate of AFI after 
HRE: 81%. 
 NBI false positive rate 26%. 
Curvers Gastro-
enterol 
2010 Randomised 
cross over 
87 AFI+NBI Tri-modal imaging superior to WLI 
in the targeted detection of 
HGD/ca. However, yield of tri-
modal imaging biopsies 
significantly inferior to overall yield 
of white light protocol guided 
biopsies 
Table 12: Electronic imaging studies in Barrett's oesophagus, WLI= white light endoscopy, NBI=Narrow Band Imaging, 
AFI=auto-fluorescence, AA=acetic acid, PPV=positive predictive value, NPV=negative predictive value, IM=intestinal 
metaplasia, HGD=high grade dysplasia, HGIN=High grade intraepithelial neoplasia, EC= epithelial cancer, Ca=cancer 
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3.12: Treatment 
 
In order to appreciate why localising neoplasia within Barrett’s is important it is 
necessary to understand how the treatment of Barrett’s associated neoplasia has 
changed in recent years. Traditionally the only treatment for high grade dysplasia 
and intramucosal adenocarcinoma was an oesophagectomy. This is a highly 
invasive intervention, associated with significant mortality and morbidity, variable 
according to centre, with high volume units producing better results (110). Post 
operative morbidity is accepted to be significant, with rates between 30% and 50%, 
with a mortality of 2-10% (111).  
 
Endoscopic resection and ablation techniques are becoming increasingly popular 
due to low morbidity and mortality. Endoscopic mucosal resection (EMR) and 
endoscopic submucosal dissection (ESD) involve removing the mucosal and 
submucosal layers of the oesophagus. EMR uses either a cap and snare kit from 
Olympus or Duette banding ligator from Cook, to remove the abnormal tissue. This 
can be taken in one piece (112) (113) (114) or, for larger areas, piecemeal excision 
can be performed. EMR gives a better histological diagnosis as compared to biopsy. 
However, if a lesion is greater than 1.5cm, then piecemeal resection can make it 
hard to determine completeness of the lateral resection margins. ESD uses a 
specialised endoscopic knife to dissect out neoplastic areas of any size in an en-
block fashion. It can provide a clear resection margin but carries increased risks, 
including that of perforation. This can be combined with argon plasma coagulation 
(APC) or multipolar electrocautery (MPEC), which both aim to destroy any residual 
abnormal tissue through either ionised argon gas or an electric current. 
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Ablative photodynamic therapy (PDT) involves the use of a photosensitizing agent 
which is preferentially taken up by tumour tissue (115). After a suitable time period 
an endoscopy is performed where the abnormal area is exposed to light at an 
appropriate wavelength. The neoplasia which has preferentially taken up the drug 
then undergoes cell death. Using this technique a randomised controlled trial (RCT) 
has shown 98% efficacy at eliminating low grade dysplasia (116). Success has also 
been demonstrated with HGD and superficial T1 cancers, with successful ablation of 
HGD as high as 93% in one prospective series (117), although a more recent RCT 
by the same author has suggested that complete HGD ablation is achieved in 77% 
of cases over a mean follow up period of 24 months (118). However, it can cause 
stricture formation and photosensitivity reactions. Radiofrequency ablation (RFA) is 
similar in concept. Radiofrequency electrodes deliver thermal energy through a focal 
device or balloon inflated to make contact with the oesophageal wall. This induces 
mucosal destruction. The depth of burn is less than with photodynamic therapy 
which improves the safety profile of RFA over that of PDT, with a low oesophageal 
stricture rate of 6%, no deaths and no perforations were seen in a large sham-
controlled trial (119). RFA is a useful technique for multifocal dysplasia (120). 
However, it is not suitable for raised nodular areas which should first be removed by 
EMR. There have been no trials conducted to date which show whether RFA 
combined with EMR is any better than EMR alone. 
 
In order to offer any localised treatment, it is essential that the lesion can be seen 
and accurately staged. It would clearly be impossible to perform EMR without some 
form of lesion localisation, and ablative therapies could be very dangerous if applied 
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to the wrong lesions. Both photodynamic therapy and radiofrequency ablation 
(HALO) do not provide the endoscopist with a tissue sample for examination. 
Therefore if an invasive cancer was inadvertently ablated, in time the patient may 
develop avoidable lymph node metastasis. Furthermore, after treatment it is crucial 
that the patient can be safely followed up. A problem with all endoscopic treatments 
is that they can leave behind residual Barrett’s metaplasia. Even with HALO ablation 
this is not uncommon. As a result the potential for metanchronous lesions exists. The 
field will often be structurally abnormal in these patients with the potential for buried 
neoplasia, making assessment challenging.   
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3.13: Summary 
 
Advanced imaging modalities are already challenging the way we manage high 
grade dysplasia and early cancer within Barrett’s oesophagus. However, the 
evidence base is incomplete and many of the new technologies are being applied 
based on limited evidence of effectiveness. Whilst certain techniques have 
demonstrated benefit in prospective cohort studies there are a lack of randomised 
controlled trials, particularly in a surveillance population. Many of the techniques, 
such as acetic acid and FICE are incompletely understood, and there are likely to be 
ways of improving the sensitivity and specificity which can be achieved with them.  
 
It is very important to appreciate just how important developments in this field are. 
Oesophageal cancer carries a very poor prognosis. Early diagnosis and treatment of 
pre-malignant or early malignant changes are, at present, the only real way to 
reduce mortality and morbidity in this field. Advances in endoscopic treatments (EMR 
and HALO ablation) have raised the game significantly. Whereas previously patients 
diagnosed with HGD faced the unpleasant prospect of oesophagectomy (if fit for this 
major operation), it is now possible to endoscopically remove visible lesions. It is 
therefore important not just to find neoplasia but to localise it.  
 
To help the clinician in the management of Barrett’s, a task force has been set up 
called BADCAT, to review the evidence for all aspects of its management. This is 
currently in the final stages of publication. One of the noted features however was 
the lack of evidence available for all of the advanced imaging modalities. At present 
there is the greatest evidence for the use of acetic acid (due in large part to the study 
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forming a part of this thesis) however, it is accepted that the case is not yet closed 
and there is an urgent need for further studies in this field. 
 
In particular the key areas in need of further research are:  
 
a) Establishing the effectiveness of acetic acid in the detection of neoplasia in a 
low risk surveillance population 
b) Understanding the role of the aceto-whitening reaction in the examination of 
neoplasia within Barrett’s 
c) Further larger studies into the effectiveness of vascular enhancement 
techniques in the examination of Barrett’s in both low and high risk 
populations. In particular studies with FICE and i-scan are needed 
d) Studies to examine whether acetic acid and vascular enhancement 
techniques can be used together to accurately localise neoplasia within 
Barrett’s and whether this is more effective than either technique on its own 
e) Randomised controlled trials of all of the above mentioned techniques  
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Chapter 4 
 
Flexible Spectral Imaging Colour Enhancement 
(FICE) 
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FICE 
 
This chapter aims to describe the principles behind FICE. To understand how this 
technology enhances vascular structures, it is necessary to outline the key steps in 
the image processing that it performs. 
 
Visible white light consists of electromagnetic waves with a wavelength of 400 to 
700nm. When white light is used to illuminate an object some light is reflected which 
is perceived by the L, M or S cones in the retina that are sensitive to red (R) green 
(G) or blue (B) light respectively. This is then perceived as colour by the occipital 
lobe of the cerebrum. Traditional charge coupled device (CCD) image capture 
systems are based on the trichromatic theory of image reproduction, characterized 
by the additive colour mixing of the primary colours red, green and blue. Each of 
these three primary colours has a wide bandwidth. The human eye is thought to be 
able to distinguish 16.7 million colours, or 256 levels for each primary colour.  
 
Traditional CCD systems have limitations. The quality of colour images is influenced 
by the spectral characteristics of the imaging device, illumination and the visual 
environment. Therefore recording and reproduction of spectral information on the 
object rather than just RGB information can result in a better and more faithful 
reproduction of the original image as it adjusts for these factors. This is the system 
used for electronic museums and digital archiving. It is now being applied to 
endoscopy. The key design concept is that a standard colour reproduction is 
inadequate to diagnose early neoplasia, and that colour reproduction can be 
improved by principal component analysis. 
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All image reproduction aims to create a two dimensional representation of a three 
dimensional structure. To achieve this, three dimensional information (x,y,z) is 
projected onto a two dimensional plane for recording. In traditional image capture 
three bands (RGB) are subsequently captured and mixed to achieve colour 
reproduction. The characteristics of an object can therefore be expressed as the 
function O (x,y,z,t,), where t=time and is the wavelength of visible light. To 
simplify this for further discussion time, special coordinates and angle of deviation 
will henceforth be disregarded to allow focus on the wavelength information of object 
O(). Light sources have a specific spectral emissivity, E(). Any filters can be 
described as having a spectral transmittance of fi(). Using these factors the image 
can be described as follows: 
 
Spectral emissivity of light source: E() 
Spectral reflectance of object: O() 
Spectral sensitivity of CCD camera: S()  
Spectral transmittance of the lens and fibre: L()  
Spectral transmittance of filters:  fi() (i=R,G,B) 
camera output:  Vi  (i=R,G,B)  
 
Camera output can be expressed with the following equation: 
Equation 1: 
Vi(x,y) = E() f(L() S() O() d
i=r,g,b 
x,y=coordinate of the object 
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This can also be expressed as a vector equation 
Equation 2: 
Vi = HiO 
 where Hi is the operator that transforms the vector O (spectral reflectivity 
characteristics of the original object) into vector Vi the ‘camera’ output in red, green 
and blue. 
 
Therefore the final colour reproduction seen on the visual display device (CRT or 
LCD screen) is determined from the input of value Vi after it has undergone a 
mathematical transformation which takes into account the characteristics of the 
display, the visual environment and light source.  
 
The aim of the exercise is to convert the input data into a visual screen output which 
captures and enhances the key characteristics and clinical features of the original 
object. The resultant image therefore takes into account: 
 
a) Spectral reflectance of the tissue being examined 
b) Spectral characteristics of the illuminating light source 
c) Spectral characteristics of the imaging system 
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However, more can be achieved than simply creating an accurate reproduction of 
the original image. The output image can be calculated with different spectral 
transmittance by the addition of digital colour ‘filters’. See figure 7. 
 
 
Figure 7: Key components of the spectral imaging system 
 
To understand how this works it is necessary to look at the spectral reflectance data 
captured from multiple samples of colorectal mucosa. Providing the spectral 
reflectance of the tissues to be examined is known, the colour reproduction can be 
predicted by the system. This has been quantitatively measured using spectroscopy 
systems built into specialised spectral endoscopes. These devices consist of a light 
source, optical endoscope, spectroscope and optical multichannel analyzer. 
Reflected light is measured by the spectroscope and analysed electronically. 
Wavelength calibration can be performed with a mercury spectrum and white plate. 
This is a very processor intensive process which has to be calculated for every point 
on an object. When this was initially attempted in the late 1980s computers were not 
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fast enough to perform this effectively. As a result attempts were made to estimate 
spectral reflectance from camera output by solving the integral equations described 
previously. The key problem is that compared with the camera output, spectral 
reflectance has a greater number of dimensions. The measurement of white light 
between 400-700nm at 5nm intervals is associated with 61 dimensions. In the graph 
below (figure 8) the spectral reflectance is plotted as a function of wavelength for 
these samples. 
 
Figure 8: Spectral reflectance as a function of wavelength (Reproduced from Mayake 
et al 2005 (121)) 
However, whilst calculating 61 dimensions would be impractical, it can be seen from 
this graph that there are three peaks corresponding to the most important 
wavelengths. Using principle component analysis of this data it has been shown that 
three components can give a good representation of spectral reflectance for 
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colorectal mucosa, with 99.7% of the reflection spectra expressed by these 
components. See figure 9. 
 
Figure 9: Three principle components (a) and cumulative contributions (b) of spectral 
reflectance of the rectal membrane 1=green, 2= red, 3=blue (Reproduced from Mayake et al 2005 (121)) 
 
To obtain a reconstructed and enhanced image of the original object (O’) based on 
spectral reflectance data an inverse transformation matrix is required Hi
-1
 . This can 
be populated using the Wiener estimation method. 
 
O’  =  Hi
-1
 Vi        
(where i – R,G & B) 
 
An endoscope was initially used to capture sample RGBs from Macbeth Colour 
checker charts corresponding to spectral reflectance O where camera output Vi 
could be measured. Illumination came completely from the light source of the 
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endoscope. This was then used to populate a ‘lookup’ table from which the matrix  
Hi
-1 can be filled. 
 
1             K1r   K1g   K1b             R 
2     =     K2r   K2g   K2b            G 
3             K3r   K3g   K3b             B 
 
Using this matrix, it is then possible to choose any set of wavelengths that captures 
and enhances the key characteristics and clinical features of the colorectal mucosa, 
based on the three principle components discussed above. Put simply whereas a 
conventional television image is made up by mixing red, green and blue light it is 
now possible to mix any frequencies to enhance particular structures.  As the system 
is based on a look up table it is not processor intensive and can be achieved in real 
time. FICE assigns the estimated spectral images to each RGB component sent to 
the display device to produce the final colour image. This final image can be 
constructed from many combinations of spectral image at different wavelengths to 
enhance the visualisation of pathology, with the optimum selection depending on the 
kind of tissue and disease being examined. In this manner, various combinations of 
wavelengths can be used to form the final displayed image. By the same logic, 
wavelengths that are not desirable can be left out. This achieves a similar function to 
a physical filter. However, it is much more flexible, as potentially a large combination 
of images can be produced and switched between rapidly. The EPX 4400 comes 
with ten frequencies pre-programmed. These are shown in table 13. 
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Preset 0 1 2 3 4 5 6 7 8 9 
R 500nm 500nm 550nm 540nm 520nm 500nm 580nm 520nm 540nm 550nm 
G 445nm 470nm 500nm 490nm 500nm 480nm 520nm 450nm 415nm 500nm 
B 415nm 420nm 470nm 420nm 405nm 420nm 460nm 400nm 415nm 400nm 
Table 13: Pre-programmed Frequencies for FICE 
 
It is currently unclear which settings are most suitable for a given task. There have 
been very few studies performed in the colon, and each study has used a different 
setting. A small picture study has suggested that setting 4 yields the clearest image 
of the colorectal mucosa (55). However, this did not examine any pathology, and has 
not been backed up by any cohort observational studies demonstrating superiority of 
one setting over another. There has been so little work conducted outside of the 
colon, it is simply not possible to comment whether one setting is superior to 
another. 
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PART B 
 
Experimental work 
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Chapter 5 
 
Colonic polyp studies 
 
Background to investigations 
 
  
123 
 
5.1 In-vivo diagnosis 
 
Polyps are commonly found during colonoscopy and it is current practice to remove 
all of these lesions, as some have the potential to develop into cancer. As described 
in the previous chapters, polyps are not all the same. It is established that 
hyperplastic polyps have negligible malignant potential, especially when small 
(<10mm) and in the left colon. These polyps account for one third of all small polyps 
(13). In contrast adenomas can progress to cancer and therefore require resection 
(14). Polyp cancers should be biopsied and referred for specialist intervention. 
 
The management pathway for polyps >10mm is clear and well described. Most large 
polyps are either likely to be adenomas which need removal or cancers, which need 
careful consideration for endoscopic or surgical resection. Even large hyperplastic 
polyps have to be removed as there is the possibility that they are serrated 
adenomas which carry malignant potential. However, the majority of polyps found 
during screening endoscopy are small, representing over 90% of the polyps 
encountered (122). The optimum management of polyps <10mm in size is not so 
well established. Because it has been traditionally felt that it is difficult for the 
endoscopist to differentiate hyperplastic polyps from adenomas, it is current practice 
for all polyps to be removed. However, polypectomy is associated with significant 
risks (15). It results in a prolongation of the procedure time which has an immediate 
impact on endoscopy output and has histology related cost implications. If an 
endoscopist could make a confident in-vivo diagnosis, then hyperplastic polyps 
<10mm could be left in-situ or removed but not retrieved to reduce pathology costs. 
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The previous chapters have described Japanese studies of in-vivo diagnosis. These 
have involved examination of polyp surface patterns (Kudo’s pit patterns) and have 
achieved excellent results (16) (17) (20). Unfortunately this work initially involved 
vital staining with crystal violet and optical magnifying endoscopes which are 
cumbersome and time consuming to use. This is only used in the assessment of 
probable cancer in Japan and is not routinely available on Western screening lists. 
There have been numerous studies into the use of indigocarmine as a diagnostic 
tool, which is easier to use than crystal violet. However, most of these studies have 
still required the use of magnifying endoscopes and analysis of Kudo pit patterns. 
Whilst this is considered acceptable in Japan, the inconvenience of dye spray and 
magnification endoscopy coupled with the perceived complexity of Kudo pit pattern 
recognition, has resulted in Western endoscopists questioning its role in Europe and 
North America. 
There has been interest in electronic imaging for the in-vivo diagnosis of colonic 
polyps. Olympus, Fujinon and Pentax have introduced vascular and surface 
enhancement features into their endoscopes. A potential advantage of these 
technologies over chromoendoscopy is that they are activated by the press of a 
button and therefore straightforward to apply on busy lists. Narrow band imaging 
(NBI) from Olympus is an optical filter technology which enhances the visibility of 
vessels on the mucosal surface (123). Whilst this does not directly replicate the dye 
spray appearances which highlight surface patterns, it was proposed that these 
could be used for the purposes of in-vivo diagnosis. A recent study has shown the 
utility of NBI in differentiating neoplastic from non neoplastic lesions <10mm in size 
(47) with an accuracy of 93%. There are also numerous assessment tools for use 
with the technology. The details of these studies were reviewed in Chapter  2.  
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Fujinon have developed a post processor technology called Flexible Spectral 
Imaging Colour Enhancement (FICE). White light endoscopy captures reflected light 
in a wide spectrum (400nm-700nm) with a CCD device. FICE processes this 
conventional image into a spectral image composed of specific wavelengths and 
displays them in real time. This was described in detail in chapter 4. Whilst the 
method of processing the image is quite different, the concept is similar to Narrow 
Band imaging. The benefits of digital processing however mean that multiple 
wavelengths can be used in image reconstruction and the endoscopist can manually 
select the best mode to assess the polyp. This enables subtle structural and vascular 
patterns on the surface of polyps to be assessed in greater detail than can be 
achieved with white light alone.  
 
It is important to recognise that whilst the concept of what FICE is attempting to 
achieve is similar to NBI, its implementation is fundamentally different. The image 
produced looks different to what is seen with NBI and therefore it would be 
potentially dangerous to assume that the assessment tools developed for NBI could 
be used with FICE. A further problem with FICE has been its complexity. To date 
there have been very few studies conducted into its effectiveness in making an in-
vivo diagnosis. The results from the published studies have been variable, with some 
claiming good results, others disagreeing. Most of the small volume of literature that 
is available has not invested in developing the appropriate tools for use with FICE, 
instead using classifications such as KUDO pit patterns which have never been 
validated for use with electronic imaging. The only published classification system for 
polyps using FICE utilised optical magnification and the authors specifically stated 
that they felt FICE could not be used without optical magnification. As a result, 
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endoscopists have been left with a lack of information on how to use this technology, 
and indeed whether it is of any value at all. Subsequently many endoscopists have 
been left dissatisfied with FICE. Common complaints are that picture quality is very 
variable, for no apparent reason, and that it is confusing to know what setting to use 
and how to interpret the images. 
 
There are therefore four key issues which need to be addressed: 
1) A tool needs to be developed for assessing colonic polyps using FICE without 
optical magnification 
2) The optimum FICE setting for examining colonic polyps needs to be 
established 
3) The impact of high definition (HD) endoscopes on FICE assessment 
4) The role of FICE in performing in-vivo diagnosis of colonic polyps 
 
Without addressing these issues FICE cannot be used in clinical practice for the in-
vivo diagnosis of neoplasia. Misdiagnosis of colonic polyps is a potentially very 
serious issue, as it can result in mismanagement of the patient. Therefore a robust 
assessment tool which is reliable and demonstrated to work in a well powered study 
is an essential requirement. 
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5.2 High definition versus standard definition endoscopy 
 
High definition endoscopy is now being offered from all of the major endoscope 
manufacturers, and it has been predicted that the uptake of high definition equipment 
will be a major growth area over the next 5 years (124).  Modern colonoscopes 
utilise charge coupled devices (CCD) with pixel densities of up to 1.3 million pixels. 
In contrast, standard definition endoscopes have CCD resolutions of around 410,000 
pixels. To define a system as high definition requires a high resolution charge 
coupled device (CCD) and a processor capable of outputting a digital high resolution 
signal to a display of at least 1024x768 pixels. However, there is remarkably little 
known regarding the potential value of high definition over standard definition 
equipment. 
 
Some work has been performed into in-vivo diagnosis of colonic polyps. However, all 
of these studies have been performed using high definition equipment, usually with 
optical magnification (20) (26) (47) (49). Unfortunately not all endoscopy units are 
equipped with enough high definition equipment to regularly run complete lists 
without resorting to the use of older, standard definition (SD) equipment.  
 
If an in-vivo diagnosis of small polyps<10mm in size could be made this would result 
in a significant cost saving (68). However, endoscopists need to feel confident that 
the equipment available is fit for this purpose. Acquiring high definition (HD) 
endoscopes represents a significant capital investment and their clinical value 
remains uncertain. In the current era of austerity it is unclear whether the expense of 
upgrading existing equipment can be justified. 
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Again the Fujinon endoscopes are under researched in this area. There are currently 
no studies to answer whether HD makes any difference to diagnostic capabilities. In 
clinical practice. the newer HD scopes are more expensive than older SD 
endoscopes and clinicians need to know the clinical advantages of these 
endoscopes to justify the extra cost.  
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5.3 Study aims 
 
1) To develop a new classification system for colonic polyps using FICE without optical 
magnification 
2) To establish the optimum FICE setting to use for assessing colonic polyps 
3) To assess the accuracy of in-vivo diagnosis of colorectal polyps<10mm using FICE 
as an electronic imaging tool using this new classification system 
4) To establish whether there is any additional gain from indigocarmine dye spray as a 
chromoendoscopic imaging tool. 
5) To compare the accuracy of standard and high definition Fujnon colonoscopes in the 
diagnosis of neoplastic polyps<10mm using white light, FICE and indigocarmine 
chromoendoscopy  
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Chapter 6 
 
Methods 
 
Development of a new polyp classification system using FICE 
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6.1: Introduction 
 
The main assessment tools available for in-vivo histology prediction are white light 
examination, electronic imaging (NBI, FICE, i-scan) and dye spray (indigocarmine). 
Whilst the established Kudo classification system for colonic neoplasia is accepted to 
be an effective tool for the in-vivo histology prediction of colonic polyps using 
indigocarmine with optical magnification, it is often perceived as being difficult and 
impractical to apply in a Western setting outside of a research programme. 
Furthermore, it is generally accepted that many of the features described in Kudo’s 
pit patterns are not always visible without optical magnification. For this reason a 
new classification system, known as N.A.C., was developed by this department for 
assessing colonic polyps with indigocarmine (125)  without optical magnification.  
 
N.A.C. stands for Non adenomatous (hyperplastic), Adenomatous and Cancer. It 
involves the assessment of two key structural elements; vascularity when viewing 
the polyp with white light, and surface patterns after indigocarmine dye spray. The 
key appearances of polyps using the N.A.C. classification are as follows: 
 
N = Non adenomatous: Relative pallor (hypovascular) on white light with the 
surface pattern after indigocarmine appearing similar to the adjoining normal mucosa 
with large, non compact crypts 
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A = Adenomas Hypervascular appearance on white light with the surface pattern 
after indigocarmine appearing regular but different from the surrounding mucosa 
(round, tubular round  or gyriform patterns)  
C =Cancer: Hypervascular appearance on white light with an irregular surface 
pattern after indigocarmine 
 
The situation for the classificiation of colonic polyps using electronic imaging with 
FICE is less clear. The only previous classification system for FICE was defined by 
Texiera et al. using optical magnification (56). This is a complex system. 
Furthermore, the authors stated that they felt it was not applicable to use this without 
optical magnification.  
Therefore a new classification system for colonic polyps using FICE without optical 
magnification was developed based on the criteria defined in the N.A.C classification 
system. This system would be based on assessment of the key structural 
components described in the N.A.C. classification system. It was felt that vascular 
patterns and surface patterns would not be visible with white light. Therefore the 
assessment of vascularity would be performed using white light, with the assessment 
of vascular patterns and mucosal patterns performed with FICE. The intention would 
be for this system to be simple to apply on a routine basis and suitable for use with 
standard (non magnifying) endoscopes. Figures 10 to 15 demonstrate the 
appearances of hyperplastic polyps and adenomas seen with white light, FICE and 
after indigocarmine dye spray when viewed with a non magnifying high resolution 
endoscope. 
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                                                              Figure 10: Hyperplastic polyp White light 
                                  
                                                                Figure 11: Hyperplastic polyp FICE setting 4 
                                  
                                                                   Figure 12: Hyperplastic polyp Indigo carmine 
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                                                              Figure 13: Adenomatous polyp White light 
 
 
Figure 14: Adenomatous polyp FICE setting 4 
 
 
Figure 15: Adenomatous polyp Indigo carmine 
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It was unclear which FICE setting would be optimal for the examination of colonic 
polyps, or which of the previously defined features of the  N.A.C. criteria would be 
visible using FICE. Therefore three pilot studies were conducted: 
 
1) Defining the optimum FICE setting (Chapter 6) 
2) Defining the N.A.C. criteria using FICE (Chapter 7) 
3) Validation of the N.A.C. criteria for FICE by making in vivo assessments 
Chapter 8) 
 
6.2: Location of the studies 
All work was conducted at Queen Alexandra Hospital in Portsmouth. This is a major 
district general hospital on the South Coast of England covering a catchment 
population of 600,000 people. It offers a tertiary advanced endoscopy service to the 
entire south coast, for the diagnosis and treatment of early cancer in the 
oesophagus, stomach, duodenum and colon with three lists a week dedicated to this, 
including two lists a month with anaesthetic support. There is an established Bowel 
Cancer Screening Programme running from the endoscopy department, with two 
screening colonoscopy lists a week dedicated to colonoscopy screening. 
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5.3: Ethics approval 
 
The Portsmouth research and ethics committee was approached for permission to 
conduct the study. It was assessed at the December 2009 meeting and was felt by 
the panel that the studies were principally of the endoscopist and their ability to make 
an in-vivo diagnosis. As it did not involve any additional procedures to the patient 
(FICE and indigocarmine are routinely used in the assessment of polyps for reasons 
other than in-vivo diagnosis, principally to delineate borders for resection), it did not 
require permission. A waiver for permission to conduct the study was granted by the 
committee REC No:.09/H0501/94. 
 
The studies were registered with the European Clinical Trials Database (EudraCT 
2009-016742-10) and with the American Clinical Trials Database (ClinicalTrials.gov, 
NCT01182623). 
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Chapter 7 
 
Defining the optimum FICE setting 
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7.1: Introduction 
 
There has been very little work performed which has examined which FICE setting is 
best suited for examining colonic polyps. The previous studies which have used 
FICE as an in-vivo diagnostic tool have all used different settings. As described in 
chapter 4, FICE is capable of reconstructing the image based on many different 
wavelengths, with 10 pre set combinations available as standard. The settings vary 
considerably in terms of their appearance, with some appearing dark and others 
much lighter. Whilst this provides considerable flexibility, it is not practical to examine 
every lesion with all 10 settings. There is currently confusion amongst endoscopists 
as to which setting should be used for examining colonic polyps. This is unfortunate, 
as it is difficult to develop or validate any classification system without first 
establishing which FICE setting should be used for the assessments. 
 
A single study from Spain attempted to use FICE in the examination of colonic 
mucosa, and concluded that setting 4 (520,500,405nm) was superior to the other 
settings for the examination of vascular and surface patterns (55). However, that 
study only examined normal colonic mucosa, which is not necessarily representative 
of the best setting for the examination of colonic polyps. 
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7.2: Aims 
 
This study aims to determine the optimum FICE setting for the examination of the 
key structural components of colonic polyps, based on the pre-programmed 
reconstructions built into the EPX4400 processor. 
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7.3: Methods 
 
The optimum settings for FICE was determined in a preliminary picture study. 
Images were prospectively collected from patients undergoing colonoscopy on 
Bowel Cancer Screening Lists. Exclusion criteria were: poor bowel preparation, 
active inflammation or the presence of melanosis coli. All procedures were 
performed using Fujinon EC530 and EC 590 colonoscopes and the EPX 4400 
processor. Optical magnification, where available, was not used. Patients had 
standard bowel preparation with three sachets of sodium picosulphate. For morning 
lists this was given at breakfast, lunchtime and in the evening on the day before the 
procedure. For afternoon lists two sachets of sodium picosulphate were administered 
on the morning of the procedure, given at 6:00 and midday.  Polyps were identified 
using white light endoscopy and examined on withdrawal. Prior to examination and 
image capture, the polyps were cleaned by flushing 10-20ml of water to remove any 
visible debris, with care taken not to traumatise the mucosa. The polyp was then 
brought around to the 6 o’clock position for detailed examination. Lesions where a 
good, stable view could not be obtained were excluded. Digital photographs were 
then taken of the polyps with white light and all 10 FICE settings. The wavelengths 
used in these reconstructions are shown below in table 14 and illustrated in figure 
16. 
Preset 0 1 2 3 4 5 6 7 8 9 
R 500nm 500nm 550nm 540nm 520nm 500nm 580nm 520nm 540nm 550nm 
G 445nm 470nm 500nm 490nm 500nm 480nm 520nm 450nm 415nm 500nm 
B 415nm 420nm 470nm 420nm 405nm 420nm 460nm 400nm 415nm 400nm 
Table 14: Wavelengths used in each FICE setting 
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Figure 16: A hyperplastic and adenomatous polyp visualised with white light and all 10 FICE settings 
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Images were saved directly from the digital source to the SD memory card built into 
the processor to avoid artefacts associated with analogue image capture from the 
other outputs from the stack. These included hyperplastic polyps, adenomas and 
cancers. Two pictures were taken with each setting for each polyp, with the lesser 
quality image discarded. The images were collated into an album using Microsoft 
Powerpoint 2007. Images were stored in uncompressed TIFF format at 1026x770 
resolution.  
The library was reviewed independently by two endoscopists (GLW+PZB) who 
scored each image for the clarity of: 
1) Mucosal surface patterns 
2) Surface vascular patterns 
3) Vascularity 
4) Visibility of artefacts  
This was rated on a four point scale: 0=poor, 1=fair, 2=good, 3=excellent. In the case 
of artefacts a low score meant that more artefacts were seen. These included stool 
debris and mucous which had the potential to obscure views of mucosal surface 
details.  
No sample sizes were calculated as this was a pilot study and there was no data 
available regarding the examination of colonic polyps with FICE. The mean scores 
and standard deviation for each assessor using white light and all 10 FICE settings 
was calculated. Mean scores from each assessor were compared using an unpaired 
Students t test and standard deviations were reported. The mean score for any 
setting which was more than two standard deviations from the overall mean score for 
a given assessor was noted.  
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7.4: Results  
 
Images of 30 polyps with white light and all 10 FICE settings were examined; 13 
hyperplastic polyps, 15 adenomatous polyps and 2 polyp cancers. The results are 
shown in table 15. Setting 4 was found by both assessors to be superior, with an 
overall score 2 standard deviations above the mean score for each assessor. The 
key benefits were in terms of clarity of mucosal and vascular patterns. There was no 
significant difference in the scores for the other settings. White light scored poorly for 
the assessment of surface and vascular patterns by both assessors. However, a 
good assessment of overall vascularity could be made with white light. Both 
assessors felt that there were less artifacts seen with white light which helped to 
bring the overall score for white light up.  
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 GLW PZB 
 Mucosal 
surface 
Vascular 
pattern 
Vascularity Artifacts Overall Mucosal 
surface 
Vascular 
pattern 
Vascularity Artifacts Overall 
W 44 46 68 63 221 42 37 69 77 225 
0 55 61 71 49 236 47 48 55 64 214 
1 55 62 71 50 238 52 51 53 61 217 
2 56 66 68 51 241 62 56 59 60 237 
3 54 66 70 56 246 61 54 58 59 232 
4 60 70 70 56 256 83 80 80 79 322 
5 50 57 66 53 226 65 60 62 62 249 
6 46 57 62 52 217 68 59 61 63 251 
7 47 58 71 49 225 60 56 56 59 231 
8 49 59 66 50 224 62 59 57 60 238 
9 52 61 63 49 225 71 59 58 59 247 
Mean 
(SD) 
52 
4.9 
 
62 
4.6 
68 
3.2 
53 
4.3 
232 
12 
61 
11 
56 
10 
61 
7.7 
64 
7.2 
242 
29 
Table 15: Numerical scores of images obtained using Fujinon EC530 and EC590 colonoscopes and EPX 4400 processor 
using either white light (W) or each of the 10 pre-programmed FICE settings (0-9). Data are presented as mean  SD 
from 30 individual polyps (Hyperplastic, adenoma and cancers) 
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7.5: Discussion 
 
Overall, vascularity could be seen clearly using white light. However, vascular and 
surface patterns could not be clearly identified using this alone. The optimum setting 
for using FICE to assess vascular and surface patterns is setting 4 (520,500,405nm). 
All of the FICE digital filters unfortunately enhance artefacts, including poor bowel 
preparation and other debris. These findings support those from the previous study 
examining the optimum FICE setting for the examination of colonic mucosa (55) and 
suggest that for the examination of colonic polyps, setting 4 provides optimum 
enhancement. 
 
The default settings provided by the manufacturer were used. Whilst it is possible to 
program the EPX4400 processor to use any combination of wavelengths, this would 
not have answered the question which most endoscopists ask, which is; how to 
rapidly set up the system for use in making an in-vivo diagnosis of colonic polyps. If 
further work is to be conducted in developing a simple and easy to apply 
classification system, it would be unlikely to gain widespread acceptance if this were 
a custom setting. This is not to say that it would not be possible to develop a setting 
which visualises surface structures in more detail. However, the range of settings 
provided as standard is quite comprehensive and one of the criticisms of FICE is that 
it is already overly complex, and there does not appear to be a need to make this 
situation any worse.  
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It should be noted that neither of the assessors felt that setting 8 provided an 
optimum image for the assessment of vascular or surface structures. The 
wavelengths utilised by setting 8 corresponds to those utilised by the physical filter of 
the Narrow Band Imaging System from Olympus. This highlights the point that NBI 
and FICE are different technologies, and that results obtained from one of the 
systems cannot be extrapolated to the other.  
 
It is important to note that surface patterns could be visualised using FICE. The 
original design concept behind all of the electronic imaging systems (NBI, FICE and 
i-scan) is that they enhance surface vasculature. However, traditional methods of in-
vivo diagnosis have relied upon surface pattern assessment using Kudo pit patterns. 
It was suggested in a previous study that FICE may be able to enhance surface 
patterns (26) and this data would appear to support this. This would suggest that 
FICE could be applied to assessment using the N.A.C criteria previously described. 
It also introduces an additional factor which can be exploited, the assessment of 
vascular structures, which cannot be done with indigocarmine. Further work is 
required in this area. 
The study was conducted using both standard definition and high definition 
colonoscopies. Whilst it was possible to identify the vascular and surface patterns 
using both standard and high definition equipment it was subjectively harder to 
obtain a high quality image using the standard definition colonoscopies. This is not 
reflected well in a picture study, where all of the images reviewed are of a high 
quality, but would have an impact when making an in-vivo assessment. A similar 
point was raised in a previous study (55) where the authors concluded that their 
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results only applied to high definition equipment. Optical magnification was not used 
in the generation of the library, and assessment of surface and vascular patterns 
could be made without magnification. This contradicts the findings of Teixeira et al. 
(56) who suggested what FICE assessments were only possible when optical 
magnification is used. 
 
In summary FICE setting 4 appears to be the optimum setting for the examination of 
colonic polyps. Surface and vascular patterns can be identified without optical 
magnification. This calls for further work into development of a classification system 
for the assessment of colonic polyps without optical magnification. 
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Chapter 8 
 
Development of N.A.C. for FICE 
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8.1: Introduction 
 
Whilst there is considerable interest in in-vivo diagnosis, it is not possible to 
recommend any technique for widespread use without the development of a robust 
assessment tool. The Kudo pit pattern classification is established for use with 
magnifying endoscopes and indigocarmine (126), and the Portsmouth research 
group has proposed the N.A.C. classification system for use with standard 
endoscopes (125). There have been numerous polyp classification systems 
proposed for use with Narrow Band Imaging (51) (53) (38). However, there is only 
one classification system proposed for use with FICE, which is only validated for use 
with optical magnification (56).  This is unfortunate as most screening colonoscopy is 
performed with standard endoscopes which lack optical magnification. Furthermore, 
many endoscopists complain that magnification colonoscopes are bulky and 
challenging to use on a routine basis. Whilst it is possible that elements of these 
classification systems may be applicable to FICE without magnification, this has 
never been proven, and Teixeira et al. specifically stated in their discussion that they 
believed their classification system only applied to high resolution endoscopes with 
optical magnification (56).  
 
It was demonstrated in the previous study that FICE is capable of enhancing surface 
and vascular patterns when used without optical magnification. These could 
potentially be used in a similar way to the surface pattern assessments used in the 
N.A.C. classification system for indigocarmine, with the additional advantage that 
vascular patterns could also be exploited. However, it is uncertain how reliably these 
patterns can be seen in-vivo when magnification is not used. How these can be used 
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in making an in-vivo diagnosis is unclear. This study aims to define the key surface 
and vascular patterns seen on hyperplastic polyps, adenomas and cancers when 
viewed with FICE, and to modify the existing N.A.C. classification system to use 
these patterns in place of conventional indigocarmine based assessment. 
 
8.2 Aims 
To define the vascular patterns and surface patterns visible on colonic polyps in a 
picture based study using FICE as the assessment tool, and to modify the previously 
defined N.A.C. classification system to be used with these patterns. 
 
8.3 Methods 
 
Images were prospectively collected from patients referred for Screening 
Colonoscopy. All procedures were performed using Fujinon EC530 and EC 590 
colonoscopes and the EPX 4400 processor. Optical magnification, where available, 
was not used.  Exclusion criteria: were poor bowel preparation, active inflammation 
or the presence of melanosis coli. Patients had standard bowel preparation with 
three sachets of sodium picosulphate. For morning lists this was given at breakfast, 
lunchtime and in the evening on the day before the procedure. For afternoon lists 
two sachets of sodium picosulphate were administered on the morning of the 
procedure, given at 6:00 and midday. Polyps were identified using white light 
endoscopy and examined on withdrawal. Prior to examination and image capture, 
the polyps were cleaned by flushing 10-20ml of water to remove any visible debris, 
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with care taken not to traumatise the mucosa. The polyp was then brought around to 
the 6 o’clock position for detailed examination. Lesions where a good, stable view 
could not be obtained were excluded.  An image library of polyps was created using 
white light and the clearest FICE settings. In each case the true pathology reported 
by an expert gastrointestinal pathologist was known for each polyp image. Images 
were saved directly from the digital source to the SD memory card built into the 
processor to avoid artifacts associated with analogue image capture from the other 
outputs from the stack. A minimum of two pictures were taken with each setting for 
each polyp, with the lesser quality image being discarded.  
 
A library of Images was created using Microsoft Powerpoint 2007 for Windows and 
stored in an uncompressed TIFF format at 1026x770 resolution. The library was 
examined by two blinded endoscopists expert in lesion recognition (GLW+PZB) to 
score each polyp picture on its vascularity, vascular and surface patterns. These 
were then compared with the true histopathology.  
 
No sample sizes were calculated, as this was a pilot study, and there was no 
previous data available to base such calculations upon. Categorical data are 
presented as frequencies and percentages.  
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8.4: Results 
 
An image library of 661 images of 67 polyps was examined. In each case the true 
histology was known. These images were examined and key structural elements 
noted. From this the N.A.C. classification system was adapted for use with FICE.  
 
It was found that one structural element could be examined with white light and three 
different structural elements could be identified using FICE:  
1) Vascularity on white light  
2) Vascularity with FICE 
3) Vascular patterns with FICE  
4) Surface patterns with FICE 
 
It was noted that more adenomas appeared hypervascular with FICE than with white 
light (94% vs 78%). Therefore whilst N.A.C. for indigocarmine was based purely on 
assessment of vascularity with white light and assessment of surface patterns with 
indigo carmine the N.A.C classification for FICE would be based on all of these 
features.  
 
 
 
The frequency of each of these changes is shown in table 16. Based on these 
features polyps would be be graded as N (non-neoplastic) A (adenoma) C (cancer).   
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Hyperplastic polyps: The white light appearances are Pale (hypoaemic). With FICE 
they appear hypovascular in the majority of cases with a low density, sparse and thin 
vascular pattern which looks similar to the surrounding mucosa. There may be the 
occasional vessel but this does not follow a pericryptal pit pattern. The surface 
pattern consists of large non compact crypts or no visible crypts.  
 
Adenomatous polyps: Dark (Hyperaemic) on white light. With FICE they appear 
hypervascular in the majority of cases, with a dense, well organised regular 
pericryptal vascular pattern which is different to the surrounding mucosa.  The 
surface pattern consists of small compact and regular crypts. 
 
Cancers: Very dark (hyperaemic) on white light. With FICE there is a disorganised 
and irregular vascular pattern that is different to surrounding mucosa. The pattern 
may be lost completely. The surface pattern is distorted, with irregular, disorganised 
crypts. 
 
Figures 17-24 demonstrate these appearances. It was noted that whilst there were 
only very subtle differences in the picture quality between SD and HD endoscopes 
when viewing the mucosa with white light, when using FICE it was easier to examine 
the surface vessel structures with an HD endoscope. See figure 25.  
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  Hyperplastic (%) Adenomas (%) Cancers (%) 
White light 
Pale (Hypoaemic) 25/30 
83% 
7/32 
22% 
0/5 
0% 
Dark (hyperaemic) 5/30  
17% 
25/32 
78% 
5/5 
100% 
FICE Vascularity 
Pale  24/30 
80% 
2/32 
6% 
0/5 
0% 
dark   6/30 
20% 
30/32 
94% 
0/5 
0% 
Very dark  0/30 
0% 
0/32 
0% 
5/5 
100% 
FICE vascular pattern 
Absent vascular pattern 15/30 
50% 
0/32 
0% 
0/5 
0% 
Faint vessels not 
following crypts 
15/30 
50% 
0/32 
0% 
0/5 
0% 
Regular Pericryptal  
pattern 
0/30 
0% 
30/32 
94% 
0/5 
0% 
Dense, irregular pattern 0/30 
0% 
0/32 
0% 
5/5 
100% 
FICE Surface pattern 
No surface pattern 19/30 
63% 
0/32 
0% 
0/5 
0% 
Large, non compact 
crypt pattern 
11/30 
37% 
0/32 
0% 
0/5 
0% 
Small, compact, regular 
pattern 
0/30 
0% 
28/32 
88% 
0/5 
0% 
Disorganised, irregular 
pattern 
0/30 
0% 
0/32 
0% 
5/5 
100% 
Cannot assess 0/30 
0% 
4/32 
12% 
0/5 
0% 
Table 16: N.A.C. criteria for FICE assessment. Data presented as frequency of occurrence of a particular characteristic for 
hyperplastic polyps, adenomas and cancers 
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Figure 17: Hyperplastic polyp demonstrating pallor (hypovascularity) with white light and high definition colonoscope 
                           
Figure 18: Hyperplastic polyp with white light and a standard definition colonoscope: Note this is hypervascular 
 
                             
Figure 19: Hyperplastic polyp FICE setting 8 and a standard definition colonoscope. Note it is hypovascular and has a 
sparse vascular pattern. The only visible vessel shows no organisation or pattern and is not following a crypt 
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Figure 20: Adenoma on white light with a standard definition colonoscope. Whilst the surface and vascular patterns are 
unclear in this image it is clearly hypervascular 
                                   
Figure 21: Adenoma with FICE on setting 4 viewed with a high definition colonoscope: It demonstrates a well organised 
pericryptal vascular pattern 
                                 
Figure 22: Adenoma on FICE setting 4 viewed with a high definition colonoscope.The lesion is hypervascular. The 
vascular pattern is less clear but is ordered and crosses the entire surface of the lesion 
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Figure 23: Cancer on white light viewed with a high definition colonoscope. Note how the lesion is hypervascular with a 
disorganised area in the centre. Whilst the pattern is unclear it is clearly abnormal 
                    
Figure 24: When viewed with FICE setting 4 the centre has a disorganised vascular pattern. The edge is ordered and is 
adenoma. If this area was biopsied it would come back as high grade dysplasia only and a misdiagnosis could be made 
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Figure 25: Adenomatous polyp viewed with an HD endoscope (A) and SD endoscope (B). Note how the capillary pattern 
is clearer in A than B 
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8.5: Discussion 
 
The key structural elements that have been used in the N.A.C. classification system 
for indigo carmine can be identified using FICE. In addition, vascular patterns can 
also be seen. There is a difference in the distribution of these patterns between 
hyperplastic polyps, adenomas and cancers, which could be utilised for the purposes 
of in-vivo diagnosis. 
 
It was reassuring to observe that surface patterns could be examined in the majority 
of cases. However, it should be noted that in 12% of adenomas it was not possible to 
assess these patterns. In contrast vascular patterns could be determined in all of the 
lesions. Therefore although FICE can identify surface pits, it is better at identifying 
vascular patterns. It is therefore necessary to assess both surface and vascular 
patterns in the classification of colonic polyps. It was also noted that a greater 
percentage of adenomas had increased vascularity when viewed with FICE than 
when assessed with white light alone (78 vs 94%). This would suggest that an 
additional advantage of using FICE in place of indigo carmine is that a more 
accurate assessment of overall vascularity can be made as indigo carmine cannot 
be used to enhance this, therefore when N.A.C. is used with indigo carmine, the 
assessment of vascularity is completely based on the white light assessment when 
using dye spray. 
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Patterns could be assessed without difficulty without optical magnification. However, 
it is important to stress that this is a picture based study and that this may prove 
more difficult in-vivo. It is generally accepted that picture studies need to be treated 
with caution in this respect. Whilst it may be acceptable to spend some time looking 
at a static image for subtle changes this is not generally possible during a procedure 
with a lightly sedated patient. It is therefore not possible from this to dismiss the idea 
that optical magnification may be of benefit in rapidly assessing surface or vascular 
patterns. It is however reasonable to propose that surface structures can be 
assessed without optical magnification, which contradicts the conclusions reached 
by Teixeira et al. in their study (56). 
 
Whilst assessments could be made with both standard definition and high definition 
images, it was noted that images captured with a high definition colonoscope were 
easier to interpret. It was not possible from the data collected to sub-analyse the 
effects of high definition images on the clarity of surface patterns, as the number of 
images was not adequate and the differences not large enough to draw any 
meaningful conclusions. However, it may be an issue for in-vivo diagnosis. 
 
A limitation of this study is that it is picture based. Whether these assessments can 
be made rapidly in-vivo is unclear. However, it provides the framework for the 
development of an in-vivo study to investigate this further. 
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In summary there are key vascular and structural patterns associated with 
hyperplastic polyps, adenomas and cancers which can be identified without optical 
magnification. These could potentially be exploited for the purposes of in-vivo 
diagnosis using the FICE system.  
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Chapter 9 
 
Validation of the N.A.C. classification system for FICE  
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9.1: Introduction 
 
It has been established that there is a clinical need for a new polyp classification 
system based around FICE without optical magnification, as there is currently only 
one validated system available for use with FICE which requires high resolution 
magnifying endoscopes (56). The last two chapters have described the development 
of provisional tools for the in-vivo classification of colonic polyps using the FICE 
system without optical magnification, based on the previously described N.A.C. 
classification system for indigocarmine. 
 
The proposed N.A.C. classification system is based on an assessment of vascularity 
with white light, followed by an assessment of vascularity, vascular and surface 
patterns using FICE. However, up to this point the development of this assessment 
tool has all been based on picture based assessments. Before this system can be 
utilised in a prospective study of in-vivo diagnosis it is necessary to demonstrate that 
the characteristics described can be reliably identified in-vivo.  
Making an in-vivo assessment is fundamentally different to the examination of a 
picture of a lesion. During live colonoscopy it is necessary to make a rapid diagnosis. 
Polyps cannot always be positioned perfectly, and movement artifacts can distort 
assessments. This can be a problem for complex systems which rely on the 
examination of subtle changes. 
This study aims to validate the N.A.C. classification developed in the last two 
chapters in-vivo on screening colonoscopy lists. 
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9.2:  Methods 
 
A pilot prospective study was performed to test the accuracy of the previously 
identified characteristics for the N.A.C. classification system for FICE in vivo. 
Patients were recruited from screening colonoscopy lists. Fujinon equipment was 
used. The endoscopes were EC-530 and EC-590 colonoscopes with an EPX 4400 
processor. Optical magnification was not used. Patients had standard bowel 
preparation with three sachets of sodium picosulphate. For morning lists this was 
given at breakfast, lunchtime and in the evening on the day before the procedure. 
For afternoon lists two sachets of sodium picosulphate were administered on the 
morning of the procedure, given at 6:00 and midday.  
 
Polyps were identified and assessed during withdrawal. The morphology and size 
was noted and the polyps were cleaned with 10-20ml water prior to examination. To 
assess the characteristics of the polyps with both white light and FICE, the image 
was frozen and the key structural elements previously identified in the picture study 
recorded prospectively on a dedicated proforma. This included vascularity with white 
light, and vascularity, vascular pattern and surface pattern assessment with FICE. 
Assessments were performed by a single endoscopist (GLW). All FICE assessments 
were performed using setting 4 (520nm, 500nm, 405nm). The lesions were then 
removed and sent for histopathological examination by an expert gastrointestinal 
pathologist. 
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No sample sizes were calculated, as this was a pilot study, and there was no 
previous data available to base such calculations upon. Categorical data was 
presented as frequencies and percentages. 
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9.3: Results from the in-vivo validation of N.A.C. for FICE 
 
In total 111 polyps were assessed with 71 polyps from male patients and 40 from 
female patients. The median age of the patients was 65 (range 44-83) and the 
median size of the polyps was 5mm (range 1-20). There were 46 hyperplastic 
polyps, 64 adenomas and 1 cancer. 
 
The vascularity with white light, and the vascularity, vascular patterns and surface 
patterns observed with FICE are shown in table 17. The results were similar to those 
obtained in the picture study, although the assessment of vascularity using white 
light appeared to be a less reliable predictor of histology than previously predicted. 
Increased vascularity seen with FICE was more predictive of adenomatous histology 
than the hyperaemia seen with white light (83% vs 63%). 
 
The presence of faint vessels not following the crypts and an absent surface pattern 
were most predictive that a lesion was non-neoplastic. The presence of large non 
compact crypts was less predictive of hyperplastic (non-neoplastic) pathology, with 
13% of adenomas having large non-compact crypts and 18% having an absent 
vascular pattern. It is possible that a very pale pericryptal pattern surrounding large 
crypts could be incorrectly identified as an absence of vascular pattern, which would 
explain these observations. 
 
 
167 
 
Table 17  Hyperplastic (%) Adenomas (%) Cancers (%) 
WLI 
Pale (Hypoaemic) 27/46 
59% 
11/64 
17% 
0/1 
0% 
Normal (Normoaemic) 2/46 
4% 
8/64 
13% 
0/1 
0% 
Dark (hyperaemic) 17/46 
37% 
45/64 
70% 
1/1 
100% 
FICE Vascularity 
Pale pattern 31/46 
67% 
11/64 
17% 
0/1 
0% 
dark  pattern 15/46 
33% 
53/64 
83% 
0/1 
0% 
Very dark pattern 0/46 
0% 
0/64 
0% 
1/1 
100% 
FICE vascular patterns 
Absent vascular pattern 22/46 
48% 
8/64 
13% 
0/1 
0% 
Faint vessels not following 
crypts 
16/46 
35% 
1/64 
2% 
0/1 
0% 
Regular Pericryptal  pattern 8/46 
17% 
55/64 
86% 
0/1 
0% 
Dense, irregular pattern 0/46 
0% 
0/64 
0% 
1/1 
100% 
FICE Surface pattern 
No surface pattern 17/46 
37% 
0/64 
0% 
0/1 
0% 
Large, non compact crypt 
pattern 
18/46 
39% 
6/64 
9% 
0/1 
0% 
Small, compact, regular 
pattern 
8/46 
17% 
56/64 
88% 
0/1 
0% 
Disorganised, irregular 
pattern 
0/46 
0% 
0/64 
0% 
1/1 
100% 
Cannot assess 3/46 
7% 
2/64 
3% 
0/1 
0% 
 Table 17: N.A.C. criteria for in-vivo FICE assessmen. Data presented as frequency of occurrence of a particular 
characteristic for hyperplastic polyps, adenomas and cancers 
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9.4: Conclusions 
 
The proposed N.A.C. criteria for FICE can be visualized in-vivo. The distribution of 
patterns correlates closely with those found in the previous picture based study. 
Patterns were visible without optical magnification and are therefore suitable for use 
in a prospective cohort study of FICE as a diagnostic tool. 
 
The last three studies have described the development and validation of a new polyp 
classification system, N.A.C. for FICE. This system is unique in that it is designed for 
use without optical magnification and does not necessitate a high resolution 
endoscope. This carries the advantage that it is applicable to standard Western 
screening colonoscopy lists where magnifying high definition endoscopes are not 
routinely available. By demonstrating that the classification system can be utilised in-
vivo the evidence has been provided to justify an in-vivo diagnostic cohort study of 
the predictive value of FICE as a diagnostic tool for colonic polyps. 
 
A limitation of this validation exercise is that it has not been able to subdivide the 
effects of using standard definition and high definition endoscopes. However, it is 
reassuring that whilst the images were noted to be clearer with a high definition 
endoscope the assessments were still possible with standard definition equipment. 
The number of cancers in the in-vivo assessment exercise was very low, with just 
one case found. However, the appearances were identical to those observed in the 
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picture study. For hyperplastic polyps and adenomas the results were very similar 
between the picture study and in-vivo study and therefore it is reasonable to expect 
that the true appearances for polyp cancers are those described in this study. The 
incidence of cancer in small polyps is very low and it is generally accepted that these 
are not the most difficult aspect of in-vivo diagnosis. It is in small lesions that in-vivo 
diagnosis is likely to have the greatest potential impact. Therefore whilst this is a 
limitation the validation, is still robust enough to justify an in-vivo diagnostic trial.  
 
The findings of this study also validate the use of a picture study in the development 
and validation of future studies of endoscopic devices for lesion characterisation. 
The findings from the picture study described in chapter 8 were a good surrogate 
marker of the findings seen in-vivo, which opens up many possibilities for future 
research. 
   
  
  
170 
 
 
Chapter 10 
 
FICE and Indigo carmine in Neoplasia Diagnosis During 
Colonoscopy 
 
 Prospective in-vivo study   
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10.1: Introduction 
 
Polyps are a common finding during colonoscopy. It is current practice to remove 
these lesions, as some have the potential to develop into cancer. However, not all 
polyps are the same. Hyperplastic polyps have negligible malignant potential, 
especially when small (<10mm) and in the left colon. These polyps account for one 
third of all small polyps (13). Adenomas can progress to cancer and require 
resection (14).  
The management pathway for polyps >10mm is simple as they are either likely to be 
adenomas which need removal, or cancers which need careful consideration for 
endoscopic or surgical resection. There is a possibility of large polyps being 
hyperplastic or serrated adenomas which need removal as well. The management of 
polyps <10mm in size is not well established. It has been traditionally felt that it is 
difficult to differentiate hyperplastic polyps from adenomas by the endoscopist. For 
this reason all polyps are removed. However, polypectomy is associated with 
significant risks (15) and results in an immediate cost in processing the samples, 
polypectomy equipment and time. If an endoscopist could make a confident in-vivo 
diagnosis then hyperplastic polyps <10mm could be left in-situ or removed but not 
retrieved to reduce pathology costs, as suggested in the DISCARD study (47). This 
has been recognised as important by the American Society for Gastrointestinal 
Endoscopy (ASGE), who have recently launched an initiative to define the standards 
which have to be met for any technology to be used for in-vivo diagnosis as a 
replacement for conventional histological examination (10). This PIVI programme 
(preservation and incorporation of valuable endoscopic innovations) has developed 
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new paradigms for colonoscopic management of diminuitive polyps and have set 
mandatory standards for these paradigms.  
The standard for a ‘resect and discard’ strategy’ for polyps<5mm in size states that 
an endoscopic technology can be accepted if it can set the endoscopic surveillance 
interval with ≥90% accuracy, as compared to standard histology for polyps of any 
size. A second standard has been set for a technology to be used to ‘leave’ 
suspected rectosigmoid hyperplastic polyps <5mm in place without resecting them. 
This standard demands that technology should provide ≥90% negative predictive 
value (NPV) for adenomas. These standards are very important and timely as most 
of the available technology will now be tested against them. 
 
Japanese studies have involved assessment by examination of polyp surface 
patterns (Kudo’s pit patterns) and have achieved excellent results (126). This was 
originally described using vital staining with crystal violet and magnifying endoscopes 
which is cumbersome and time consuming. This has not been routinely adopted in 
Western practice and is now only used in Japan for the diagnosis of cancer invasion 
depth.  There is also concern about the safety of crystal violet (18). Indigo carmine 
has been used with optical magnification for in-vivo diagnosis of colonic polyps (20) 
(21). This does not bond to or react with human tissue in any way, as it simply sits on 
the surface of tissues, highlighting surface patterns, and has no safety concerns. 
There has been interest in electronic imaging for the in-vivo diagnosis of colonic 
polyps. Olympus, Fujinon and Pentax have introduced vascular and surface 
enhancement features into their endoscopes. Narrow band imaging (NBI) from 
Olympus is an optical filter technology which enhances the visibility of vessels on the 
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mucosal surface (123). A recent study has shown the utility of NBI in differentiating 
neoplastic from non neoplastic lesions <10mm in size, with an accuracy of 93% (47). 
 
Fujinon has developed a post processor technology called Flexible Spectral Imaging 
Colour Enhancement (FICE). White light endoscopy captures reflected light in a wide 
spectrum (400nm-700nm) with a CCD device. FICE processes this conventional 
image into a spectral image composed of rays of specific wavelengths and displays 
them in real time. The system has ten preset wavelength patterns and the 
endoscopist can manually select the best mode to assess the polyp. This enables an 
endoscopist to assess the subtle structural and vascular patterns on the surface of 
polyps in greater detail than can be achieved with white light alone. This could have 
implications for bowel cancer screening programmes, where in-vivo diagnosis could 
be used to reduce histopathology related costs (68). However, most of the studies on 
FICE have included large polyps or been based on the assessment of pictures (26) 
(54) (35) (56). There have not been any studies investigating the in-vivo diagnostic 
capabilities of FICE in a Bowel Cancer Screening population, and only one study 
which has involved an in-vivo assessment without optical magnification on 
lesions<10mm in size (26). 
 
10.2: Aims 
 
This study aims to assess the accuracy of in-vivo diagnosis of colorectal 
polyps<10mm in the U.K. Bowel Cancer Screening Programme (BCSP), using FICE 
as an electronic imaging tool without optical magnification. It also aims to establish 
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the advantage of IC dye spray (without magnification) when used as an additional 
technique after evaluation of polyps with FICE.  
 
10.3: Methods 
The study has ethical approval (REC No. 09/H0501/94) and was registered with the 
European Clinical Trials Database Eudra CT 2009-016742-10 and with Clinical 
trials.gov NCT01182623.  
This was a prospective single blinded observational study performed on consecutive 
asymptomatic patients within the U.K. Bowel Cancer Screening Programme (BCSP). 
All patients had a positive faecal occult blood test prior to colonoscopy. Exclusion 
criteria were: a diagnosis of a familial polyp syndrome, a diagnosis of inflammatory 
bowel disease, poor bowel preparation or melanosis coli, which alters surface 
pattern visualisation and could influence polyp assessment. No other exclusion 
criteria were permitted to preclude selection bias. All consecutive polyps were 
prospectively assessed. As the aim of the study was to establish the effectiveness of 
FICE and IC as diagnostic tools, it was important to avoid the potential confounding 
factor of multiple endoscopists with differing skills in in-vivo diagnosis. Therefore all 
assessments were performed by a single endoscopist (PB) with expertise in in-vivo 
diagnosis of polyps for over 8 years. The endoscopies were performed using EC-530 
and EC-590 Fujinon colonoscopes and EPX 4400 processor without optical 
magnification. A flat screen Sony 24 inch WUXGA LCD display was used (LMD-2450 
MD) with a 1125 x 1080 resolution. Connections between the EPX4400 processor 
and monitor were via a digital video interface (DVI) connector. Polyps were cleaned 
of any debris using 10-20ml of water with 2ml of 10% simethicone before 
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assessment. Care was taken not to traumatise the surface of the lesions.  Size of 
polyps was determined endoscopically using the biopsy forceps (measuring 8mm 
with open Jaws). Polyps <10mm in size were assessed using white light (WLI) 
followed by FICE. Indigocarmine dye spray was then applied to the polyp. Before 
each change in imaging modality, the predicted diagnosis was recorded by a 
member of the research team for that modality, with no possibility for revisiting the 
prediction once made. Based on the pilot work performed prior to this study the FICE 
settings used for this work was preset 4 (R:520nm G:500nm B: 405nm).  Indigo 
carmine (IC) dye spray was made up in a concentration of 0.2% and 5ml was passed 
down the biopsy channel via a 20ml syringe. 
 
WLI, FICE and chromoendoscopy were used to assess the polyp morphology, polyp 
colour, density of vessels, vessel pattern and surface pattern using the N.A.C. 
criteria developed and described in the previous chapters. 
 
Finally the polyps were removed and sent for histological analysis by a consultant 
histopathologist, who was blinded to the diagnosis made by the endoscopist. All 
pathology reporting was performed by an accredited Colon Cancer Screening 
pathologist. Serrated adenomas were treated as neoplastic for the purpose of 
calculating accuracy of in-vivo histology prediction (i.e. the in-vivo diagnosis was 
considered to be incorrect if the endoscopist called a serrated adenoma 
hyperplastic). 
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10.4: Statistical analysis 
The study was prospectively powered. The assumptions were made that 40% of 
polyps found are hyperplastic, that the true sensitivity for neoplasia with both FICE 
and indigocarmine would lie between 85-95%, and that the true specificity with FICE 
and indigocarmine lies between 75-90%.It was felt that analysis should be performed 
on a per lesion basis. With 80% power, assuming a 5% significance level and phi 
coefficient of 0.2, 150 polyps would need to be assessed to achieve statistical 
significance. To demonstrate a 10% difference in the accuracy between FICE and 
indigo carmine, 200 polyps would need to be assessed to produce significant results. 
IBM SPSS-18 for Windows was used for statistical calculations. Accuracy, sensitivity 
and specificity of in-vivo diagnoses using WLI, FICE and indigo carmine was 
compared to histology and calculated with 95% confidence limits. The comparisons 
between white light, FICE and IC are ‘within subject’ on a per lesion basis. Therefore 
the McNemar’s test for repeated measurements was used. 
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10.5: Rescope intervals 
 
A prediction of rescope interval was made using FICE and IC dye spray assisted 
diagnosis, according to British Society of Gastroenterology (BSG) guidelines (127) 
and the American Society of Gastrointestinal Endoscopy (ASGE) guidelines (128).  
This was compared to the actual surveillance interval based on the true histological 
diagnosis. 
 
10.6: Financial analysis 
Financial costs were identified for tissue fixation, processing, staining and pathology 
reporting. Costs were then calculated per polyp for the whole cohort. Cost estimates 
were then calculated for various clinical approaches, on a per patient and per cohort 
basis. 
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10.7: Results 
 
In total 138 patients underwent colonoscopy for bowel cancer screening from 
September 2009 to September 2010, of which 124 patients met the inclusion criteria 
and consented to enter the study. 89 were found to have polyps <10mm in size. 
Either standard definition (SD) or high definition (HD) endoscopes were randomly 
allocated by nursing staff on a basis of availability, with the endoscopist blind to the 
resolution of endoscope allocated. In total 232 consecutive polyps <10mm were 
assessed. See figure 26. The size, location and morphology of polyps are shown in 
table 18.  
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Assessed for eligibility (n=138) 
Excluded (n=14) 
   Not meeting inclusion criteria (n=6) 
   Declined to participate (n=8) 
   Other reasons (n=0) 
No. polyps<10mm analysed (n=89) 
 Polyps<10mm excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Allocated to SD endoscopy (n=58)   
 Patients found to have polyps<10mm (n=40) 
 Number of polups<10mm found (n=89) 
Lost to follow-up (n=0) 
 
Allocated to HD intervention (n=66) 
 Patients found to have polyps<10mm (n=49) 
 No. of polyps<10mm found (n=143) 
No. polyps<10mm analysed  (n=143) 
 Polyps<10mm excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized allocation of endoscope (SD or HD) 
Enrollment 
Total No. polyps analysed (n=232) 
Total No. of polyps excluded (n=0) 
Figure 26: Flow chart for patient recruitment 
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Table 18: Demographics of patient population 
 
  
Table 18 Number of Patients 
Total patients 89 
Male 70 
Female 19 
Mean age 
SD 
65 
6.7 
Polyps 
Mean size (mm) 
(range) 
SD 
232 
4.7 
(2-9) 
2.7 
Right sided 
Left sided 
79 
153 
Morphology 
a) Pedunculated 
b) Non pedunculated (flat) 
i) is 
ii) iia 
iii) iib 
iv) iia+iic 
 
15 
217 
112 
101 
3 
1 
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10.8: True histological diagnosis 
The breakdown of the histology of the cohort showed that 77/232 (33%) were 
hyperplastic and 155/232 (67%) were neoplastic. We defined neoplasia as low risk 
as adenomas with no villous component and no high grade dysplasia. There were 
121 tubular adenomas with low grade dysplasia. High risk neoplasia was defined as 
polyps with a villous component, HGD or cancer. There were 34 high risk lesions (31 
TVA+LGD, 1 TVA+HGD and 2 cancers). 
 
10.9: In-vivo diagnosis 
The accuracy, sensitivity and specificities are shown in table 19. There was a 
significant difference in the accuracy and sensitivity between WLI, FICE and IC. 
FICE significantly (P<0.002) improved the sensitivity to 88% as compared to 75% 
with WLI. IC improved the sensitivity even further to 94% (P<0.0001). The additional 
use of IC showed a numerical improvement over FICE alone, but this difference 
failed to reach statistical significance (P=0.07). 
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 Image modality P- Values, pair-wise comparisons 
WLI FICE IC WLI vs FICE WLI vs IC FICE vs IC 
Accuracy 
(95% C.I.) 
165/232 
71% 
(65-76) 
200/232 
86% 
(81-90) 
211/232 
91% 
(87-94) 
<0.0001 <0.0001 0.11 
Sensitivity 
(95% C.I.) 
116/155 
75% 
(71-79) 
137/155 
88% 
(85-91) 
146/155 
94% 
(91-96) 
0.002 <0.0001 0.07 
Specificity 
(95% C.I.) 
49/77 
64% 
(55-72) 
63/77 
82% 
(74-88) 
65/77 
84% 
(78-89) 
0.011 0.003 0.67 
PPV 
(95% C.I.) 
116/144 
81% 
(76-85) 
137/151 
91% 
(87-94%) 
146/158 
92% 
(89-95) 
0.012 0.002 0.596 
NPV 
(95% C.I.) 
49/88 
56% 
(48-63) 
63/81 
78% 
(74-88) 
65/74 
88% 
(81-93) 
0.002 0.000 0.099 
Table 19: in-vivo diagnosis of neoplasia in polyps<10mm by endoscopic modality. WLI=white light, IC=indigo carmine, 
PPV=Positive predictive value, NPV=negative predictive value 
 
 
There were two cancers in this cohort of polyps and both of these were correctly 
diagnosed by FICE and IC dye spray. One was diagnosed as an adenoma under 
white light. See table 20. 
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 WLI FICE IC 
Hyperplastic  49/77 
64% 
63/77 
82% 
65/77 
84% 
Low risk Adenoma (tubular adenoma) 89/121 
74% 
106/121 
88% 
114/121 
94% 
High risk neoplasia (TVA+LGD, 
TVA+HGD + Cancer) 
27/34 
79% 
31/34 
91% 
32/34 
94% 
Table 20: Accuracy of in-vivo diagnosis by true histology of polyp. WLI= white light, IC=indigo carmine, TVA=tubule 
villous adenoma, LGD= Low grade dysplasia, HGD=high grade dysplasia 
 
10.10: Accuracy by polyp size<5mm 
In this cohort there were 155/232 polyps <5mm in size (diminuitive polyps). A sub-
group analysis of accuracy was performed for 155 lesions <5mm using WLI, FICE 
and IC. This is shown in table 21. Indigocarmine after FICE was significantly more 
sensitive for neoplasia than FICE alone (P=0.037). The negative predictive value for 
indigocarmine after FICE was numerically superior to FICE assessment (90% vs 
78%). However, this difference just failed to reach statistical significance (P=0.066). 
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 WLI FICE IC WLI vs FICE WLI vs IC FICE vs IC 
Accuracy 104/155 
66.5% 
(60-74) 
129/155 
83% 
(77-88) 
139/155 
90% 
(84-93) 
0.001 P=0.000 P=0.097 
Sensitivity 59/90 
66% 
(59-71) 
 
75/90 
83% 
(78-88) 
 
84/90 
93% 
(88-97) 
P=0.006 P=0.000 P=0.037 
Specificity 45/65 
69% 
(60-77) 
 
54/65 
83% 
(75-89) 
55/65 
85% 
(79-89) 
P=0.064 P=0.061 P=0.812 
PPV 59/79 
75 
(67-81) 
75/86 
87 
(81-91) 
84/94 
89 
(85-92) 
P=0.04 P=0.011 P=0.653 
NPV 45/76 
59 
(51-66) 
54/69 
78 
(70-84) 
55/61 
90 
(83-95) 
P=0.014 P=0.000 P=0.066 
Table 21: Accuracy of diagnosis polyps<5mm by endoscopic modality. WLI=white light, IC=indigo carmine, PPV=Positive 
predictive value, NPV=negative predictive value.  
 
10.11: Cost effectiveness of in-vivo diagnosis 
The UK (NHS) costs for pathology was utilised, which equates to a cost of £58.90 
($94.30) per cassette of tissue. This is in keeping with the standards laid out in the 
Lord Carter independent review into pathology services and is competitive with other 
similar laboratories across Europe and North America (9). The cost for histological 
assessment of the cohort using three different protocols was calculated.  
A) Traditional protocol: Retrieve and send all polyps<10mm for histological 
assessment 
B) Portsmouth protocol: Retrieve and send suspected adenomas and 
cancers<10mm but not hyperplastic polyps<10mm for histological 
assessment 
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C) Futuristic protocol:  Discard all adenomas and hyperplastic polyps<10mm 
and only send suspected cancers for histological examination 
 
10.12: Implications for the study cohort 
The potential costs for each of these strategies are shown in table 6. Based on our 
data a potential cost saving of £109 ($174.51) per person undergoing screening 
colonoscopy could be made.  
 
10.13: Implications for the National Bowel Cancer Screening Programme 
Within the national BCSP 12153 colonoscopies are performed per annum with 
11,619 benign polyps <10mm removed per year. Using this data and taking the 
same approaches outlined above we have calculated that in-vivo diagnosis could 
represent a potential saving of £678,252.81 ($1,085,900) per annum for histology 
related costs, or £55 ($88.03) per person. This is shown in table 22. 
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 Traditional protocol 
(A) 
Portsmouth Protocol 
(B) 
Futuristic protocol 
(C) 
Whole cohort £13,644.80 
($21,845.66) 
£9247.30 
($14,805.60) 
£176.70 
($282.90) 
Cost saving over 
traditional protocol 
(A) 
NA A-B 
£4397.5 
($7040.51) 
(1.5 fold) 
A-C 
£13,468.1 
($21,552.41) 
(77 fold) 
Bowel Cancer 
screening 
programme U.K. 
£684,319.51 
($1,095,090) 
£318,766.8 
($510,766.80) 
£6066.7 
($9711.38) 
Cost saving over 
traditional protocol 
NA A-B 
£365,552.71 
($585,165.20) 
(2.2 fold) 
A-C 
£678,252.81 
($1,085,900) 
(113 fold) 
Table 22: Evaluation of histopathology costs within the study population 
 
There were 39 adenomatous polyps incorrectly diagnosed by the endoscopist using 
white light, 18 using FICE and 9 with IC. Taking the cost of histological examination 
of all polyps in the cohort as £13,644.80 ($21,845.66) the additional expense 
incurred to correctly diagnose these by sending all polyps for histological 
examination in place of endoscopic assessment was calculated. For white light this 
cost was £350 ($560.27). When using FICE this increased to £758 ($1213.38) and if  
IC assessments were used the additional pathology cost increased to £1516 
($2,426.77). 
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10.14: Surveillance intervals 
 
A predicted rescope interval was estimated for the cohort. 20/89 patients had 
additional larger polyps which would have influenced the rescope interval and  were 
excluded. In the remaining 69 patients WLI correctly predicted the rescope interval 
for 57/69 (83% CI: 72%-90%) of patients using BSG guidelines and 58/69 (84%, CI:  
74%-91%) using ASGE guidelines.  
FICE correctly predicted rescope intervals for 67/69 (97%, CI: 89% - 100%) of 
patients using BSG and ASGE guidelines.  
IC correctly predicted rescope intervals for 67/69 (97%) of patients (CI: 89% - 100%) 
using BSG guidelines and 68/69 (99%, CI: 91% - 100%) using ASGE guidelines.   
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10.15: Discussion 
This is the first study reporting outcomes of FICE followed by IC in the assessment 
of polyps<10mm in the BCSP. It shows that WLI endoscopy can accurately predict 
in-vivo histology in 71% of cases. FICE improves this to 86% and the additional use 
of IC increases this further to 91%. With FICE it would be possible to set the rescope 
interval accurately in 97% of patients and with IC in 98% of cases. This 
demonstrates that both FICE and indigo carmine dye spray, when used after FICE, 
are excellent tools for making an in-vivo histological diagnosis for small 
polyps<10mm and fulfil the standards outlined in the ASGE PIVI for adopting a 
resect and discard policy (10). It is important to diagnose all adenomas accurately 
and this study has demonstrated that FICE and IC are significantly superior in 
making that diagnosis, compared to WLI. There may be some additional benefit from 
dye spray when assessing difficult to call lesions. These results are comparable to 
those reported in a large Japanese series. In the Japanese series magnification 
endoscopy was used to achieve a 98% sensitivity for adenomas but the specificity 
was poor at 52% (20). 
 
No statistically significant difference was seen between FICE and IC when assessing 
lesions<10mm. However, for lesions <5mm, the additional use of indigo carmine 
resulted in an improvement in the sensitivity for neoplasia (93% vs 83%) which was 
significant (P=0.037). This resulted in the negative predictive value improving from 
78% to 90%. This is important as it is one of the key standards outlined in the ASGE 
PIVI for in-vivo diagnosis (10). Whilst FICE is adequate for a resect and discard 
policy, it is inadequate for use as a technology to guide the decision to leave 
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suspected rectosigmoid hyperplastic polyps <5mm in size in place (without 
resection). The technology would need to provide a negative predictive value greater 
than 90% for adenomatous histology when used for this purpose, which was not 
demonstrated in this study. In contrast indigocarmine dye spray demonstrated a 90% 
NPV and is probably adequate. This information provides important guidance for the 
endoscopist in how to the use both of these approaches for in-vivo diagnosis. 
 
Colorectal cancer is a major cause of mortality worldwide, and removal of adenomas 
has been shown to reduce mortality from the disease (9). This has led to the 
development of colorectal cancer screening programmes. These need to be 
delivered to a mass population, and as such are expensive. In a period of economic 
austerity it is necessary to control costs if such programmes are to be sustainable. 
 
The U.K. national BCSP has shown that the majority of polyps detected in the 
programme are <10mm (122). Accurate in-vivo diagnosis, as shown in this study, 
can reduce the need for resection and pathological analysis of all of these polyps. 
The data has shown that this could lead to a potential cost saving of £678,253 
($1,085,900) within the U.K. BCSP. 
 
A recent study based on Markov modelling suggested that adoption of a resect and 
discard policy within a U.S. screening population (using Narrow Band Imaging for in-
vivo assessments) could result in savings of $25 per person, resulting in an annual 
undiscounted saving of $33 million, without any meaningful impact on screening 
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efficacy (68). The results from our study support this. Using both this data and the 
United Kingdom Bowel Cancer Screening data would suggest that the actual savings 
could be greater than those predicted by the Markov model. However, it should be 
noted that the U.K. programme employs faecal occult blood screening prior to 
colonoscopy, and therefore the incidence of polyps found at colonoscopy is high, 
potentially further increasing the pathology costs, and potential cost saving from in-
vivo diagnosis, for each procedure.  
Some work has been performed with indigo carmine in predicting polyp histology, 
with sensitivities and specificities for neoplasia between 82% to 98% and 64% to 
95%, respectively (20) (22) (28) (129). In all of these studies magnifying endoscopes 
were used, which is impractical in daily practice in Western countries. It is therefore 
difficult to draw any useful conclusions from these studies about the role of IC in the 
management of polyps<10mm in daily Western practice with non magnifying scopes.   
One study compared indigo carmine with magnification to standard colonoscopy and 
found that magnification increased the accuracy for polyp differentiation from 84% to 
96% (21).   This data shows a very high accuracy and sensitivity for in-vivo diagnosis 
of polyps using indigo carmine dye spray after evaluation of polyps with FICE.  
 
In a recent study five endoscopists assessed 144 pictures of 19 polyps to establish 
the diagnostic accuracy of WLI, FICE and indigo carmine in making a histology 
prediction for polyps <10mm in size. The results were disappointing, with a mean 
diagnostic accuracy without magnification for WLI of 57%, FICE of 58.9% and IC of 
70.5% (55). However, there was considerable variation in the results obtained 
between the five endoscopists, and the number of lesions from which the pictures 
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were taken was small. These results were different to an earlier large cohort study of 
150 flat lesions under 20mm in size (54). This prospective series showed that using 
FICE, with low and high magnification, a sensitivity for neoplasia of 89.9% and 
96.6%, specificity of 73.8% and 80.3%, and diagnostic accuracy of 83% and 90% 
was achieved. Results were comparable to that of conventional chromoendoscopy. 
However, this study was based on the assessment of pictures rather than a true in-
vivo assessment and polyps of up to 20mm in size were included. In practice polyps 
>10mm always need removal, and differentiation of adenomas from hyperplastic 
lesions in this group is merely an academic exercise. One can also argue that in-vivo 
diagnosis is a lot easier for polyps >10mm, although the sensitivity in this study is 
similar to the results presented in this chapter. A further prospective randomised 
study was conducted by the same group (26), with the primary aim to investigate the 
impact of FICE on adenoma detection rates (ADR). It showed that FICE did not 
improve ADR. However, FICE and indigocarmine were both able to differentiate 
adenomas from hyper plastic polyps<10mm in size. The findings demonstrated a 
sensitivity of 93% and specificity of 61.2% in differentiating adenomas from 
hyperplastic polyps with FICE, comparable but not superior to indigocarmine 
(90.4%), with no statistically significant difference between the two techniques 
(p=0.44). The study described in this chapter compliments the published literature by 
demonstrating a high clinical accuracy of FICE in the assessment of small polyps 
<10mm in a Bowel Cancer Screening population. We have also shown a small 
insignificant benefit of IC dye spray when used after FICE assessment. This is a very 
pragmatic design and clearly identifies the role of FICE and IC in daily practice. 
The estimated rescope interval is important in the management of patients found to 
have adenomatous polyps. Current practice involves resection or biopsy of all 
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polyps. Surveillance intervals are predicted on the basis of number of polyps and the 
interval is then re-adjusted after the true histology becomes available after 1-2 
weeks. This results in extra work and a delay in setting the accurate surveillance 
interval. This study has shown that this can be correctly set in 97% of cases with 
FICE and IC at the time of endoscopy before the patient leaves the department. 
 
The UK Bowel Cancer Screening Programme is generating a large volume of 
samples for already overstretched pathology departments. A small study has 
suggested that community pathologists correctly identified 91% polyp cancers, 94% 
adenomas and 75% of hyperplastic polyps (130). As a result of this, all polyps within 
the programme have to be reported on by an expert gastrointestinal pathologist. This 
is in many ways unfortunate as it diverts a significant proportion of their time away 
from performing other tasks, despite these lesions having very low malignant 
potential. During the same time period there has been a growth in the technique of 
endoscopic mucosal resection, resulting in the generation of complex multi piece 
specimens for expert pathologists to report. These are complex reports requiring a 
lot of expertise and time. It is not unreasonable to question whether the practice of 
sending all small polyps for histological assessment can be justified, when there are 
now accurate methods for endoscopists to use to assess polyps in-vivo with minimal 
impact on clinical care, especially when the pathologist’s time is needed so 
desperately for more complex tasks.    
 
One of the limitations of this study could be the use of a single centre and single 
endoscopist. However, the aim was to demonstrate the potential accuracy of FICE 
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as an assessment tool and therefore it was necessary to exclude the potentially 
confounding influence of multiple endoscopists with differing levels of ability in in-vivo 
diagnosis. However, similar results have been published by other groups using 
multiple endoscopists and other techniques such as Narrow Band Imaging. As such 
there is no reason to believe that the technique could not be learnt and applied by all 
screening endoscopists. There will always be a need for training in these techniques 
but the learning curve is relatively short (131). One of the other limitations of this 
study is that the design does not allow the direct comparison of indigo carmine with 
FICE, as one could argue that the IC assessment was positively biased by the WLI 
and FICE assessment performed prior to it. Whilst this remains a possibility, the data 
addresses the more important question of what IC adds after FICE assessment. 
From a practical point of view this is the question that most endoscopists want 
answered. The study has a pragmatic design which is applicable to daily clinical 
practice when an endoscopist will use WLI followed by FICE in an attempt to make 
an in-vivo diagnosis. Most endoscopists will resort to IC spray following electronic 
imaging if they are uncertain of the diagnosis and this data shows a small but 
statistically insignificant incremental benefit of IC used after FICE for polyps<10mm, 
but a significant benefit when assessing diminuitive polyps<5mm.  
Surveillance intervals can now be determined based on in-vivo diagnosis without 
waiting for histology, and the practice of routinely sending all polyps for histological 
examination is difficult to justify.  This data proves the feasibility and applicability of 
in-vivo diagnosis of polyps<10mm in size and that it is cost effective in a screening 
population. It calls for a multicentre study to prove that it can be generalised on a 
national basis. 
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10.16: Implications for clinical practice 
 
Surveillance intervals can now be determined based on in-vivo diagnosis without 
waiting for histology, and the practice of routinely sending all polyps for histological 
examination is difficult to justify. This data proves the feasibility and applicability of 
in-vivo diagnosis of polyps<10mm in size and it is cost effective in a screening 
population. Bowel cancer screening in the United Kingdom is performed by 
endoscopists who undergo specialist training and examination prior to practice. This 
is therefore an ideal environment for such techniques to be implemented safely. It 
would also provide an ideal cohort of endoscopists to test and validate training tools 
on as there would be mandatory assessment involved. If this proves successful then 
it could potentially be expanded to a wider population. 
 
In-vivo diagnosis is of relevance beyond simple cost savings. As discussed 
previously lesions can be poorly managed if an inappropriate assumption is made by 
the examining endoscopist. In particular small cancers can be wrongly removed (and 
location not marked) if no attempt at diagnosis by the endoscopist is made. Likewise, 
some small polyps can be located in very challenging positions, and removal can 
prove risky and challenging. For hyperplastic polyps a point can be reached where 
risk outweighs benefits. In these cases a high degree of certainty regarding lesion 
histology in-vivo would be beneficial in guiding the endoscopists decision in whether 
to proceed with resection. Therefore all endoscopists could benefit from examining 
lesions with these techniques even if they do not feel confident in adopting a resect 
and discard policy on a routine basis. 
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10.17: Implications for research 
 
This study provides the evidence base to justify a multicentre study to determine 
ehether in-vivo diagnosis could be generalised on a national basis. This is required 
to address the key limitation of this study that it is single centre and single 
endoscopist based. For the data to be generalisable it should ideally be expanded to 
incorporate in-vivo diagnosis with techniques utilising Narrow Band Imaging, i-scan 
and indigo carmine chromoendoscopy as a single modality of assessment. This 
would encoporate a much wider range of equipment scenarios where in-vivo 
diagnosis would be possible making in-vivo diagnosis a more attractive option. Such 
a study will require the training of many endoscopists in the technique of in-vivo 
diagnosis. Research is therefore needed into the development of effective training 
tools before such a study can be conducted. Ideally these tools should be easy to 
use with a short learning curve. 
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10.18: Conclusions 
 
This study demonstrates that FICE is an excellent tool for the evaluation of colonic 
polyps<10mm. There is a trend towards a further improvement in accuracy from 
indigo carmine chromoendoscopy after FICE assessment for polyps<10mm in size, 
and a significant improvement in sensitivity for neoplasia in polyps<5mm in size. Our 
data suggests that an in-vivo diagnosis, in place of conventional histological 
analysis, would have a negligible impact on the rescope interval of the patients 
involved and could reduce costs and the pathology workload incurred from screening 
colonoscopy considerably. It has the potential to replace histological assessment of 
polyps<10mm in size. 
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Chapter 11 
 
 
High definition vs Standard definition endoscopy in the 
assessment of colonic neoplasia 
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11.1: Introduction 
 
There have been considerable developments in endoscopic technology in recent 
years. High definition endoscopy is now being offered by all of the major endoscope 
manufacturers, and it has been predicted that the uptake of high definition equipment 
will be a major growth area over the next 5 years (124). Modern colonoscopes have 
charge coupled device (CCD) pixel densities of up to 1.3 million pixels, compared to 
standard definition endoscopes which have CCD resolutions of around 410,000 
pixels. Whilst precise definitions vary between manufacturers, it is generally 
accepted that to define a system as high definition requires a high resolution charge 
coupled device (CCD) connected to a processor capable of outputting a digital high 
resolution signal to a display of at least 1024x768 pixels. However, there is 
remarkably little known regarding the potential value of high definition over standard 
definition equipment. 
 
Polyps are a common finding during colonoscopy, and there have been numerous 
publications examining the role of the endoscopist in performing an in-vivo diagnostic 
assessment of these lesions in place of traditional histological analysis (47) (26). 
However, all of these studies have been performed using high definition equipment 
(26) (54) (56) and usually with optical magnification (54) (56). Unfortunately, not all 
endoscopy units are equipped with enough high definition endoscopes or with 
magnifying endoscopes.  
 
If endoscopists start making decisions based on in-vivo diagnosis of polyps<10mm in 
size then a substantial cost saving could be achieved related to histopathology (68). 
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However, for this strategy to be adopted, endoscopists need to feel confident that the 
equipment available is fit for this purpose. The recent ASGE PIVI (preservation and 
incorporation of valuable endoscopic innovations) has attempted to address this 
issue, by defining the standards a device needs to meet if it is to be used for in-vivo 
diagnosis (10). In order for polyps <5mm in size to be resected and discarded 
without pathologic assessment, endoscopic technology should provide a 90% 
agreement in assignment of post-polypectomy surveillance intervals, when 
compared to decisions based on pathological assessment of all identified polyps. In 
order to leave rectosigmoid hyperplastic polyps <5mm without resection, the 
technology should provide a negative predictive value for adenomatous histology 
greater than 90%. It has been difficult to achieve such high standards with standard 
endoscopes but one wonders if high definition scopes will help achieve this. 
 
Acquiring high definition (HD) endoscopes represents a significant capital investment 
and their clinical value remains uncertain. In the current era of austerity, it is unclear 
whether the expense of upgrading existing equipment can be justified. This study 
aims to compare the accuracy of standard and high definition Fujnon colonoscopes 
in the diagnosis of neoplastic polyps<10mm using Flexible Spectral Imaging Colour 
Enhancemant (FICE) without optical magnification and indigocarmine dye spray. 
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11.2: Methods 
 
The study has ethical approval (REC No. 09/H0501/94) and was registered with the 
European Clinical Trials Database (Eudra CT 2009-016742-10) and with (Clinical 
Trials.gov NCT01182623).  
 
This study was a retrospective analysis of the data collected in the study described 
in the previous chapter, where consecutive polyps<10mm in size were assessed by 
a single endoscopist (PB) who was trained and experienced in in-vivo diagnostic 
methods. Patients were all referrals for screening colonoscopy on a standard Bowel 
Cancer Screening list, where a mix of standard and high definition colonoscopes 
were routinely used. Exclusion criteria were; a diagnosis of inflammatory bowel 
disease, familial polyp syndromes or poor bowel preparation, all of which could 
influence surface pattern assessment. The endoscopies were performed using 
Fujinon colonoscopes and an EPX 4400 processor. The endoscope was allocated 
randomly by the nursing staff on a basis of availability and was not influenced by the 
endoscopist who was blinded to the resolution of the colonoscope being used. This 
was not therefore a randomised controlled trial, as a prospective randomization was 
not performed prior to the study commencing. However, allocation was random, with 
no influence from the research team. Each colonoscope had a unique number from 
which its resolution could be identified. This was not unblinded until the end of the 
study. 
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The colonoscopes were equipped with either a standard definition CCD (SD) EC-530 
410,000 pixel, or a high definition Super CCD (HD). This included the EC-530 or EC-
590-zw 650,000 pixel colonoscopes. Procedures where polyps were examined with 
SD colonoscopes were grouped as group A and procedures where polyps were 
examined with HD colonoscopes were grouped as group B. Optical magnification 
was not used in either of the groups. For each procedure this was prospectively 
recorded. A flat screen Sony 24 inch WUXGA LCD display was used (LMD-2450 
MD) with a 1125 x 1080 resolution, connected to the EPX4400 processor via a digital 
video interface (DVI) connector. Therefore, the only component of the system where 
the resolution was being changed was the CCD in the colonoscope. Polyps were 
initially identified with white light endoscopy. They were cleaned of debris prior to 
assessment using 10-20ml of water with 2ml of 10% simethicone. Care was taken 
not to traumatise the surface of the lesions.  The size of the polyps was determined 
endoscopically using the open jaws of the biopsy forceps measuring 7mm in 
diameter. Polyps <10mm were assessed using WLI and FICE and the diagnosis 
made by the endoscopist (neoplastic vs non neoplastic) was recorded for each 
modality of imaging. Finally the polyp was assessed using Indigo carmine (IC) dye 
spray, made up in a concentration of 0.2% and 5mls was passed down the biopsy 
channel via a 20ml syringe. Again, the diagnosis made by the endoscopist was 
prospectively recorded. The maximum time allocated for assessment with each 
modality was 30 seconds. See figure 27. 
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Figure 27: Study design flow chart 
 
11.3: Endoscopic assessment tool 
 
Assessment of the polyp morphology, polyp colour, density of vessels, vessel pattern 
and surface pattern was performed. Based on the pilot work described in chapters 7 
8 and 9, FICE setting 4 (R:520nm G:500nm B: 405nm) was used for all of the 
assessments. Vascular patterns were examined with FICE using the NAC 
classification system described in the previous chapters. Finally, the polyps were 
removed and sent for histological analysis by a consultant histopathologist, who was 
blinded to the diagnosis made by the endoscopist. All pathology reporting was done 
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by an accredited Colon Cancer Screening pathologist. For the purposes of analysis, 
serrated adenomas were defined as neoplastic lesions, and therefore, if the 
endoscopist called such polyps as hyperplastic, this would represent an incorrect 
diagnosis. Patient data was collected using a dedicated form. 
 
11.4: Statistical analysis 
 
For the comparison of SD versus HD endoscopy a power calculation was performed. 
This was based on the following assumptions; that 70% of the polyps found were 
neoplastic, that the true sensitivity for neoplasia with FICE and indigo carmine using 
HD endoscopes would be between 90-99%, and that the true sensitivity for FICE and 
indigo carmine using SD endoscopes would be between 80-90%. To demonstrate a 
15% absolute difference in the accuracy for neoplasia between HD and SD 
endoscopy with 80% power (assuming a 5% significance level and phi coefficient of 
0.2), a total of 152 neoplastic polyps would need to be assessed, with 76 in each 
group, requiring a total sample of 218 polyps to produce significant results. IBM 
SPSS-18 for Windows was used for statistical calculations and analysis was 
performed on a per lesion basis. McNemar’s test was used for the pairwise 
comparisons. The accuracy for correct diagnosis of neoplasia using WLI, FICE and 
indigo carmine, for both SD and HD endoscopes, was compared to histology and 
95% confidence intervals calculated.  
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11.5: Study population 
 
In total 124 patients underwent colonoscopy for bowel cancer screening. 
 
Group A (SD): 58 patients, 40 of whom were found to have polyps 
Group B (HD): 66 patients, 49 of whom were found to have polyps 
 
In Group A 89 polyps <10mm in size were found. In group B 143 polyps<10mm in 
size were found. The groups were comparable in terms of age, gender, size, location 
and morphology of polyps, as shown in table 23. 
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 Group A (SD) Group B (HD) 
Total patients 40 49 
Male 31 39 
Female 9 10 
Mean age 
Standard Deviation 
66 
14.7 
64 
4.2 
Polyps 
Mean size (mm) 
(range) 
Standard Deviation 
89 
4.95 
(2-10) 
2.7 
143 
4.55 
(2-10) 
2.6 
Right sided 
Left sided 
46 
43 
33 
110 
Morphology  
Pedunculated 
 Non pedunculated  
Is  
iia  
iib  
iia+iic 
 
4 
85 
38 
45 
2 
0 
 
11 
132 
74 
56 
1 
1 
Lesion size 
<5mm 
5-10mm 
 
52 
37 
 
103 
40 
Table 23: Patient demographics for study population 
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11.6: True histological diagnosis 
In Group A (SD group) 61/89 (69%) lesions were neoplastic and 28/89 (31%) were 
non neoplastic. In Group B (HD group) 95/143 (66%) were neoplastic and 48/143 
(34%) were non neoplastic. 
11.7: Accuracy for neoplasia 
The accuracy for diagnosis of neoplasia was compared between group A and Group 
B. There was a significant improvement in the sensitivity of FICE using HD scopes. 
High definition scopes did not have any significant impact on the sensitivity or 
accuracy of WLI or IC diagnosis. See table 24. 
Accuracy for neoplasia Group A (SD) Group B (HD) P Value 
WLI 
 
(95% C.I.) 
44/61 
72% 
(65-78%) 
72/95 
76% 
(70-81%) 
0.51 
FICE 
 
(95% C.I.) 
49/61 
80% 
(74-84%) 
88/95 
93% 
(88-96%) 
0.02 
IC 
 
(95% C.I.) 
57/61 
93% 
(88-96%) 
89/95 
94% 
(89-97%) 
0.95 
Table 24: Accuracy for neoplasia Standard definition (SD) versus High definition (HD) colonoscopes 95% confidence 
intervals are in brackets. WLI= white light. IC= indigo carmine 
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11.8: Additional gain from indigo carmine 
HD colonoscopes did not improve the accuracy of the IC assessment. However, 
when IC was used after FICE with SD scopes, the assessment was superior to FICE 
assessment alone with SD scopes (p=0.032). Additional assessment with IC did not 
provide any additional benefits as compared to FICE with HD scopes (p=0.77).  
 
11.9: Accuracy for non neoplastic lesions 
There was no significant difference in the accuracy for hyperplastic polyps between 
group A (SD) and group B (HD). In both groups FICE and IC assessment was 
significantly better than white light assessment (P=0.011). See table 25. 
 Group A (SD) Group B (HD) P Value 
WLI 
 
(95% C.I.) 
17/28 
61% 
(46-74%) 
32/48 
67% 
(56-76%) 
0.6 
FICE 
 
(95% C.I.) 
24/28 
86% 
(72-94%) 
39/48 
81% 
(72-87%) 
0.62 
IC 
 
(95% C.I.) 
25/28 
89% 
(78-96%) 
40/48 
83% 
(75-89%) 
0.48 
Table 25: Accuracy for non neoplastic lesions standard definition (SD) versus high deginition (HD) colonoscopes. 95% 
confidence intervals are in brackets. WLI= white light. IC= indigo carmine 
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11.10: Accuracy for neoplasia in polyps by polyp size 
 
A sub group analysis was performed on neoplastic lesions based on lesion size. For 
all modalities of imaging, accuracy for neoplasia was better for lesions>5mm in size, 
regardless of the resolution of endoscope used. This was statistically significant for 
WLI and FICE but failed to reach significance for IC. (WLI p=0.003, FICE p=0.045, 
IC=0.879). Accuracy for neoplasia was significantly better with high definition 
endoscopes when using FICE in polyps 5-10mm in all sizes (P=0.038). There was a 
trend towards an improvement when using HD scopes to assess polyps 5-10mm in 
size when using white light and indigo carmine, although this was not statistically 
significant (P=0.09). No improvement was seen from HD scopes when assessing 
polyps <5mm when using white light or indigo carmine. There was a trend towards 
an improvement when using FICE, although the study was not powered adequately 
for this test and the difference failed to achieve statistical significance. See table 26. 
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Table 26: Group A (SD) Group B(HD) P value 
<5mm 
WLI 20/31 
65% 
39/59 
71% 
1.000 
FICE 23/31 
74% 
52/59 
88% 
0.09 
IC 30/31 
94% 
54/59 
92% 
0.343 
5-10mm 
WLI 24/30 
80% 
33/36 
92% 
0.28 
FICE 26/30 
87% 
36/36 
100% 
0.038 
IC 27/30 
90% 
35/36 
97% 
0.32 
Table 26: Breakdown of accuracy for neoplasia of in-vivo diagnosis by polyp size 
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11.11: Rescope intervals 
A comparison of rescope intervals using BSG and ASGE guidelines was performed. 
Whilst a trend was observed towards improved accuracy in the setting of the rescope 
interval using high definition endoscopes with FICE and indigo carmine, no 
statistically significant difference was observed. See table 27. 
 BSG guidelines ASGE guidelines 
White Light 
SD 26/31 
84% 
27/31 
87% 
HD 31/38 
82% 
31/38 
82% 
P value 0.8 0.53 
FICE 
SD 
 
29/31 
94% 
29/31 
94% 
HD 
 
38/38 
100% 
38/38 
100% 
P value 0.112 0.112 
Indigo carmine 
SD 29/31 
94% 
30/31 
97% 
HD 38/38 
100% 
38/38 
100% 
P value 0.112 0.265 
Figure 3: Rescope intervals predicted from in-vivo histology prediction with standard definition (SD) or high definition 
(HD) colonoscopes using BSG and ASGE guidelines 
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11.12: Discussion 
 
This study shows that when using Fujinon coloscopes a high resolution 650,000 
pixel CCD (super CCD) is superior to a standard definition 450,000 pixel CCD 
colonoscope for the examination of neoplastic polyps<10mm using FICE. On sub-
group analysis when assessing diminuitive polyps<5mm in size, FICE with high 
definition endoscopes showed a trend towards improved accuracy for the diagnosis 
of neoplasia, but this failed to reach statistical significance. A future trial is needed to 
investigate this further. For polyps 5-10mm in size FICE was significantly better 
when using high definition endoscopes for the diagnosis of neoplasia. The other 
important finding of our study was that high definition scopes do not improve the 
accuracy of diagnosis with white light or whilst using indigo carmine 
chromoendoscopy. FICE and indigocarmine dye spray are both excellent tools for 
making an in-vivo histological diagnosis for small polyps. FICE is significantly better 
when used with an HD scope, whilst IC performance is very good with standard 
definition colonoscopes and does not get any better with high definition 
colonoscopes. It is important for endoscopists to understand the equipment that they 
are using, and in particular the limitations imposed by a particular setup. This study 
is of direct clinical significance as it suggests a potential algorithm for the in-vivo 
assessment of small polyps. When using a high definition Fujinon endoscope, there 
is no additional gain from indigo carmine dye spray. However, when using a 
standard definition scope, it may be necessary to dye spray some lesions, as there is 
a statistically significant gain from indigo carmine after assessment with FICE using 
a standard definition endoscope. 
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There has been a significant drive from endoscope manufacturers in recent years to 
market their latest high definition endoscopes. Worldwide the global endoscopy 
market is worth $2,385 million, with 75% of the market held by four major players. 
Olympus is the market leader, controlling 47% of the market share followed by 
Fujinon corporation with 10%. It is felt that the adoption of high definition technology 
could drive this up to $3,524 million by 2016 (53). However, there has been a lack of 
literature demonstrating any benefit from this. In the current era of austerity, it is 
necessary for all clinicians and health care providers to make difficult decisions as to 
where money should be spent, and updating endoscopy equipment should be based 
on evidence as far as possible. 
 
As discussed earlier, there has been a recent study published examining the 
potential cost savings within a United States of America screening population which 
could be made from in-vivo diagnosis (68). Using Narrow Band Imaging for in-vivo 
assessments with a resect and discard policy, the Markov model predicted that an 
annual undiscounted saving of $33 million could be made, without any meaningful 
impact on screening efficacy. Whilst this may be the case it is important that the 
endoscopist feels confident that the technology they have available in their unit is 
capable of producing the same results. This study provides important information for 
users of Fujinon equipment and provides a potential argument for justifying the cost 
of updating to high definition equipment if a resect and discard policy is to become 
widely adopted. It is important to note that no benefit was seen from high resolution 
endoscopes in making an indigo carmine based assessment using Fujinon 
equipment. This is reassuring, as even units with older equipment can make 
accurate in-vivo assessments by using IC chromoendoscopy.  
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There has been limited work published on FICE previously, with all of the studies 
utilising high resolution endoscopes (55) (54) (26), with most of the studies using 
optical magnification (55) (54). This data suggests that excellent results can be 
achieved with FICE and indigo carmine without optical magnification, and defines the 
role of high definition endoscopes for in-vivo diagnosis of small colonic polyps. It is 
important to be aware that the performance of HD scopes depends on various 
factors and it is important to have a high resolution screen connected to the stack via 
a digital video interface (DVI) output, as used in this study.  
 
High definition endoscopes have been on the market for some time but their clinical 
role remains uncertain.  This study demonstrates some of the differences between 
SD and HD Fujinon endoscopes. HD scopes do not alter the diagnostic accuracy of 
WLI and IC assessments in the diagnosis of neoplastic polyps<10mm, but 
significantly improves (p=0.02) their assessment with FICE. This defines a clinical 
benefit of Fujinon HD scopes above that of the older SD scopes.  
 
11.13: Implications for clinical practice 
 
With considerable talk about in-vivo diagnosis it is important for clinicians to 
understand the limitations of the equipment they are using. With standard definition 
endoscopes in regular use this study provides a valuable insight into what their 
limitations are and how they can be overcome. This could potentially prevent the 
endoscopist from making an incorrect diagnosis due to over confidence in the 
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equipment they are using. It is unknown whether similar limitations would be seen for 
other forms of vascular enhancement (Narrow Band Imaging and i-scan) as all of the 
studies into these technologies have been performed using high resolution 
endoscopes. However, it raises an important safety question which, until resolved, 
would suggest that it may be better to restrict in-vivo diagnosis using vascular 
enhancement to high resolution endoscopes where the accuracy of diagnosis is 
more evidence based. The results with indigo carmine however would suggest that a 
chromoendoscopy assessment is independent to the resolution of the endoscope 
and would offer a safe alternative to vascular enhancement when high resolution 
endoscopes are unavailable. 
 
11.14: Implications for research 
 
It is unknown whether similar limitations may be seen with standard definition 
endoscopes when used with Narrow Band Imaging or i-scan. All of the studies into 
these technologies have been conducted with high resolution endoscopes and there 
is therefore an urgent need to ascertain whether they can be used at all for in-vivo 
diagnosis without high resolution endoscopes. This has critical safety implications 
and there is therefore an urgent need for research into this. 
 
  
215 
 
11.15: Conclusions 
 
This retrospective analysis demonstrates that FICE and indigo carmine dye spray 
are excellent tools for the evaluation of small colonic polyps<10mm in size. High 
definition scopes can improve the sensitivity of FICE. Results with indigo carmine are 
independent of the type of scope (HD or SD). The data suggests that the use of 
either FICE or IC in place of conventional histological analysis would have a 
negligible impact on the rescope interval of the patients involved. It has the potential 
to replace histological assessment of small polyps<10mm. 
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Chapter 12 
 
Barrett’s Neoplasia Study 
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12.1: Introduction 
 
The incidence of oesophageal adenocarcinoma is rising in the Western world. It is 
responsible for 14,500 deaths per year in the United States (132) and 7,000 per year 
in the UK (3). Barrett’s dysplasia is a well established precursor, which is the basis 
for endoscopic surveillance of patients with Barrett’s oesophagus. Standard 
protocols require the collection of large numbers of biopsies which are conventionally 
taken in a random quadrantic fashion at 2cm intervals. Non targeted multiple 
biopsies have remained standard practice as most of the dysplastic areas are 
difficult to see with standard resolution white light endoscopes, and only 13% of early 
neoplastic lesions appear as macroscopically visible nodules (133). It has been 
shown that intensive surveillance biopsies as per the Seattle protocol using jumbo 
forceps does not improve the detection of intramucosal adenocarcinoma any more 
reliably than less intensive protocols with standard biopsy forceps (134). Endoscopic 
surveillance of Barrett’s oesophagus makes clinical sense due to its malignant 
potential, but the poor pick up rate of neoplasia during routine surveillance with white 
light endoscopy and quadrantic biopsy questions the cost effectiveness of this 
strategy (135). Recent developments have led to improvements in the optical 
resolution of endoscopes and new technologies have been developed which 
enhance mucosal visualisation. Improved methods for identifying in-vivo dysplastic 
areas use either chromoendoscopy (78) (90) (79) (136), of which acetic acid is one 
method, or narrow band imaging (99), and spectral imaging techniques like Flexible 
Spectral Imaging Colour Enhancement (FICE) (137). 
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Chromoendoscopy for the detection of Barrett’s metaplasia has been available for 
many years. The three dyes commonly used are methylene blue (MB) (74), indigo 
carmine (IC) (77) and acetic acid (AA) (84).  
Acetic acid dye spray is used routinely for the detection of cervical pre-cancerous 
lesions, including glandular lesions, at colposcopy (87). Acetic acid was originally 
used in the oesophagus as an aid to detect small segments of residual Barrett’s 
metaplasia after ablation therapy. 
Acetic acid, when sprayed on Barrett’s mucosa, leads to reversible acetylation of 
nuclear proteins, leading to an aceto-white area, causing vascular congestion and 
improving the visualisation of the mucosal surface (80). This allows the mucosal 
surface patterns to be assessed, improving the diagnosis of dysplasia or cancer. The 
reaction only lasts a few minutes, with dysplastic tissue losing the aceto-whitening 
more quickly than background Barrett’s epithelium, further highlighting abnormal 
areas. See figures 28-29.  
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Figure 28: Barrett's metaplasia without any evidence of neoplasia 
             
Figure29: Neoplasia within Barrett's 
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12.2: Questions to be answered 
The key clinical problems in the management of patients with Barrett’s oesophagus 
are: 
1) The detection of neoplasia within Barrett’s epithelium 
2) Localisation of the focus of neoplasia 
Unfortunately, traditional protocol guided mapping biopsies do not detect all 
neoplasia (134). Furthermore they are cumbersome and imprecise at localising 
neoplasia. For this reason there is a clinical need for improved methods for 
neoplasia detection. There has been interest in the modern advanced electronic 
imaging technique tri-modal imaging, which combines the techniques of Narrow 
Band Imaging and autoflourescence. However, a recent large multi-centre 
randomized tandem endoscopy study has suggested that the technology delivers 
disappointing results when used for this task, and the authors have concluded that 
tri-modal imaging cannot be used in place of mapping biopsies, even in a high risk 
population (105).This is discussed in detail in chapter 3. 
12.3: Justification for the acetic acid studies 
Prior to this work there has been a lack of studies examining the role of acetic acid in 
the detection and localisation of neoplasia. This is very important as the identification 
of HGD within Barrett’s changes management from surveillance to treatment. Given 
the growth of advanced endoscopic resection techniques now available, the need to 
localise neoplasia within Barrett’s has never been more acute. Even if a non targeted 
therapy is to be considered (radiofrequency ablation or photodynamic therapy), it is 
still important to be able to localise neoplasia. Ablative techniques do not yield any 
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pathology. Therefore if a misdiagnosis is made and an area of invasive cancer is not 
seen, it can have disastrous consequences, with potentially curable patients being 
left undertreated. Therefore there is a massive clinical need for localisation 
techniques. 
 
The aim of this study will be to use acetic acid to localise neoplasia within Barrett’s 
oesophagus. Acetic acid has already been used in small pilot studies to examine 
Barrett’s metaplasia (81) (82), and assessment tools have been developed for 
identifying patterns associated with metaplastic and neoplastic Barrett’s epithelium 
using the technique (83) (88) (89). These studies have been very small with limited 
numbers of neoplasia cases, but demonstrate the potential for acetic acid to be used 
for in-vivo diagnosis.  
 
Acetic acid is widely available and could potentially be used with any endoscope. 
This makes the study of its use as a diagnostic tool important as, if successful, it 
would carry the benefit over other advanced imaging techniques of not being 
dependent on the availability of a high end endoscope from a particular 
manufacturer. This would make widespread dissemination of any benefits from the 
research much easier to apply in the wider endoscopy community. 
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12.4: Hypothesis 
We hypothesise that acetic acid guided chromoendoscopy will improve the detection 
of neoplastic foci within Barrett’s epithelium by improving the visibility of the 
neoplastic foci and allowing targeted biopsies of that area, as compared to white light 
assessment. 
 
12.5: Primary aim 
To establish the effect of acetic acid in improving the visualisation of neoplasia in 
Barrett’s oesophagus as compared to white light examination 
 
12.6: Secondary aim 
To establish the sensitivity and specificity of acetic acid assisted neoplasia detection 
within Barrett’s oesophagus 
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12.7: Ethics 
This study was discussed with the Portsmouth Ethics Committee. Acetic acid is a 
recognised technique for the identification of Barrett’s metaplasia, and hence could 
be used in the oesophagus during gastroscopy if desired, as part of the medical 
consent for the procedure. From a research governance perspective the ethics 
committee considered this to be a study of the endoscopist’s ability to interpret the 
findings from endoscopy, and as such did not require ethics committee approval. 
Each patient had signed an informed consent form for the endoscopy procedure.  
 
12.8: Statistical analysis 
Before starting the studies the design was discussed with the department of 
Mathematics and Biostatistics within the University of Portsmouth. Unfortunately 
there were no prior studies suggesting what the potential sensitivity or specificity for 
neoplasia with acetic acid would be. As such power calculations could not be 
performed. Therefore the advice was to conduct the investigation as a pilot study.  
 
A recruitment target of 100 patients was set. Spearman’s rank correlation coefficient 
(r) was calculated to assess the correlation between predicted and true histology. 
The proximity of r to one shows the strength of correlation, with r=1 being a 100% 
correlation. Chi2 test was used to assess the statistical significance of the difference 
between two limbs (WLI vs AA). P<0.05 was considered to be statistically significant. 
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It is the accepted standard of care to follow up patients post EMR with 3 monthly 
gastroscopies to look for metanchronous neoplasia. Appearances can change post 
treatment, and patients do develop dysplasia between endoscopies, which is why 
they are followed up. Previous endoscopy results should not influence the findings 
on a given procedure. Therefore the analysis was performed on a per procedure 
basis rather than per patient. It is important that if targeted treatments are to be 
performed that it is possible for patients to be safely followed up, and this is reflected 
in the study design.  
12.9: Feasibility 
The department is a specialist centre for the assessment and treatment of early 
gastrointestinal neoplasia, taking referrals from across the South of England for the 
endoscopic management of dysplasia and intramucosal cancer within Barrett’s 
oesophagus. 
 
12.10: Methods 
All patients undergoing AA dye spray for evaluation of Barrett’s oesophagus were 
recorded prospectively on a computer database. All procedures were performed by a 
single experienced endoscopist (PB) with expertise in lesion recognition and 
endoscopic mucosal resection (EMR).  
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12.11: Patient population 
The patient population included Barrett’s cases where dysplasia had never been 
identified previously (group A), and tertiary referrals for suspected oesophageal 
neoplasia where dysplasia had been found or suspected on random biopsy and post 
EMR follow up cases where dysplasia had been treated endoscopically (group B). 
Patients would be recruited from screening endoscopy lists. They would consist of 
three distinct populations: 
12.11.1: Inclusion criteria 
1) Symptomatic patients with Barrett’s metaplasia but no previous history of 
neoplasia referred for close inspection of the Barrett’s 
2) Patients with neoplasia detected on random biopsy. It should be invisible to 
the referring endoscopist. 
3) Patients with previous neoplasia, endoscopically treated by either EMR or 
radiofrequency ablation 
12.11.2: Exclusion criteria 
1) Oesophagitis or other coexisting inflammation 
2) Contact bleeding 
3) Systemic connective tissue disorder 
4) Oesophageal motility disorder 
5) Coagulopathy 
6) Acute mucosal trauma to the oesophagus during the procedure  
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12.12: Endoscopic protocol 
All patients were endoscoped on a dedicated chromoendoscopy list. 25% of the 
cases were performed under local anaesthetic with xylocaine (10mg spray), with 
75% choosing conscious sedation using i.v. midazolam, starting at 2.5mg and 
increasing in 1mg intervals as required to a maximum of 5mg. Each procedure was 
allocated 15-20 minutes. Gastroscopy was performed using Fujinon EG-590zw and 
EG-590wr gastroscopes with the EPX 4400 processor (Fujinon, Tokyo, Japan). 
Magnification, if available, was not used for the detection of neoplasia.  
 
12.13: Mucosal cleansing 
 
It was noted than mucous impaired views and made inspection for subtle 
irregularities difficult. Therefore patients were given 50 mL of a solution containing 5 
ml of 10% N-acetyl cysteine and 5 ml of simethicone to drink prior to undertaking the 
procedure to act as a mucolytic and bubble-bursting agent. Endoscopy was then 
performed.  
 
12.14: Standardisation of technique 
Inflammation can often mimic low grade dysplasia and can confuse the diagnosis of 
more serious changes. Therefore severe oesophagitis, contact bleeding or acute 
mucosal trauma were exclusion criteria for the study. An initial pilot assessment was 
performed on 10 patients with Barrett’s metaplasia.  
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Acetic acid comes as a 5% solution for medical use. Initially three different dilutions 
of acetic acid were trailed which had been used in the previous studies reported in 
the literature: 
 1.25% 
 2.5% 
 5% 
It was found that the supplied 5% concentration caused mucosal oozing which, 
whilst mild, interfered with subtle surface pattern assessment, defeating the point of 
the exercise. See figure 30. 1.25% and 2.5% did not result in inflammation. However, 
1.25% led to patchy aceto-whitening. Whilst adequate for surface pattern 
assessment, the variable nature meant that aceto-whitening timings may have been 
unreliable. Therefore 2.5% solution was used for the study. This was made up by 
mixing 10mls of 5% solution with 10mls of 0.9% normal saline in a 20ml syringe. 
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Figure 30: Traumatized mucosa after 5% acetic acid 
 
There were two potential methods for applying the acetic acid; one method would 
have been to flush 20mls of 2.5% acetic acid down the biopsy channel of the 
endoscope, the other was to use a spray catheter.  Both approaches were attempted 
during the pilot study. However, flushing the dye straight down the endoscope 
sometimes resulted in non uniform coverage of the oesophagus. Spray catheters are 
inexpensive and readily available in every endoscopy unit. Therefore, it was decided 
that a spray catheter should be used in every procedure. This allows for targeted 
application of the acetic acid, facilitating uniform coverage of the Barrett’s epithelium. 
This is particularly valuable in assessing long segments of Barrett’s. 
 
229 
 
12.15: Assessment tool 
To help identify dysplasia after AA spray, an assessment of the following features 
was made: 
 Surface pattern (ridged, villous, nodular,round, irregular) 
 Mucosal vascular pattern (regular or irregular) 
 Acetowhitening reaction: (normal or abnormal) 
Barrett’s mucosa was classified by the endoscopist as non dysplastic if the surface 
pattern was round, tubular, villous or ridged, the vascular pattern was normal and the 
acetowhitening reaction was normal.  
Mucosa was defined as dysplastic if the following was observed; irregular surface 
patterns, increased vascularity, an irregular microvascular pattern or early 
disappearance of aceto-whitening from a focal area of mucosa as compared to the 
rest of the Barrett’s mucosa (83).  
Mucosa was defined as invasive cancer if there was a complete loss of surface 
patterns, increased vascularity, disorganised and dense microvascular pattern and 
rapid disappearance of the aceto-whitening. In addition depressed areas (Paris type 
IIc) were regarded as suspicious for malignancy.  
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12.16: Study design 
 
Patients were first examined with conventional WLI, with any debris thoroughly 
removed and any visible abnormality suspicious of neoplasia noted (limb A of figure 
31). The length of the Barrett’s segment was measured from the top of the gastric 
fold to the squamocolumnar junction, with islands of Barrett’s recorded separately. 
Twenty ml of AA (2.5%) dye spray was then applied using a spray catheter to identify 
additional dysplastic foci within the Barrett’s segment over and above that which was 
seen by WLI. (limb B of figure 31). 
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Figure 31 Protocol for AA chromoendoscopy 
 
 
After AA chromoendoscopy all lesions that became visible were noted and a 
targeted biopsy was taken and sent in a separate pot to pathology (limb C of figure 
31).This was followed by quadrantic biopsies at every 2 cm of the remaining Barrett’s 
segment. These were sent separately for pathological review (non targeted 
histology). If a suspicious lesion was seen on WLI, but appeared normal after AA dye 
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spray it was biopsied as a part of the quadrantic biopsy strategy. In cases where an 
abnormality was seen on acetic acid targeted biopsy, four quadrant biopsies were 
not taken from the same quadrant at the same latitude as the targeted biopsy.  The 
final histological diagnosis was achieved by combining the results of the targeted 
biopsies (limb C) and non targeted quadrantic biopsies (limb D of figure 31). All 
histological slides were reviewed by two expert pathologists. Analysis was performed 
on a per-procedure basis, and not on a per lesion basis. 
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12.17.1: Demographics 
 
In total 190 procedures were performed on 119 patients with Barrett’s metaplasia 
and neoplasia. The recruitment pathway is shown in figure 32. 78 procedures were 
performed in group A (patients with no prior history of dysplasia) and 112 procedures 
were performed in group B (tertiary referral group). The median age of the patient 
cohort was 65 (range: 35-87) with 75% male. The median length of Barrett’s 
segment was 4cm (range: 2-15).  
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Figure 32: Flow chart for patient recruitment 
 
 
 
Assessed for eligibility (n=202) 
Excluded  (n=7) 
   Not meeting inclusion criteria (n=2) 
   Declined to participate (n=5) 
   Other reasons (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to intervention (n=195) 
 Received allocated intervention (n=190) 
 Did not receive allocated intervention (inflamed mucosa prevented examination (n=5) 
Intervention 
Analysis 
Follow-Up 
Enrollment 
Analysed group A (n=78) 
Excluded from analysis (n=0) 
Analysed group B (n=112) 
Excluded from analysis (n=0) 
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12.17.2: True neoplasia 
Histologically confirmed Barrett’s neoplasia was found in 46% of the study population 
(88 out of 190 procedures). There were 21/88 cases of early cancer (T1a and T1b), 
51/88 cases of high grade dysplasia and 16/88 cases of low grade dysplasia. 
 
12.17.3: Visible abnormalities 
Visible neoplasia was noted by the endoscopist during 43/190 procedures with WLI 
endoscopy, and during 102/190 following acetic acid dye spray. Use of WLI 
endoscopy alone, significantly under diagnosed Barrett’s neoplasia. AA dye spray 
significantly (P=0.001) improved the Barrett’s neoplasia detection rate (2.5 fold) 
compared to WLI alone as shown in table 28. 
 
 
 Conventional WLI  
Visible abnormality  
Limb A 
AA predicted in 
vivo histology 
Limb B 
B-A 
P=<0.001 
Normal 147 88 -59(1.6 fold) 
Neoplasia 43 102 59(2.3 fold) 
Table 28: WLI vs AA predicted diagnosis (WLI=white light, AA=acetic acid) 
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12.17.4: Targeted histology 
Histology results obtained from AA dye spray targeted biopsies were compared with 
the final pathological diagnosis (a combination of random and targeted biopsy 
results). An excellent correlation was identified (r=0.9). See table 29. AA targeted 
biopsies diagnosed 63 of the 67 dysplasia cases. All 21 of the 21 cancers were 
diagnosed by AA targeted biopsies compared to 13 of the 21 with WLI. In some 
patients more than one area of dysplasia was found by targeted biopsy. However, in 
all cases where dysplasia was found on targeted biopsy, there were no additional 
abnormalities found on random biopsy. 
 Targeted histology  
Group C 
Actual Histology (random + 
targeted ) Group D 
Dysplasia  (HGD+LGD) 63 67 
Cancer  21 21 
Correlation                           r=0.99  
Table 29: Targeted vs true histology (LGD=Low grade dysplasia, HGD=high grade dysplasia) 
12.17.5: Sensitivity and specificity of AA targeted histology 
Four out of 88 Barrett’s neoplasia cases were not identified on targeted histology, 
giving a false negative rate of 4.5% for all neoplasia. If the low grade dysplasia 
population is excluded then the false negative rate falls to 2.7% (2/72). 
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20/102 non dysplastic Barrett’s mucosa, suspected to be neoplastic following acetic 
acid dye spray because of visible abnormalities, turned out to be inflammation, giving 
a false positive rate of 19.6%.  
 
The overall sensitivity for identification of neoplasia was 95.5% with a specificity of 
81%. See table 30. On subgroup analysis we found a sensitivity of 77% and 
specificity of 85% for Group A and a sensitivity of 98.7% and specificity of 75% for 
group B. 
 
 Sensitivity (%) Specificity (%) Prevalence of 
Neoplasia (%) 
Whole cohort 95.5 81 46.3 
Group A 77 85 16.7 
Group B 98.7 73 66.9 
Table 30: Sensitivity and specificity by patient group 
 
12.17.6: Missed neoplasia 
There were no missed cancers in either group. 
There were four missed cases of dysplasia; 2 LGD and 2HGD.  
Three out of the four missed dysplasia were in group A. Two of these cases were 
classified as low grade dysplasia and one was classified as high grade dysplasia on 
the initial multiple quadrantic biopsies but were not identified on AA spray. All these 
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patients have had at least two further gastroscopies at 6 month intervals with 
multiple further biopsies and no further evidence of dysplasia has been found. One 
patient had missed high grade dysplasia in group B. This patient had received two 
previous endoscopic mucosal resections and APC ablation, so had multiple islands 
of neo-squamous epithelium.   
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12.18: Discussion 
This is a large series of acetic acid chromoendoscopy, with a large number of 
neoplasia cases being detected by this technique. This series shows that acetic acid 
dye spray significantly improves the detection of neoplasia in Barrett’s oesophagus 
as compared with white light endoscopy. It illustrates that acetic acid targeted 
biopsies can diagnose dysplasia in the majority of patients (95.5%), without the need 
of further multiple non-targeted biopsies. It also illustrates that no cancers are 
missed by acetic acid targeted biopsies. 
Only four out of 88 patients with neoplasia were missed by acetic acid dye spray, two 
of these were low grade dysplasia, the other two were high grade dysplasia. These 
mucosal dysplasias were picked up on conventional quadrantic biopsy. All of these 
cases were challenging both for the endoscopist and the pathologist. Low grade 
dysplasia is a difficult histological diagnosis to make, with an element of subjectivity 
involved, and at times inflammation can raise a possibility of LGD. There is a 
departmental policy of repeating endoscopy in patients with LGD after 8 weeks of 
high dose proton pump inhibitor therapy (omeprazole 40mg o.d.). Both the patients 
have had two further gastroscopies on high dose acid suppression with multiple 
biopsies but no further LGD has been discovered, suggesting that the initial finding 
could be inflammation related. 
Another patient from group A had HGD diagnosed on one of the several biopsies 
taken as a part of the quadrantic biopsy strategy. He has had three further 
gastroscopies and no further dysplasia has been found. This raises the possibility of 
1 microscopic monofocal HGD. 
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The 4th patient with missed dysplasia was from group B and was found to have HGD. 
This was a challenging case with a history of two previous EMRs and APC ablation 
resulting in multiple islands of neo-squamous epithelium. He went on to undergo 
further HALO ablation and has had no further recurrence of disease.  
The remaining 84 cases of Barrett’s neoplasia were detected by targeted biopsy. 
Additional quadrantic biopsies did not alter the overall diagnosis. This is an important 
finding and it questions the logic of further quadrantic biopsies in patient groups 
where neoplasia is already detected by acetic acid dye spray. This finding potentially 
has significant cost and resource implications for the endoscopist and the 
pathologist. 
The findings from this series are similar to another study quoting a surprisingly high 
sensitivity of 100% and specificity of 97.7% (88). However, only 13/100 of the 
patients in the study had dysplasia, making it difficult to draw any meaningful 
conclusions from it with respect to dysplasia detection. 
Whilst patients with excessive inflammation were excluded, a significant factor in the 
false positive rate of 19.6% was the presence of inflammatory changes appearing 
like dysplasia. This highlights the importance of treatment with proton pump 
inhibitors prior to endoscopy. When Barrett’s epithelium looks inflamed it is 
sometimes necessary to arrange further assessment after 8 weeks on a higher 
dosage of acid suppression, and this intervention should not be overlooked.    
There was a high prevalence of neoplasia in group A of 16.7%. In a Barrett’s 
surveillance population this would be expected to be much lower. However, it should 
be noted that this population was not a standard surveillance population. It consisted 
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of Barrett’s surveillance cases and symptomatic patients who had no prior diagnosis 
of dysplasia who had been listed for assessment on a chromoendoscopy list. 
Therefore it is not surprising that the prevalence of dysplasia in this cohort is higher 
than a standard asymptomatic surveillance population.  
Group B is a complex group, consisting of all patients with previously diagnosed 
dysplasia being assessed for EMR and post EMR follow up patients to look for 
metanchronous neoplasia. Endoscopic treatment in this cohort depends on accurate 
localisation of neoplasia and we were reassured to find that dysplasia could be 
targeted with a high degree of accuracy in this cohort.  
Electronic imaging techniques like narrow band imaging (NBI), and spectral imaging 
(FICE) have been reported in the evaluation of Barrett’s neoplasia (93). However, 
the studies have been very small and it is not possible to draw any firm conclusions 
from these studies. A problem with all ‘virtual chromoendoscopy’ techniques is that 
they have cost and resource implications as they require commitment to a particular 
endoscope manufacturer, and need the most recent image processors and 
endoscopes. Many units (even in the Western world) do not have the latest models 
of processor and endoscopes, and therefore cannot use this technology. Acetic acid 
dye spray can be performed in any unit and is compatible with all makes and models 
of endoscope, irrespective of the manufacturer. 
12.19:Strengths 
This is a single centre, single endoscopist study, performed by an experienced 
endoscopist. Whilst this can be seen as a weakness it can also be regarded as a 
strength. The design was intended to test the technique, rather than the 
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endoscopists ability to use it correctly. Therefore the results do represent what can 
be achieved by using acetic acid, and it avoids the criticism that missed nesoplasia 
could be due to the endoscopists inexperience in applying the technique and in 
interpreting the results. Furthermore, there were a large number of neoplasia cases 
in the study. The data is therefore robust and a true reflection of acetic acid as a 
diagnostic test, and unlikely to be distorted by a single wrong diagnosis. The design 
reflected how acetic acid is likely to be used in clinical practice and answers the 
important clinical questions of whether neoplasia can be localised and if high risk 
patients can be followed up safely. It also demonstrated that the technique could be 
used with standard endoscopes without optical magnification, which reflects routine 
Western practice. 
 
12.20: Limitations 
This is a single centre study, where all endoscopies have been performed by a 
single experienced endoscopist (PB). The results are therefore not generalisable to 
all endoscopists. It is probable that to achieve similar results formalised training 
would need to be undertaken in lesion recognition This is an accepted part of 
endoscopy, and if dye spray is to be used widely in the assessment of Barrett’s it will 
be necessary to address this issue. However, it is probable that intensive training in 
a large volume expert centre can help achieve the expertise in a relatively short 
period of time.  
The study is not a randomised controlled trial, and as such it is not possible to say 
how much of the dysplasia would have been found or missed by random biopsies 
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had dye spray not been used. That would be best assessed by a tandem endoscopy 
at a 6-8 week interval. However the data does show that dysplasia was visible in 
only 50% of our patients on high resolution WLI. Could protocol guided quadrantic 
biopsies every 2cm be able to pick up the dysplasia in the remaining 50% of patients 
with invisible (WLI) dysplasia? This is a difficult question to answer from the design 
of this study, but it is reasonable to propose that it would be very difficult to diagnose 
the dysplasia by quadrantic biopsies alone in this group of patients with invisible 
dysplasia. Even if it does, then it would require a very large number of biopsies with 
significant resource implications. Alternatively, the endoscopist could elect to use 
acetic acid spray and that will help better define the dysplasia that is already seen on 
WLI and also highlight the invisible (WLI) dysplasia as seen in 50% of the dysplastic 
population. 
This data is not enough to completely abandon the strategy of protocol guided 
biopsies in all patients with Barrett’s, but it does justify the role of acetic acid in 
patients with invisible dysplasia on WLI and also questions the additional gain of 
multiple non-targeted biopsies after dysplasia has been seen with acetic acid spray. 
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12.21 Implications for clinical practice 
 
In a high risk population this study would suggest that acetic acid is a very effective 
tool for the identification and localisation of neoplasia within Barrett’s oesophagus, 
and is more accurate than white light assessment alone. This has very important 
clinical implications as it enables targeted treatment for neoplasia to be performed 
such as endoscopic mucosal resection (EMR). This can potentially avoid the need 
for oesophagectomy in the majority of patients with high grade dysplasia or 
intramucosal cancer. It would be a realistic long germ goal to abandon non targeted 
biopsies when no visible neoplasia is seen with acetic acid. However, this is a cohort 
study and a randomised controlled trial is needed to reproduce these findings before 
this practice can be adopted. Acetic acid may have a role in a routine surveillance 
population. However, this data is insufficient to recommend this practice at present. 
 
12.22 Implications for future research 
 
A randomized tandem endoscopy study in a high risk population is the next logical 
step in evaluating this technique further. This would serve the function of both 
demonstrating reproducibility of this data in a robust way and would also 
demonstrate its wide spread applicability in a high risk population. A multi-centre 
multi endoscopist cohort study is also needed in a surveillance population to 
establish whether acetic acid could be used to replace random biopsies. This would 
need to be large as the prevalence of neoplasia would be much lower in this cohort. 
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The development of training tools in the use of acetic acid are important if the 
technique is to become widely used, and the duration of the learning curve to 
competence needs to be established. This may be achievable through picture or 
video based assessments, and a study will be required to establish whether this form 
of training is possible. 
 
There is currently no data available concerning the use of acetic acid followed by the 
additional use of vascular enhancement techniques (NBI, FICE or i-scan), and 
whether there is any additional gain frim this is unclear. Further research into this is 
needed. However, the studies would need to be large given the high sensitivity 
demonstrated in this study and it could be argued that even if a statistically 
significant benefit was seen it may not be clinically significant. 
 
12.21: Conclusions 
This study demonstrates that acetic acid  targeted biopsies are an excellent tool to 
localise  prevalent neoplasia within Barrett’s esophagus. It is cheap, quick, 
universally available and effective. It questions the relevance of additional non 
targeted biopsy in patients where AA has already identified neoplasia. 
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Chapter 13:  
 
Use of the Aceto-whitening timing in the diagnosis of Barrett’s 
neoplasia 
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13.1: Introduction 
 
In the previous study it was demonstrated that neoplasia within Barrett’s could be 
detected using acetic acid assisted chromoendoscopy (138). It is known that acetic 
acid leads to reversible acetylation of nuclear proteins and vascular congestion 
which improves the visualisation of surface and vascular patterns. The detection of 
neoplasia within Barrett’s has been based on the assessment of the following: 
 Mucosal Surface pattern (ridged, villous, nodular, round, irregular) 
 Mucosal vascular pattern (regular or irregular) 
 Aceto-whitening reaction: (normal or abnormal) 
The surface and mucosal vascular patterns have been described in several studies 
and are relatively well understood (88) (89) (90) (91) and have been demonstrated to 
be effective in the localization of neoplasia. However, the aceto-whitening reaction is 
poorly understood.  
In the study described in the previous chapter, assessment was predominately on 
surface patterns. It was noted during the previous study that dysplastic tissue 
appeared to lose its whitening early compared to metaplastic Barrett’s epithelium. 
However, the difference in the timings has never been studied. This has left 
endoscopists uncertain how to interpret these changes. The aim of this study is to 
explore the clinical significance of the aceto-whitening reaction in the diagnosis of 
Barrett’s neoplasia. 
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13.2: Hypothesis 
The loss of aceto-whitening can be quantified to accurately distinguish between 
Barrett’s metaplasia, dysplasia and invasive cancer. 
 
13.2.1: Primary aim 
To quantify the aceto-whitening timing thresholds for distinguishing between 
metaplasia, dysplasia and invasive cancer within Barrett’s oesophagus. 
 
13.2.2: Secondary aim 
To determine the sensitivity and specificity of the aceto-whitening reaction in the 
diagnosis of Barrett’s neoplasia. 
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13.3: Methods 
 
The investigation was constructed as a prospective case control study. Barrett’s 
epithelium was examined to identify areas of neoplasia. All procedures were 
performed by a single experienced endoscopist (PB) with expertise in lesion 
recognition and endoscopic mucosal resection (EMR).  
 
13.3.1: Inclusion criteria 
 Patients with known Barrett’s metaplasia where dysplasia had never been 
identified previously 
 Patients who had undergone endoscopic treatment for neoplasia previously 
and were under surveillance for metanchronous neoplasia 
 Patients suspected of neoplasia referred for evaluation for endoscopic 
mucosal resection or other targeted endoscopic treatment of the lesion  
 
3.3.2: Exclusion criteria 
 Oesophagitis 
 Contact bleeding 
 Acute mucosal trauma  
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13.4: Ethics committee approval 
 
The study was reviewed by the Oxford ethics committee. Patient consent was 
required for entry into to the study on a per-procedure basis as procedures could 
take longer than a standard acetic acid enhanced gastroscopy, due to the timing 
involved. Approval was granted REC reference number 10/H0605/30.   
 
13.5: Statistical analysis 
 
Unfortunately there were no prior studies suggesting what the differential timings in 
the aceto-whitening reaction may be. As such power calculations could not be 
performed. Statistical advice was requested from the Department of Mathematics 
and Biostatistics within the University of Portsmouth. The recommendation was to 
conduct the investigation as a pilot study. It was suggested that a minimum of 100 
lesions should be examined: 50 healthy areas of Barrett’s metaplasia, 30 areas of 
dysplasia (10 low grade and 20 high grade), 10 intra-mucosal cancer and 10 
invasive cancers. The best method of analysis was to use the data to generate a 
receiver operator curve (ROC) to determine threshold timings for the diagnosis of 
invasive cancer, intramucosal cancer, high grade dysplasia and metaplasia. In the 
event that the numbers were not large enough to be statistically significant, the study 
would still be likely to generate the information required to confidently power a larger 
study. 
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13.6: Endoscopic protocol 
All patients were endoscoped on a dedicated chromoendoscopy list. 25% of the 
cases were performed under local anaesthetic with xylocaine (10mg spray), with 
75% choosing conscious sedation using i.v. midazolam, starting at 2.5mg and 
increasing in 1mg intervals as required to a maximum of 5mg. Each procedure was 
allocated 15-20 minutes. Patients were given 50 mL of a solution containing 5 mL of 
10% N-acetyl cysteine and 5 mL of simethicone to drink prior to undertaking the 
procedure to act as a mucolytic and bubble-bursting agent. Gastroscopy was then 
performed using Fujinon EG-590zw and EG-590wr gastroscopes with the EPX 4400 
processor (Fujinon, Tokyo, Japan). Magnification, if available, was not used for the 
detection of neoplasia or for the purposes of aceto-whitening timings. Assessment of 
the mucosal surface and any obvious abnormalities seen with white light 
examination was recorded prior to dye spray with acetic acid. Acetic acid was 
applied using a spray catheter to areas of healthy Barrett’s epithelium and the time 
taken for the aceto-whitening to disappear was recorded. 
 
In each case the time taken for the aceto-whitening to disappear was recorded. The 
areas were then biopsied to confirm the diagnosis. Histology was correlated to the 
aceto-whitening disappearance time to establish whether there was a correlation 
between the degree of neoplasia (cancer, high grade dysplasia or low grade 
dysplasia) and the aceto-whitening time. Figure 33 shows the process of 
assessment. 
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Figure 33: Protocol for acetowhitening study 
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13.7: Assessment tool 
The aceto-whitening time was measured using a stop clock in minutes and seconds.  
The start time was defined as beginning after the entire length of Barrett’s 
oesophagus had been completely coated with acetic acid and all excess dye sucked 
away (Time A).  
The stop time for disappearance of aceto-whitening was defined as the moment of 
first appearance of erythema within the aceto-white Barrett’s epithelium (time B). 
Acetowhitening time= B - A 
 
This was trialled in 20 patients prior to introduction into the study to decide the best 
way of timing (stopwatch versus on-screen clock), the best person to record the 
timing (endoscopist versus investigator) and the potential implications of it in terms of 
increased time taken for the procedure. It was found that the endoscopist calling the 
start and stop times, with a researcher recording these on the data proforma, were 
most reproducible and worked well. The onscreen clock was more precise as the 
endoscopist could read it straight off the screen and the researcher transcribe it 
directly onto the data sheet. The procedure was not found to be delayed by timing, 
as it would take at least 5 minutes to adequately visually assess the Barrett’s 
epithelium, record measurements according to Prague criteria and complete the 
procedure. Washing the mucosa thoroughly prior to quadrantic biopsy was found to 
be essential as excess acetic acid could cause local oozing which interfered with 
views.  
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13.8: Results 
13.8. True histology 
In total 133 patients were approached to enter the study. 131 met the inclusion 
criteria and 129 consented to enter the study. At the time of gastroscopy a further 8 
cases were subsequently excluded as not meeting the inclusion criteria for acetic 
acid chromoendoscopy due to the presence of significant visible inflammation on 
white light. In total data was collected from 146 areas of Barrett’s were collected in 
121 patients, of which 84% were male. The pathway for recruitment is shown in 
figure 34. The breakdown of the true histology is shown in table 31: 
 
 
True 
histology 
Metaplasia LGD HGD IMC Invasive 
cancer 
Number 86 14 27 7 12 
Table 31: True histology of cohort. LGD= low grade dysplasia, HGD=high grade dysplasia, IMC=intra-mucosal cancer 
 
Areas were identified by assessment of surface patterns, surface vasculature and 
vascularity. In total, 72/86 normal Barrett’s epithelium was correctly identified as 
normal. HGD was correctly identified in 26/27 cases, 15/15 IMC and 12/12 of the 
invasive cancer was recognised correctly by the endoscopist. 6/14 LGD was 
correctly identified. This resulted in a sensitivity for high risk neoplasia of 98% with a 
specificity of 89%. 
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13.9: Aceto-whitening timings: Metaplasia versus high risk neoplasia 
Amongst cases correctly identified the mean and range of timings for the 
disappearance of the aceto-whitening time by histology are shown in table 32. The 
time for disappearance of LGD, HGD, IMC and invasive cancer was significantly less 
than that of metaplasia, with a mean aceto-whitening time greater than two standard 
deviations less than that for metaplasia (p<0.05).  
 
Histology Mean time for 
acetowhitening to 
disappear (seconds) 
Standard 
deviation 
Median time for 
acetowhitening 
to disappear 
(seconds) 
Range 
Metaplasia 387 164 350 142-621 
LGD 58 28 58 15-90 
HGD 54 28 53 20-140 
IMC 24 13 20 12-50 
Invasive cancer 23 26 10 3-81 
Table 32: Mean acetowhitening times by lesion histology (LGD= low grade dysplasia, HGD=high grade dysplasia, 
IMC=intra-mucosal cancer) 
 
13.10: Aceto-whitening timings: Cases incorrectly diagnosed 
There were 14 false positive cases in the series. In 4/14 of these cases the changes 
were very subtle and it was suspected clinically that the histology may be metaplasia 
only. In the remaining 10 cases the areas had the appearances of dysplasia with a 
disordered surface pattern. In all cases there was a mild degree of inflammation 
present which affected the diagnosis. There were 9 false negative cases, one HGD 
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and 8 LGD. In 2 of the cases of LGD coexisting areas of HGD had been correctly 
identified in the same endoscopy.  
 
13.11: ROC curve: Differentiation of high risk neoplasia from metaplasia using 
aceto-whitening timings 
 
A ROC curve was produced for the identification of high risk neoplasia (HGD, IMC 
and invasive cancer) using the aceto-whitening timings. The area under the curve 
was 0.93, demonstrating a low probability that a randomly chosen positive case will 
exceed the value for a randomly chosen negative case. The asymptomatic 
significance was 0.000. (95% C.I. 0.89-0.97). Using a cut off threshold of 142 
seconds a sensitivity for neoplasia of 98% (95% C.I. 89-100) and specificity of 84% 
(95% C.I. 74-91) could be achieved. If the threshold was increased to 288 seconds a 
sensitivity of 100% could be achieved but this compromised the specificity by 
reducing it to 60.5%. If the threshold was reduced to 60 seconds the sensitivity was 
reduced to 72% with a small improvement in specificity to 86%. See tables 33 and 
36 and figure 35. 
 
 Acetowhitening time of 
142 seconds 
95% C.I. 
Sensitivity 97% 89-100 
Specificity 84% 74-91 
Table 33: Sensitivity and specificity of acetowhitening for neoplasia 
 
258 
 
Figure 35: ROC Curve for metaplasia Vs neoplasia 
 
 
13.12: ROC curve: Differentiation of HGD from IMC and invasive cancer using 
aceto-whitening timings 
A ROC curve was produced for HGD versus IMC/invasive cancer. The Area under 
the curve was 0.829. The asymptomatic significance was 0.000 (95% C.I. 0.703-
0.95). If the threshold timing is set at 30 seconds a sensitivity of 74% (95% C.I. 49-
91) and specificity of 82% (62-94) is seen. If a cut off timing is increased to 51 
seconds, a sensitivity for cancer of 90% and specificity of 54% could be achieved. If 
the threshold is changed to 23 seconds a sensitivity of 63% and specificity of 85% is 
seen. See table 34 and figure 36. 
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 Acetowhitening threshold 
of 30 seconds 
95% C.I. 
Sensitivity 74% 49-91 
Specificity 82% 62-94 
Table 34: Sensitivity and specificity for acetowhitening HGD vs Cancer 
 
Figure 36:ROC curve HGD vs Cancer 
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13.13: ROC curve: Differentiation of HGD+IMC from invasive cancer using 
acetowhitening timings 
A ROC curve was produced for HGD + IMC versus invasive cancer. The 
asymptomatic significance was 0.004. The area under the curve was 0.786 (61-96). 
This demonstrated that using a cut off of 20 seconds, a sensitivity for invasive cancer 
of 67% (95% C.I. 35-90%) and specificity of 85% (69-95%) could be achieved. If the 
timing threshold was increased to 41 seconds a sensitivity of 75% and specificity of 
62% was obtained. If the cut off was decreased to 11 seconds a sensitivity of 58% 
and specificity of 97% was seen. See table 35 and figure 37. 
 
Table 35 Acetowhitening threshold 
of 20 seconds 
95% C.I. 
Sensitivity 67% 35-90 
Specificity 85% 69-95 
Table 35: HGD and IMC vs Invasive cancer 
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Figure 37: ROC curve HGD+IMC vs Invasive Cancer 
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Table 36: Coordinates of the Curve 
Positive if Less Than or Equal To
a
 Sensitivity 1 – Specificity 
2.0000 .000 .000 
3.5000 .022 .000 
4.5000 .043 .000 
7.0000 .109 .000 
9.5000 .130 .000 
11.0000 .174 .000 
13.0000 .196 .000 
14.5000 .217 .012 
16.0000 .261 .012 
18.5000 .283 .012 
22.5000 .348 .012 
25.5000 .348 .023 
27.0000 .391 .035 
29.0000 .413 .035 
33.5000 .457 .035 
39.5000 .478 .035 
43.5000 .478 .047 
47.0000 .565 .058 
49.5000 .587 .070 
51.5000 .630 .070 
54.0000 .674 .070 
55.5000 .674 .081 
57.5000 .696 .081 
59.5000 .717 .093 
62.5000 .761 .140 
67.5000 .783 .140 
71.0000 .826 .151 
72.5000 .848 .151 
73.5000 .848 .163 
76.0000 .870 .163 
79.5000 .891 .163 
85.5000 .913 .163 
115.0000 .957 .163 
141.0000 .978 .163 
148.0000 .978 .174 
164.0000 .978 .186 
177.5000 .978 .198 
195.5000 .978 .209 
216.5000 .978 .221 
230.5000 .978 .233 
239.0000 .978 .244 
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Positive if Less Than or Equal To
a
 Sensitivity 1 – Specificity 
244.0000 .978 .279 
251.5000 .978 .291 
257.5000 .978 .302 
263.5000 .978 .314 
268.0000 .978 .326 
269.5000 .978 .337 
274.5000 .978 .372 
282.0000 .978 .384 
286.5000 .978 .395 
288.5000 1.000 .395 
294.5000 1.000 .407 
301.0000 1.000 .477 
306.5000 1.000 .488 
319.5000 1.000 .512 
329.0000 1.000 .523 
331.5000 1.000 .535 
335.5000 1.000 .547 
344.0000 1.000 .570 
350.5000 1.000 .593 
352.5000 1.000 .605 
354.5000 1.000 .616 
357.5000 1.000 .628 
363.0000 1.000 .651 
380.0000 1.000 .663 
395.5000 1.000 .674 
397.5000 1.000 .686 
400.0000 1.000 .698 
406.5000 1.000 .709 
413.5000 1.000 .721 
418.0000 1.000 .733 
425.0000 1.000 .744 
435.5000 1.000 .756 
443.0000 1.000 .779 
449.0000 1.000 .791 
458.5000 1.000 .802 
472.0000 1.000 .814 
488.5000 1.000 .837 
 
 
 
 
264 
 
Positive if Less Than or Equal To
a
 Sensitivity 1 – Specificity 
518.5000 1.000 .849 
546.0000 1.000 .860 
564.0000 1.000 .872 
580.0000 1.000 .884 
588.0000 1.000 .895 
596.0000 1.000 .907 
610.5000 1.000 .919 
622.5000 1.000 .930 
630.5000 1.000 .942 
652.5000 1.000 .953 
686.0000 1.000 .965 
834.0000 1.000 .977 
978.0000 1.000 .988 
993.0000 1.000 1.000 
 
 
a. The smallest cutoff value is the minimum observed test value minus 1, and the largest cutoff value is the 
maximum observed test value plus 1. All the other cutoff values are the averages of two consecutive ordered 
observed test values. 
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13.14: Discussion 
 
This study demonstrates that the aceto-whitening time is an important tool for the 
diagnosis of high risk neoplasia within Barrett’s. It has shown that by using a 
threshold of 141 seconds, a sensitivity for all neoplasia of 97% can be achieved with 
a specificity of 84%. This makes the aceto-whitening timing an excellent diagnostic 
tool for the identification of high risk neoplasia. However, it is also possible to use the 
technique to further characterise the neoplastic area to predict the presence of sub-
mucosally invasive disease. By examining the curve with the differentiation of 
mucosal neoplasia from invasive cancer as the focus, a specificity for invasive 
cancer of 85% can be achieved by using a threshold timing of 20 seconds. Whilst the 
possibility that the lesion is not invasive cannot be excluded if the aceto-whitening 
disappears after this time (sensitivity 67%), the probability that the lesion is invasive 
(and hence not endoscopically resectable) is very high if the aceto-whitening 
disappears before 20 seconds. This is more `effective than other proposed methods 
of predicting depth of invasion such as endoscopic ultrasound (139) (140) (141) 
(142).  
 
The exact cut off point for metaplasia vs neoplasia and mucosal neoplasia vs 
invasive disease is a trade off between sensitivity and specificity. As demonstrated in 
the results the values quoted are the optimal cut offs for each assessment. 
Practically the vast majority of neoplasia becomes apparent within 90 seconds. 
However, by observing for 141 seconds more subtle but significant findings do 
occasionally become apparent. Waiting for 288 seconds (nearly 5 minutes) is likely 
to add so little and result in so many over called areas that this approach cannot be 
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recommended. Likewise, invasive cancer can take longer than 20 seconds to 
appear. Disappearance over this threshold therefore does not mean definitively that 
a lesion is intramucosal (and therefore endoscopically treatable). However, it does 
provide the endoscopist with additional valuable information to stratify risk.  The ideal 
points will always involve a degree of compromise, which is inherent in this kind of 
numerical test. It should be noted that surface pattern assessment also involves 
judgement calls, but these will always be more subjective and therefore difficult to 
reproduce.   
 
13.15: Strengths of the study 
 
The development of this tool provides an objective tool for examining areas of 
neoplasia. The traditional assessment of surface patterns is difficult, subjective and 
ideally requires optical magnification. There is a learning curve associated with this 
and a question remains regarding reproducibility of such assessments. In contrast, 
the timing for the disappearance of aceto-whitening is an objective numerical 
measure with hard end points. This is easy to interpret by any endoscopist and can 
be translated into clinical practice with minimal training. Furthermore, it can be used 
without optical magnification.  
 
Acetic acid is an important tool in the assessment of Barrett’s. There have been two 
large studies published recently which have suggested that acetic acid is an effective 
tool for localising neoplasia. A German study of 701 patients found a sensitivity of 
96.7% and specificity of 66.5% for dysplasia (143). The other published study is 
described in this thesis (138). This large study conducted by the Portsmouth 
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research group in the United Kingdom consisted of 190 procedures. Acetic acid 
identified invisible dysplasia or cancer 2.2x more frequently than WLI, with a 
sensitivity of 97% and specificity of 80% for the detection of dysplasia or cancer. 
Both of these studies were conducted without the benefit of this data on how best to 
exploit the aceto-whitening reaction. It is possible that by combining surface pattern 
assessment with the differential in the aceto-whitening that the sensitivity and 
specificity could be improved further. This is an important area for future research. 
 
13.16: Limitations 
 
A limitation of this study is that the moment of disappearance of the acetowhitening 
is subjective and dependent on a single endoscopist’s interpretation. However, it was 
found that in practice once the area started to lose the whitening it changed over a 
matter of a few seconds. Therefore this is unlikely to significantly impact on the 
findings. The study has a pragmatic practical design which reflects how endoscopy is 
practiced. In order for the acetowhitening reaction to be clinically exploited, a simple 
measurement has to be used, or it could not be applied on busy lists. A simple timing 
can easily be performed by every endoscopist in any unit without the need for 
specialist equipment.  
 
In a similar way to surface pattern assessment the aceto-whitening timing is affected 
by co-existing inflammation. As such there is a false positive rate associated with the 
test. It is necessary therefore to completely treat inflammation prior to assessment. 
Furthermore, it is not effective in the accurate identification of low grade neoplasia, 
where the accuracy is just 33%. However, this is not such a major issue. It is the 
268 
 
identification of high risk neoplasia which alters management, and it is here that the 
aceto-whitening timings are very effective. Therefore the focus of the study was on 
the differentiation of high risk neoplasia from metaplasia, and high grade dysplasia 
from invasive cancer. The diagnosis of high grade neoplasia changes management 
from observation to treatment, and the diagnosis of invasive cancer changes 
management from endoscopic treatment to surgical care.  
 
 
13.17: Implications for clinical practice 
 
A concern for all endoscopists who treat Barrett’s neoplasia within Barrett’s has been 
the consequences of failing to correctly identify submucosally invasive cancer. These 
lesions cannot be cured by endoscopiic mucosal resection and if resection is 
attempted the risk of perforation is high. If ablative techniques are used such as 
radio-frequency ablation the consequences can be even worse as no tissue sample 
is obtained and the patient may be denied potentially curative surgery on the 
mistaken belief that the disease has been cured. Until now there has been no 
techniques which could predict depth of invasion of a lesion. This study would 
suggest that the aceto-whitening time is a specific indicator for invasive disease. 
Whilst a longer time to disappearance of aceto-whitening does not exclude 
submucosally invasive disease, a rapid disappearance should be considered to be 
concerning and raise a high index of suspicion that a lesion is advanced and 
potentially not curable by an endoscopic approach. 
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13.17: Future research needs 
 
There is a need for a multicentre, multiendoscopist study to verify these findings. If 
confirmed this could form the basis of the development of an endoscope based 
technology to automate the test. All of the modern endoscopes capture data digitally 
using a charge coupled device (CCD). Most can measure in some form the spectral 
reflectance from tissues. It would not require a significant change in endoscope 
design to be able to objectively measure the parameters described in this study and 
automatically alarm when whitening had disappeared in an area. In the case of 
Fujinon and Pentax endoscopes, which already contain micro-processors designed 
for image processing, a software update may be all that is required. Whilst this is 
some way away it provides a starting point for future research. This study does not 
attempt to address how the aceto-whitening reaction occurs and why there is a 
differential in the timings. It can be speculated that neoplastic tissue is highly 
vascular, and that in turn results in early reversal of the changes observed, but this is 
not proven. This data calls for further research into the mechanism behind the aceto-
whitening reaction. 
13.19: Conclusions 
 
Understanding of the aceto-whitening reaction has been limited. This study 
addresses this apparent deficiency in the literature and by exploiting the aceto-
whiting reaction, it is possible to both localise and predict the severity of neoplastic 
change. It is likely that this phenomenon can be exploited to improve the sensitivity 
and specificity of acetic acid chromoendoscopy in the detection of high risk 
neoplasia. 
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PART C 
 
Summary of the work 
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Chapter 14 
 
The potential clinical impact of the studies 
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14.1: Significance of the results 
 
The central ethos behind this thesis has been around the concept of clinical 
judgement during endoscopy. In clinical practice it is a central role of the doctor to be 
able to interpret clinical symptoms and signs and make a diagnosis based on 
objective criteria. In the field of endoscopy however this process has become diluted. 
In the assessment of colonic polyps standard practice has been to just remove 
lesions and send to histopathology for a diagnosis. Likewise, in the oesophagus, 
assessment of Barrett’s has been based around mapping biopsy on the theory that 
the endoscopist cannot make a diagnosis of early neoplasia and requires a 
pathologist to do this. Historically the reasons for this are clear. Early endoscopes 
had a poor image quality and only gross abnormalities could be seen. Therefore the 
best which one could hope to achieve was to take a biopsy. However, this position 
has changed. In an era of high resolution endoscopy, vascular enhancement, 
magnifying endoscopes and chromoendoscopy a wealth of diagnostic possibilities 
have been opened. However, they will not be adopted unless tools for their use can 
be developed and evidence that they work produced. This is analogous to the work 
performed into bedside clinical examination by the 19th century physicians which is 
so central to modern practice today. The studies described in this thesis go some 
way towards addressing this issue, by examining the emerging roles of advanced 
diagnostic techniques in the detection and examination of neoplasia in the upper and 
lower gastrointestinal tract. The central theme has been to empower the endoscopist 
by providing a set of evidence based tools which can be easily learnt and applied in 
routine Western practice. 
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14.2: Colonic neoplasia studies 
A new and simple to use polyp classification system has been developed. This has 
been designed for use by Western endoscopists who are unfamiliar with the 
complexities of the Japanese polyp classification systems and with the standard non 
magnifying endoscopes, which are the standard of care in Western practice. It 
utilises the FICE vascular enhancement system which is currently under researched 
and until now has lacked any validated tools. 
 
This tool was developed using a picture library and then validated with an in-vivo 
study.  It was then shown to work effectively in a large prospective series in a Bowel 
Cancer Screening population. This not only demonstrated that the classification 
system worked, but also validated the concept that picture based studies are a good 
surrogate marker for in-vivo assessment. This is important as it provides a model for 
the development of future tools for in-vivo assessment using other devices. 
 
The studies described in this thesis have demonstrated that small colonic 
polyps<10mm can be examined in more detail than previously thought and that an 
accurate prediction of histology can be made with a non magnifying endoscope. This 
has significant cost implications within the National Bowel Cancer Screening 
Programme. The studies have also demonstrated the role of high definition 
endoscopes. There is a benefit from using the newer high definition scopes if 
electronic vascular enhancement techniques are to be used but are of no additional 
benefit over older standard definition equipment if dye spray assessments with 
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indigocarmine are to be performed. This has the potential to form the basis of 
guidelines for endoscopists as to which method should be used to perform an in-vivo 
diagnosis dependent on equipment available. The research addresses the key 
standards proposed by the ASGE in their recent PIVI that a technology needs to 
meet in order to be used for in-vivo histology prediction for colonic polyps (10).  
 
The cost implications should not be underestimated. These studies have 
demonstrated that just within the U.K. National Bowel Cancer Screening Programme 
£678,253 could be saved per annum. This figure is consistent with predictions made 
by previous studies based on mathematical models (68). It is a reality that all health 
care systems are under financial pressure. If costs can be reduced without harm to 
patients, then there is a duty for health care providers to do so. What is an 
acceptable degree of accuracy when assessing polyps<10mm in size? It is important 
to understand that small adenomas less than 10mm in size are low risk lesions. 
Every day clinicians are making judgement calls, from the GP who sees a patient 
with a headache to the surgeon who examines a patient with abdominal pain. For 
safe and effective management, this is essential. The system would collapse if 
everyone with a headache was sent for a computed tomography scan to exclude a 
brain tumour. Indeed, it could be argued that over investigation can actually cause 
harm, both physical and psychological. Conceptually the situation is no different for 
the endoscopist, and proposals in this thesis are really no different. Is it not 
reasonable that an endoscopist, empowered with the appropriate evidence based 
tools, should be expected to be able to make a diagnosis and a clinical decision on 
such low risk lesions?  
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It is important to understand that the benefits in making an in-vivo diagnosis are not 
simply of economic interest. In the U.K. there is a delay of anything from one to six 
weeks for biopsy specimens to be reported on, depending on urgency of request. 
During this period patients can experience considerable anxiety wondering what the 
lesion is. Likewise, if the endoscopist is uncertain of the significance of a lesion then 
an inappropriate treatment might be undertaken (e.g. removal of a cancer by an 
inadequate technique) which could impact on future management. Furthermore, 
most pathology departments are already overburdened with work. It is questionable 
whether it is a good use of the histopathologists time to be reporting on small polyps 
of low malignant potential if an accurate in-vivo diagnosis can be made by the 
endoscopist. Freeing the pathologist up from this low risk, high volume work would 
enable more time to be spent on examining high risk lesions such as multipiece 
endoscopic mucosal resection specimens from large polyps, where the risk of 
invasive disease is much higher.  
 
14.3: The challenge 
 
14.3.1: Medico-legal issues 
A common concern raised by endoscopists is the medico-legal implications of in-vivo 
diagnosis. These are of course entirely justified. Without appropriate tools for 
assessment, training in their use, and guidance on how to apply them in routine 
clinical practice, this kind of change in practice cannot occur. The ASGE PIVI has 
gone a long way in developing a framework of standards for in-vivo diagnosis. This 
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will provide the endoscopist with protection by defining what an acceptable level of 
accuracy is. The work in this thesis addresses some of the issues around validated 
assessment tools for this purpose and identifies tools which meet the defined 
standards. Electronic image capture systems will enable high quality images of the 
discarded lesions to be kept, which could be reviewed at a later date if a query over 
the diagnosis is raised. A key priority for the national and international endoscopy 
associations should be to assemble the evidence as it becomes available to guide 
clinicians in the application of new advanced techniques as they become available.   
 
14.3.2: Training 
New innovation brings with it new challenges. A question which can be raised 
regarding in-vivo diagnostic techniques relates to the learning curve for acquiring the 
skills. The studies described in this thesis cannot answer this question as they have 
been conducted by a single skilled endoscopist. It is an area where more work is 
urgently needed. There have however been some preliminary studies which 
suggests that the techniques for examining colonic neoplasia are not particularly 
difficult to learn and can be acquired using picture based training programmes in as 
little as 20 minutes (131). Whilst this position may be optimistic, it has been the case 
since the early days of modern clinical practice that clinicians have to be prepared to 
learn new skills and adopt new practices as evidence dictates. In the United 
Kingdom there have been considerable strides taken in recent years to improve the 
quality of gastrointestinal endoscopy, with quality standards set for completion rates 
and polyp detection rates. A similar position is seen in many countries across Europe 
and in the United States. This is a similar position to that seen in surgical procedures 
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and it is accepted that endoscopists must be prepared to audit their completion rates 
and demonstrate competence to practice. In the U.K. Bowel Cancer Screening 
Programme endoscopists are even more tightly controlled, with additional 
examinations required before being appointed as screening practitioners. Therefore 
the necessity for training should not be seen as a barrier but as an opportunity to 
provide a better service. 
 
14.3.3: Tools 
Training requires effective, validated and easy to use training tools. As previously 
described, all of the validated classification methods for indigo carmine and FICE 
have been developed for use with magnification endoscopes. Magnifying 
endoscopes are not in common practice in the U.K. They are perceived as bulky, 
cumbersome and difficult to use and most endoscopists do not like their handling 
characteristics. They are also expensive to purchase. In order for effective training to 
be delivered it is therefore essential to have robust assessment tools which are 
validated for use with the tool the endoscopist will actually be using. In the U.K. 
Western Europe and North America this is realistically a standard endoscope without 
optical magnification. The development of the N.A.C. system goes some way 
towards addressing this problem as it is a validated and relatively simple tool which 
is designed for use without optical magnification. The work in this thesis has 
demonstrated that these assessments can be performed on standard western lists 
without increasing procedure time. 
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14.3.4: Culture 
Within Western practice there has been a tendency towards believing that a good 
examination is a quick one. This is reflected by the densely packed lists seen in 
general endoscopic practice. This may have been acceptable when the aim was to 
simply identify gross pathology, but for screening it is necessary to identify subtleties. 
It is for this very reason that every Bowel Cancer Screening list is limited in terms of 
the number of procedures which can be put onto it. However, it is not enough to 
simply reduce the number of procedures on a list and to expect clinicians to change 
working practices which have been developed over decades. At present, endoscopy 
is driven by a biopsy dependent culture. In order for management to improve it is 
necessary to adopt a new philosophy of ‘see more, biopsy less’, where the 
endoscopist is actively engaging in making a diagnosis. The concept is not intended 
to render the pathologist redundant. It does however require a mindset where the 
endoscopist accepts that diagnosis should be seen as a collective responsibility, and 
intelligently targets and selects what is sent for histopathological examination, 
thereby making best use of resources and ensuring that the best chance of 
achieving a correct diagnosis is achieved.   
 
The development of new in-vivo diagnostic techniques can help in overcoming these 
challenges. They provide the endoscopist with the tools to identify and characterise 
subtle pre malignant and early cancerous lesions, and also provide a method to 
reduce expenditure in confirming that a non-neoplastic lesion is indeed harmless. 
This is a very important concept. Investment in training of clinicians in new 
techniques has to be justifiable in terms of both benefit to patients and cost 
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effectiveness. Sometimes a new innovation only offers an advantage in one of these 
areas making uptake difficult. In the current challenging economic climate, health 
economists have to feel confident that introduction of a new test is financially 
sustainable. Therefore it is a reality of modern practice that in proposing a new 
diagnostic paradigm, attention is paid to this issue. 
 
14.4: Future research needs 
There is a need for multi-centre, multi endoscopist studies to assess the applicability 
and reproducibility of colonic in-vivo histology prediction using both vascular 
enhancement techniques and indigocarmine dye spray on a wider basis. It is 
generally accepted that whilst single centre studies are best suited to prove the 
effectiveness of a technique, these results can be difficult to achieve with a larger 
group of clinicians and pose different challenges. Furthermore, additional studies into 
learning curves for these techniques should be undertaken to establish how best to 
train endoscopists in the future. In many ways these two areas should be conducted 
in tandem, as to conduct multi-centre studies will require many more endoscopists 
performing in-vivo diagnosis and it would be a golden opportunity to demonstrate 
how long or arduous the learning curve actually is. These studies need to be 
undertaken on busy lists that are applicable to real world practice if the studies are to 
be taken seriously, and should use endoscopes from a variety of equipment 
manufacturers. 
It is important to stress that the development of vascular enhancement techniques 
has opened up a new research challenge in endoscopy. The three main 
manufacturers (Olympus, Fujinon and Pentax) have all introduced spectral imaging 
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technology into their equipment, but they all work quite differently. Therefore it is 
generally accepted that results from one system cannot be applied to the other 
systems (55). It could be argued further that it is dangerous to extrapolate from one 
system to another as it could leave the endoscopist with a false reassurance that a 
particular technique was more effective than it actually is. To date, the vast majority 
of the research has been published on Olympus Narrow Band Imaging. This thesis 
helps to address this disparity but there is still some distance to be covered until all 
of the differences between the systems are completely understood. In particular 
there is a lack of evidence for the Pentax i-scan technology. This system is unique in 
having a 1.3million pixel CCD as standard, and given the difference in the diagnostic 
capabilities of FICE using high definition endoscopes compared to standard 
definition endoscopes, it will be of interest to know what capabilities are seen with 
this very high resolution system. Studies need to be conducted comparing NBI with 
FICE and i-scan, with and without optical magnification to establish if one system is 
superior for the purposes of in-vivo diagnosis. It is also necessary to compare 
vascular enhancement techniques to confocal endomicroscopy. There has been one 
study performed which has done this (57), but this was underpowered and combined 
NBI and FICE into a single category. The results using vascular enhancement 
techniques were disappointing and not in keeping with other studies.  
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14.5: Barrett’s neoplasia studies 
The studies in this thesis have demonstrated that acetic acid is an effective tool for 
diagnosing and localizing neoplasia within a high risk Barrett’s population. This 
challenges the current paradigm in Barrett’s surveillance which is based around non-
targeted mapping biopsies. Furthermore, the acetowhitening reaction can be utilised 
diagnostically to improve the sensitivity and specificity in improving this test. This is 
an objective numerical assessment tool which is simple to learn and apply to routine 
practice. Furthermore, It has been shown to have potential for differentiating high 
grade dysplasia from intramucosal cancer and from invasive cancer. This is very 
important. Whilst high grade dysplasia and intramucosal cancer are endoscopically 
treatable invasive cancer is not. There are currently no other tools available which 
can do this. The acetowhitening timings have been shown to be effective for this 
task. Whilst not 100% accurate they provide the endoscopist with much more 
information than previously thought possible and so empowers him or her to make a 
better decision as to how to best treat the patient. 
 
14.6: The challenge 
The current culture in Barrett’s surveillance is biopsy driven. If the endoscopist could 
‘see more and biopsy less’ then more effective surveillance could potentially be 
performed. By targeting neoplastic lesions using acetic acid chromoendoscopy it 
may be possible to improve both screening efficacy and the cost effectiveness of 
surveillance by reducing the number of biopsy cassettes required for each patient.  
However, this requires a shift away from a protocol biopsy driven culture.  
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Changing the current mind set of endoscopists away from the current biopsy driven 
culture will not be an easy challenge. Even with evidence based tools, there will be a 
reluctance to move away from the established standard of care which endoscopists 
feel comfortable using, and it should be recognised that it will take time for such 
concepts to become fully adopted. It is likely that before endoscopists become 
confident to adopt a ‘see more and biopsy less’ strategy that a move towards ‘see 
more and biopsy more’ will occur, where a combination of advanced imaging and 
biopsies will be used. This should not be discouraged. It is by observing the 
accuracy and usefulness of advanced imaging with the additional safety of biopsies 
that the endoscopist will gain confidence in to adopt new techniques. There may also 
be a generational effect, where newly trained clinicians are trained from the ground 
up, with a different mind set being more willing to embrace this new philosophy. 
  
It is important to understand that a change in approach is needed. As discussed in 
chapter 3, there have been concerns raised regarding the efficacy and cost 
effectiveness of Barrett’s screening, and the question has been raised as to whether 
it is of any benefit at all (6). Because of this, studies have been commissioned to 
investigate this issue, including the multicentre Barrett’s oesophagus surveillance 
study (BOSS) based in the United Kingdom. Biopsy forceps are small compared to 
the overall surface area of Barrett’s metaplasia and even the most intensive 
protocols only examine 3% of the total Barrett’s present. It is therefore not surprising 
that small neoplastic foci can be missed by such methods, making surveillance 
ineffective. The analogy would be to find a needle in a haystack by randomly 
sampling the hay. Therefore a localisation method is critically needed. The BOSS 
study may not answer the question which needs to be answered as it is working 
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along the principle of protocol driven biopsy based surveillance, and a better 
question of whether the cost benefit profile of surveillance can be improved by using 
an enhancement technique such as acetic acid chromoendoscopy is not being 
addressed.  Much of the expenditure in screening endoscopy is on the processing of 
pathology specimens. It is important to appreciate that reimbursement for pathology 
costs is on a per cassette basis. To follow Seattle or Cleaveland clinic protocols 
effectively requires each biopsy to be sent in a separate cassette (so that an 
abnormality can be localised). This can amount to anything between 8-40 cassettes 
per patient. For surveillance programmes to be sustainable they need to detect 
pathology in a cost effective manner. The use of acetic acid targeted biopsies in 
place of mapping biopsies could reduce the number of biopsies required and so 
reduce the pathology related costs of screening. 
 
14.6.1: Training in chromoendoscopy techniques for lesion recognition 
Training in lesion recognition and assessment is essential if in-vivo diagnosis is to 
become successful. Barrett’s assessment poses particular challenges in this respect. 
As described previously, bowel cancer screening is performed by expert consultant 
colonoscopists who have to complete mandatory additional training and assessment 
prior to undertaking screening lists. In contrast, Barrett’s surveillance is typically 
delegated to more junior staff, with the majority now performed by nurse 
endoscopists. Furthermore, the number of assessments performed per year can be 
low. For training to be successful and cost effective, it will be necessary to have both 
validated and simple to use assessment tools, but also to rationalise who and how 
many endoscopists perform the assessments.  
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It is important to understand that it is the lesion recognition skills which take time and 
effort to acquire, not the practical skills of flushing dye down the endoscope. This 
may seem obvious, but it highlights one of the fundamental challenges in a move 
towards in-vivo diagnosis. There is a culture amongst clinicians to see endoscopy as 
a practical skill, and that endoscopy training should involve being taught a practical 
technique. However, it is a knowledge base which has to be developed to make in-
vivo diagnosis safe, and this needs to be based on robust and reproducible 
evidence.  
 
14.6.2: Mass application of the techniques 
If acetic acid enhanced chromoendoscopy is to be applied to the screening 
population on a national basis, a change in the way screening is approached is 
necessary. Rather than the current paradigm, it is likely that screening on expert 
Barrett’s lists in high volume specialised centres, run by a small number of trained 
individuals, would represent the most cost effective way forward. The clinicians 
performing these procedures would be exposed to neoplasia on a regular basis, and 
could maintain the skills in a similar manner to that seen in Bowel Cancer Screening. 
Furthermore, the lists could then be set up with the appropriate equipment to 
conduct the procedures effectively and would avoid the hurdle of all endoscopy units 
needing to invest in this respect. Auditing of outcome would be easier and it would 
make the identification of potential problems easier. 
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14.7: Future research needs 
 
14.7.1: Acetic acid in a surveillance population 
There is a clinical need for more studies investigating the role of acetic acid in a 
Barrett’s surveillance population. This poses a particular challenge. The data 
presented in this thesis comes from a high risk group where the prevalence of 
neoplasia is high. From a skills perspective this means that the endoscopist 
assessing these patients is exposed to neoplasia on a regular basis and is therefore 
constantly seeing the subtle changes associated with high risk lesions. In a low risk 
surveillance population the prevalence would be less by a factor of 10. It is not 
known if the results described in this thesis will be equally good in a surveillance 
population. However, there is an urgent need for research into the use of acetic acid 
to improve the gain for Barrett’s surveillance.  As described previously, Barrett’s 
surveillance in the United Kingdom is largely performed by junior endoscopists. They 
are different to the clinicians examining high risk patients who are all consultants with 
an interest in early cancer diagnosis. Therefore any future studies looking at a 
surveillance population should be undertaken with this in mind and study design 
should utilise the kind of endoscopist who will be performing these procedures in 
mainstream practice. Again learning curves for lesion recognition have not been 
established and work needs to be done in this area. 
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14.7.2 Risk stratification of patients with Barrett’s 
It is likely that the Barrett’s population is a heterogenous group with varying levels of 
risk, and what is needed for the future is a better way to risk stratify patients, so that 
high risk individuals can be offered more intensive surveillance, and low risk patients 
can be reassured and discharged from follow up. At present basic demographic 
factors are understood, including male gender, Caucasian origin, smoking history 
and length of Barrett’s segment, but this is a crude measure. The development of 
molecular markers to flag risk is needed. There has been some work already done 
investigating nuclear atypia by flow cytometery in Barrett’s biopsies (144) (145) and 
this may enable patients with metaplasia on biopsy to be further sub-divided. This is 
likely to be the tip of a very large iceberg. Circulating DNA markers and specific 
molecular markers that could be identified on a simple blood test are badly needed. 
If these factors could be used in combination, a risk profile could potentially be 
established. Advanced endoscopic imaging would also be important here. It is 
possible that acetic acid assisted chromoendoscopy for Barrett’s assessment could 
be another tool in the risk stratification of patients. Future research is needed into the 
use of a one-off advanced endoscopy with acetic acid combined with biomarkers to 
risk stratify the patients.  
 
14.7.3: Randomized controlled trial of acetic acid chromoendoscopy versus 
protocol guided mapping biopsies 
There have not been any randomised controlled trials performed comparing acetic 
acid chromoendoscopy to protocol driven mapping biopsies. This is perhaps not 
surprising as the studies published had been so small that a randomised controlled 
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trial could not be clinically justified. The cohort studies presented in this thesis 
provide a justification for a randomised controlled tandem endoscopy study in a high 
risk population. This is important as positive results were initially seen using tri-modal 
imaging for the identification of Barrett’s neoplasia in cohort studies (104) but were 
not repeated in a multicentre tandem endoscopy study (58).  
 
14.7.4 Acetic acid versus trimodal imaging and confocal endomicroscopy 
There are currently several different techniques available for examining Barrett’s for 
the presence of neoplasia, including trimodal imaging and confocal endomicroscopy. 
It is currently however unclear which of these techniques is superior. Studies 
comparing these techniques are therefore needed. 
 
14.7.5: Acetic acid and electronic imaging combined 
The combination of acetic acid with electronic imaging has never been studied. 
Given that NBI, FICE and i-scan all enhance vascular areas, and that the loss of 
acetowhitening has been shown in this thesis to be central to the use of acetic acid 
as a diagnostic tool, it is not unreasonable to postulate that it may be possible to 
make the technique more sensitive by the additional use of electronic imaging after 
acetic acid dye spray. The concept of combining two techniques has already been 
proven to be of benefit in tri-modal imaging, and the concept here is not dissimilar. A 
potential problem with investigating this is that the sensitivity of acetic acid alone is 
already very good. Therefore a large study would be needed to show a statistically 
significant gain. However, even a small gain would be of clinical significance when 
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the consequence could be a missed early treatable cancer, so this kind of study is 
easy to justify. 
 
14.7.6: Low grade dysplasia 
Most of the work described so far has concerned high grade dysplasia within 
barrett’s. This is perhaps unsurprising as it is the development of high grade 
dysplasia which alters management from surveillance to treatment. However, low 
grade changes should not be dismissed as unimportant. Diagnosis still necessitates 
increased intensity of surveillance and can cause significant anxiety and distress to 
the patient. Studies investigating whether chromoendoscopy, electronic imaging or 
confocal endomicroscopy have any role in the evaluation of low grade dysplasia are 
needed. 
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14.8: Conclusions 
 
This set of studies demonstrates the feasibility of in-vivo diagnosis of neoplastic 
lesions in the upper and lower gastrointestinal tract using a combination of dye 
sprays and vascular enhancement techniques. It demonstrates and quantifies some 
of the differences between standard definition and high definition endoscopes. It also 
evaluates the potential financial impact that in-vivo diagnosis can make in selected 
populations of patients. The studies provide validated tools for lesion 
characterization and assessment and empower the endoscopist to act as a clinician 
and make a diagnosis, rather than as a technician who just collects biopsies. The 
tools used could potentially be applied to the assessment of other novel endoscopic 
devices and validate a method for such studies in the future.  
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